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ABSTRACT 
Allergy is a disorder of the immune system caused by an immune response to 
otherwise harmless environmental allergens. Currently 20% of the US population is 
allergic and 90% of pediatric patients and 60% of adult patients with asthma have 
allergies. These percentages have increased by 18.5% in the past decade, with predicted 
similar trends for the future. Here we design sensitive, multiplexed platforms to detect 
allergen-specific lgE using the Interferometric Reflectance Imaging Sensor (IRIS) for 
various clinical settings. 
A microarray platform for allergy diagnosis allows for testing of specific IgE 
sensitivity to a multitude of allergens, while requiring only small volumes of patient 
blood sample. However, conventional fluorescent microarray technology is limited by i) 
the variation of probe immobilization, which hinders the ability to make quantitative, 
assertive, and statistically relevant conclusions necessary in immunodiagnostics and ii) 
the use of fluorophore labels, which is not suitable for some clinical applications due to 
the tendency of fluorophores to stick to blood particulates and require daily calibration 
methods. This calibrated fluorescence enhancement (CaFE) method integrates the low 
VI 
magnification modality of IRJS with enhanced fluorescence sensing in order to directly 
correlate immobilized probe (major allergens) density to allergen-specific IgE in patient 
serum. However, this platform only operates in processed serum samples, which is not 
ideal for point of care testing. Thus, a high magnification modality of IRJS was adapted 
as an alternative allergy diagnostic platform to automatically discriminate and size single 
nanoparticles bound to specific IgE in unprocessed, characterized human blood and 
serum samples. These features make IRIS an ideal candidate for clinical and diagnostic 
applications, such a POC testing. 
The high magnification (nanoparticle counting) modality in conjunction with low 
magnification of IRJS in a combined instrument offers four significant advantages 
compared to existing sensing technologies: IRIS i) corrects for any variation in probe 
immobilization, ii) detects proteins from attomolar to nanomolar concentrations in 
unprocessed biological samples, iii) unambiguously discriminates nanoparticles tags on a 
robust and physically large sensor area, iv) detects protein targets with conjugated 
nanoparticle tags (~40nm diameter), which minimally affect assay kinetics compared to 
conventional microparticle tagging methods, and v) utilizes components that make the 
instrument inexpensive, robust, and portable. This platform was successfully validated on 
patient sermn and whole blood samples with documented allergy profiles 
(ImmunoCAP®, ThermoFisher Scientific). 
Vll 
TABLE OF CONTENTS 
Chapter 1 Introduction .................................................................................................. 1 
1.1 Biosensors .............................................................................................................. 1 
1.1.1 High throughput biosensors .............. .................................. ............ ....... ......... 3 
1.2 Background on allergy ............................. ............. ........................... ....... ... ... ...... ... 6 
1.2.1 Immunology ..................... ..... ........ ... .. ........... .. ...... ......... ....... .. .... ....... .. ..... .. .... 6 
1.2.2 Clinical problem .............................................................................................. 8 
1.3 Conventional allergy diagnostics .............. ................. ........... .... .. .... .. ... .. ........ ...... .. 9 
1. 3. 1 Skin prick testing .......................................................................................... 1 0 
1.3 .2 Commercialized tests to detect allergen-specific IgE .............. .. ........ ........... 11 
1.3.2.1 General specific IgE testing protocol.. ............................ .. .. ...... ................ 13 
1.4 Limitations of conventional specific IgE testing ........ ................ ...... .... ............ ... 15 
1.5 Point of care (POC) testing .......................... ...... .. ... ........... ...... .. .. ...... .... ..... ......... 15 
1.6 Overview of the dissertation ........................................................................ ........ 17 
Chapter 2 Interferometric Reflectance Imaging Sensor (IRIS) .............................. 20 
2.1 Biomass measurement ...................................... ..... .............................................. 21 
2.1.1 Detection principle ....................................................................................... . 21 
2 .1.1.1 Reflective interferometry .......................................................................... 21 
2.1.2 Quantification of biomolecular mass by measuring film thickness .......... .... 24 
Vlll 
2.1.3 Data processing .................. ... ............... ........ .. ............................. ..... ............. 25 
2.1.4 Evolution of IRIS ................................... ........... ..... ....... ....... ......................... 26 
2.2 Single nanoparticle counting .... .............. .................. .... .. ........ ........ ......... ............ 28 
2.2.1 Detection principle ........ ........ ... ..... ...... .............. .... ... ... .............................. .... 28 
2.2.1.1 Interferometric microscopy .. ............................. ............................. ....... .... 28 
2.2.2 Data processing ... ......... .............................. ............. ... ................................... 30 
2.2.2.1 Size-discrimination of single nanoparticles on the sensor surface .... ....... 30 
2.2.3 IRIS prototype for single nanoparticle counting ............... ........... ....... ... ....... 33 
2.3 Micro array fabrication ................................... ............... ................... ................... . 35 
2.3.1 Surface chemistry ............... ............. ............................ .......................... ... ..... 35 
2.3.2 Protein immobilization ....... ... ................ ........... ............. ................................ 40 
2.3 .3 Improving spot morphology .. .... ..... ...................... ... .......... .............. ............. 41 
2.4 Conclusions .................... .... ...................... ............ ...................................... .. ........ 43 
Chapter 3 Dual label-free and fluorescence detection using silicon biochips for 
improved protein microarray performance ................................................................. 44 
3.1 Introduction .... · .................. ............ ..... ..................... .............. ...... .. .......... .............. 44 
3 .1.1 Modulation of fluorescence intensity by the construction of optical 
interference on oxidized silicon substrates ................................................. .. .... .. ...... 4 7 
3. 2 Materials and methods ....... ....... ...... .. ... .. ... .... ..... ....... ... ...... ...... .. ... ...... .... .... ......... 51 
3 .2.1 Reagents ................ ..... ......... ....... ........... .......... ....... ...... ....... ... ....... ... ... .. .... ... . 51 
3 .2.2 Silicon chip micro fabrication .. ... ..... ....... ......... ..... ......... .... .. .. ...... ... .. ... .. ... ... .. 51 
3.2.3 Detection setup ..... ......... ........ .. .... ..... ..... .... ..... ... ....... ... ..... ..... ... .... ........... ...... 52 
IX 
3.2.4 Surface chemistry .......... .............. .... ..................................................... ......... 53 
3 .2.5 Protein microarray experiments ....... ...... .' ... .......... .... .......... .. ....... ..... ........ ..... 53 
3.2.6 Deterrnination ofthe Limit of Detection (LOD) ....................... ... ..... ............ 54 
3.3 Results and discussion .. ....... .. .......... ............. ............................ ......... ...... ............ 54 
3.3 .1 Concept .... ....... ...... ........ .......... ... ... .. .. ........ ... ... ...... .... .... .... ............. ... ............ 54 
3.3.2 Optimization of probe solubilization conditions .. ... ..... ... ........... .. ..... ... ......... 56 
3.3.3 Optimization of protein immobilization conditions ....................... .... ........... 58 
3.4 Conclusions .. ................ ............................................................................ ....... ... .. 62 
Chapter 4 Calibrated fluorescence enhancement (CaFE) method to quantify 
allergen-specific lgE ............................................................ ............................................ 63 
4.1 Irreproducibility of protein microarrays ..... ............... ................ ............ ......... .. ... 64 
4.2 Design of a platform for enhanced fluorescence emission and calibration 
measurement for intra- and inter- chip variability ....... ................................ ..... ....... ..... 66 
4.3 Materials and methods ..... ..... ......... ... ... ....... ...... ..... ..... .... ............. ... ... ............ .. .... 68 
4.3.1 Platform design simulations ............. ................ .. ...... ... ........... ....... .. .............. 68 
4.3.2 Reagents and equipment .... .............................. .......... .............. .......... ........ ... 71 
4.3.3 Si/Si02 coating by copoly(DMA-NAS-MAPS) .. ....... ....... ......... .... .... .......... 71 
4.3.4 Proof of concept of CaFE using IgG and 13-lactoglobulin .... ...... .......... .... .... 71 
4.3.4.1 IgG Calibration .... .... .......... .... ... ... ...... .. ..... .. ........ .......... ...... ....... ....... .... .... 72 
4.3 .4.2 13-lactoglobulin calibration ........ ..... .......... ..... .. ....... ... ... ....... .... ... .. .. .... .... ... 72 
4.3.4.3 CaFE Implemented as an Allergy Testing Platform ...... ..... ... ...... .. .... ... .... 73 
4.4 Results and discussion .. .... ..... .. .... ... ..... .. ... ... ...... .... .... ..... .... ......... ... ..... .... .. ...... .... 74 
X 
4.4.1 Platform Design Simulations ... ........................ ..... ............... .............. ....... .... 74 
4.4.2 Proof of Concept of Quantification and Calibration of CaFE using IgG and 
~-lactoglobulin ............. .............. ................ ... ..................... ... ....... ....... ........ .. ........ .... 76 
4.4.3 CaFE Implemented as an Allergy Testing Platform .......... ....................... .... 78 
4.5 Effect of substrate design on fluorescence enhancement ... ........... ... ......... ...... .... 81 
4.6 A dual label and label-free microscope to self-calibrate fluorescence 
micro arrays ...................... ............... ...................... .................... .... ....... ....................... . 82 
4.7 Conclusions ...... ......... ..... .................... .............. ......................... .... ....................... 83 
4. 7.1 Future work ..... ......................... .......... .... ....... ......... ........... .... ..................... ... 84 
Chapter 5 Single nanoparticle detection for multiplexed protein diagnostics with 
attomolar sensitivity in serum and unprocessed whole blood .................................... 86 
5.1 Clinical need for high sensitivity biomarker detection over a large dynamic range 
in unprocessed whole blood ................ ................. ..... .. .... .......... .................................... 87 
5.2 Conventional detection techniques to detect biomarkers in biological samples and 
their limitations ............... ... ............ .. ........................................................... ... ... .... ........ 88 
5.3 IRIS single nanoparticle detection of biomarkers in biological samples ............ . 90 
5.4 Materials and Methods ......... .... .. ............................................ ....... ........ .. ............. 92 
5.4.1 Reagents and equipment .. ....... ...... ............ .... ........ ........................................ 92 
5 .4.2 Substrate fabrication ............... ... .... ...... .. ............... .......................... ............. . 93 
5.4.3 Surface functionality ......... ....................... .... .... ..... ....... .. ... .. ... .. ... .... ........ ...... 93 
5 .4.4 Optical detection ... ..... ...... .... ... ....... ..... ...... ... ......... .... ....... ... ... ... ..... .. ... ... .. ..... 93 
5 .4.5 Gold nanoparticle functionalization of secondary detection antibodies ... .... 94 
Xl 
5.4.6 Verification of the size of detection complex ................................ ... ... ......... 94 
5.4.7 Protein immobilization .. ................................ ... .................... ........ ...... .. ....... .. 95 
5.4.8 Choosing an anticoagulant for whole blood assays ............. .............. .......... . 95 
5.4.9 Detection of ~-lactoglobulin targets spiked in undiluted serum or 
unprocessed whole blood ........................ ....... ........... ......... .......... ...... .... ................... 96 
5.4.9.1 Optimization of incubation time for detection complex ................ ....... .. .. 96 
5.4.9.2 Dilution curves for ~-lactoglobulin in undiluted serum or unprocessed 
whole blood .. ................... ......... ... .............................................. ........... ... ..... ..... .... 97 
5 .4.1 0 Elimination processes to ensure accurate detection of gold nanoparticles 
with IRIS ...... ... ............ ................. ..................................... ..... ....................... ............ 98 
5 .4.11 Determination oflimit of detection ............. ........ ............. ...................... ..... 99 
5.4.12 Determination of the lower and upper limits of quantitation .. .... ........... ... 101 
5.5 Results and discussion ... .......................................... ................... .... ... ............. ... 102 
5.5.1 Quantification and verification of bound AuNPs using elimination processes 
on IRIS ........................ ......... ......................................... ... ... ...................... ... ........... 102 
5.5.2 Attomolar detection of ~-lactoglobulin in undiluted serum and unprocessed 
whole blood ... ... ...... .... .... ........................ ......... .... ........ .......... ......... .. ............. ...... .. .. 105 
5.5.3 Advantages of increasing biological sensor area to improve assay 
sensitivity ... .......... ..... .. .. ... ..... ..... ..... ........... .... .............. ....... ... ... ... .. ... ........... ... ....... 108 
5.5.4 Determination of the lower limit of quantitation (LLQ) and upper limit of 
quantitation (ULQ) ..... ... ... ..... ... ................ ... .... ..... ... .... ...... .... .. ............. ... ..... ........... 112 
5.6 Conclusions ...... .... ...... .... .... ..... ......... .. .. ... ..... .. ..... ... ... ...... .... .. ... ... .. .... ...... ... ........ 113 
Xll 
5. 6.1 Future directions .................................................... ...... ............... ................ 114 
Chapter 6 Detection of allergen-specific lgE using IRIS single nanoparticle 
cou~:ing in unprocessed whole blood ............................................................................ 117 
6.1 Clinical need for an allergy diagnostic platform that can operate in unprocessed 
blood samples .................... .............................................. ...... ...................... ............. .. 117 
6.2 Materials and Methods ....... ................. ....................... ............................. ......... .. 118 
6.2.1 Reagents and equipment .................... .............................. ........................... 118 
6.2.2 Substrate fabrication ............................................................... .................... 118 
6.2.3 Surface functionality .......... .................................. ... ................... ................. 118 
6.2.4 Optical detection .................................................................................... ..... 118 
6.2.5 Gold nanoparticle functionalization of secondary detection antibodies ..... 119 
6.2.6 Verification of the size of detection complex ............................................. 119 
6.2.7 Multiplexed allergen immobilization .......................................................... 119 
6.2.8 Detection of allergen-specific lgE in characterized patient serum and 
whole blood ....................... ..... ......................... ................. .. .................................... 119 
6.2.9 Elimination processes to ensure accurate detection of gold nanoparticles with 
IRIS 121 
6.3 Results and discussion ... .......................................................................... .......... 123 
6.3 .1 Quantification of allergen-specific lgE in characterized serum and whole 
blood using IRIS nanoparticle counting ........ ................................. ....... .. .... ........... 123 
6.4 Conclusions ................. ....................... ..................... .... .... ... ... ............ .. .. ............. 127 
6.5 Future directions .. ..... ......... .. ............................................. .... .. .......... ................. 128 
X111 
Chapter 7 Accurate sizing of unknown particles using gold reference particles. 130 
7.1 Introduction ................................................................................................... ...... 130 
7.2 Materials and methods ....................................................................................... 132 
7.2.1 Reagents and equipment ........ ... .... ... ............ ....... .. .. .. .. ................................ 132 
7.2.2 Substrate fabrication ................................................................................... 132 
7.2.3 Surface functionality ..... ............................. ..... ... ....... ................ .. .............. .. 133 
7.2.4 Embedding reference nanoparticles (RNPs) onto substrate ........................ 133 
7.2.4.1 RNP Blanket coating and characterization ........ ............ ............ ............. 133 
7.2.4.2 RNP Spotting and characterization ....................... .................................. 134 
7.2.5 Optical detection ......................................................................................... 135 
7.2.6 Gold nanoparticle functionalization of secondary detection antibodies ..... 135 
7.2.7 Verification of the size of detection complex ....... ...................................... 136 
7.2.8 Faster image acquisition time of IRIS prototype .............. ................ ........ .. 136 
7.3 Results and discussion .......................................... .. ..... ............ ... .................... ... 136 
7.3.1 RNP blanket coating and characterization ........ .... ...................................... 136 
7.3.1.1 Time ofincubation .................................................................................. 136 
7.3.1.2 Biological testing .................................................................................... 138 
7.3.1.3 Faster image acquisition .............................. .... .... ............................. ...... 139 
7.3.2 RNP spotting and characterization .... ... .................................... ......... ... ....... 140 
7.3 .2.1 Buffer optimization ................................................................................. 140 
7.3.2.2 Time ........................................................................................................ 141 
7.3.2.3 Concentration optimization ..... ......... ....... .......... .......... ............... ............. 142 
XlV 
7.3.2.4 Preliminary biological testing ...... ............ .......... ... ... ..... .... .... .. ................ 143 
7.4 Conclusions and future direction ... ........ ............. ............ ...... ... .... .......... .... .... .... 144 
Cbapter 8 Conclusions and future directicm .......................................................... 146 
8.1 Conclusions ........... .......... ... .. ..... ..... ........... .... ............ ... ..... ...... ..... ... .. ... .... .... ...... 146 
8.2 Future directions ................................ ............ ... ................... ............. ....... ...... .. .. 148 
8.2.1 Stabilized referencing substrates and detection antibodies up to 4 weeks .. 149 
8.2.2 Development of a single-use cartridge for rapid detection of allergen-specific 
lgE in under 40 minutes ..... .. ............. ..... .. ............ ......... ................. .......... .. ...... ..... .. 150 
8.2.3 Integration of the cartridge into the IRJS platform ... ........ .......... ................ 150 
8.2.4 Clinical validation ofiRIS as a POC IVD allergy test ... ... .. ........ ............... 150 
Appendix A Dipole emission simulation code .......................................................... 152 
Appendix B Faster image acquisition using reference particles ............................ 156 
Bibliography .................................................................................................................. 159 
Curriculum Vitae .......................................................................................................... 1-71 
XV 
LIST OF TABLES 
Table 1. Comparison of skin and commercialized specific IgE testing ............................ 12 
Table 2. LOD determined for specific antibodies (pg/mL). Reproduced from [6]. .......... 61 
Table 3. Partial list ofhealthy levels of protein biomarkers in serum [1, 2] .................... 88 
XVI 
LIST OF FIGURES 
Figure 1. Principle ofBiosensors. Adapted from [7]. .................................. .... ................... 2 
Figure 2. Allergic cascade ........ ............... .. ..... .. ................................... ... ..... .... ....... ....... .. .... 7 
Figure 3. Skin prick testing ................ .................... .............................. .................. .... ....... 10 
Figure 4. Generalized slgE testing protocol ..................................................................... 14 
Figure 5 Optical Setup of IRIS ......................................................................................... 21 
Figure 6. IRIS calibration relates the optical path difference to amount of deposited 
biomolecules on the surface ................................................................................ .. .... 24 
Figure 7. Spot finding algorithm .................................... ...... .............................. ...... ......... 26 
Figure 8. Evolution of IRIS ........ ....................................................... ............................... 27 
Figure 9. IRIS single nanoparticle counting ..................................................................... 30 
Figure 10. IRIS size discrimination processes ................ ............ ...................................... 31 
Figure 11. Single nanoparticle detection of protein in whole blood ................................. 33 
Figure 12. IRIS prototype for single nanoparticle counting ............................................. 34 
Figure 13. Graphical representation of various forms of surface chemistry for solid phase 
assays ........ ...... ..................... ................ ....... ..... ......... .. ..................................... .. .... ... 36 
Figure 14. Graphical representation of copoly (DMA-NAS-MAPS) .......................... .. .. . 38 
Figure 15. Copoly (DMA-NAS-MAPS) swelling ................................. .. ..... ~ .......... .. ....... 40 
XVll 
Figure 16. Controlling spot morphology using 20mMTrehalose in PBS. Images were 
acquired with IRIS using a high magnification objective .................................. ..... .. 42 
Figure 17. Concept design of dual label-free and label chip .. ............. ... .. .. ................. ... .. L!.6 
Figure 18. Dipole emission model. .............. .... ... ....... .......... .............. ....... ............. ....... .... 50 
Figure 19. Fluorophore emission signals measured on different substrates and collected 
with different NAs . ... ...... ... .............. ..... .. .. .. ... ............. .................. ......... ................... 51 
Figure 20. Dual label and label-free silicon chip ...... .. .... .................... ................. .. ... ........ 55 
Figure 21. Dual sensing chip allows assay optimization ....... ... .. ... .......................... ......... 57 
Figure 22. Optimization of protein immobilization .... ...... ................. .. ............ ................. 60 
Figure 23. Design of dual sensing chips ....... ........................ ....... ... .............. ................ .... 69 
Figure 24. CaFE chip with immobilized proteins ..... ..... ............ ............ .. .... .............. ....... 70 
Figure 25. CaFE method calibrates fluorescence to immobilized biomass . ............ ......... 77 
Figure 26. IRIS and fluorescence tests versus ImmunoCAP® ...... .............. ............. ........ 79 
Figure 27. Calibration of allergen-specific IgE using the CaFE method ..... .. ........ ........... 80 
Figure 28. Effect of oxide thickness on silicon substrate compared to glass substrate on 
Cy3 and Cy5 emission (NA~0.7) ....... ........... .. ... ...................... ........... ... .. .... ............. 82 
Figure 29. The CaFE instrument combines IRIS and fluorescence microscopy in a single 
instrument ........ .. ..... .... ....... .... .. .. ....... ........ ........ .... .................. ....... .. ........... .... .......... 83 
Figure 30. Diameter oflabels influence the reaction kinetics of an assay .......... .. ............ 90 
Figure 31. EDTA and heparin anticoagulants used for whole blood incubations . .......... . 96 
Figure 32. Time study for optimizing incubation of functionalized secondary antibodies 
specifc forB-lactoglobulin .. ....... .... ...... ... .. ..... ..... ...... ... ... ...... .. ... ..... .... ........ .... .. ... ... . 97 
XV111 
Figure 33. The normal probability plot of the background signal per test, or spot (AuNPS 
permm2) .............. . .........•..•. ..... . . .. ........• ... . . ..................•............... . .... . ...... . .... . ... .... .. •... 99 
Figure 3L!·. Background signal to determine the limit of detection ....... .. ............. ..... ...... 100 
Figure 35. Detection of target in serum and whole blood samples ........ ... ................ ...... 103 
Figure 36. Size-discrimination improves assay performance ................ ... .............. .. ... .. . 104 
Figure 3 7. Dilution curves for target detection in serum and whole blood ...... .... .......... 105 
Figure 38. Anti-P-lactoglobulin and BSA spot images acquired with the IRIS 
nanoparticle counting modality to digitally detect P-lactoglobulin at varying 
concentrations in undiluted serum ... ........................................................ ............... 1 06 
Figure 39. The limit of detection (LOD) for serum and whole blood ............................ 109 
Figure 40. Repeatability ofLOD using human samples ............ ... ........ .. .. ...... ...... ........ .. 111 
Figure 41. The lower limit of quantitation (LLQ) per m.nl as a function of sensor size for 
unprocessed whole blood ... ... ...... .. .... ....... ........................ ....................................... 113 
Figure 42. The upper limit of quantitation (ULQ) ... .... .... ... ........................................... 113 
Figure 43. Detection of target in serum using homogenous capture in solution ............ 116 
Figure 44. Comparison of ImmunoCAP® ISAC, fluorescence, and IRIS protocols and 
imaging modalities to detect allergen-specific IgE. ...... ........................ ..... ......... .... 121 
Figure 45. Four replicates of 10 allergens (listed) were printed onto the CaFE chip for 
dual label (fluorescence or AuNP detection) and label-free measurements ........... 122 
Figure 46. Multiplexed assay to detect specific lgE to 8 allergens ..... ... ............. .. ...... ... 123 
Figure 47. Pre and post anti-IgE functionalized AuNPs incubation images acquired with 
IRIS . ..... ...... .. ....... .... ..... ... .. .. ...... ............. ....... .... .. ......... .. ....... .... ...... ........ ... .... .... ..... 125 
XIX 
Figure 48. Four patient samples characterized with the IRJS platform .......................... 126 
Figure 49. Discrepancy oftests ....................................................................................... 127 
Figure 50. Blanket coating of 70nm AuNPs with immobilized probe ........................... 133 
Figure 51. Spotting schematic for probe and 70nm AuNPs ........................................... 135 
Figure 52. RP Blanket coating as a function of incubation time .................................... 137 
Figure 53. Repeatability ofRP blanket coating for 3 samples at 4, 6, 8, and 10 hours .. 138 
Figure 54. RP blanket coating biological testing ............................................................ 139 
Figure 55. Three different spotting buffers (IX PBS, 150mM NaPB pH 7.5, and 150mM 
NaPB pH 8.5) were examined to optimize AuNP immobilization for different 
periods (1, 2, 3, 4, 5, 20 hours) ............................................................................... 141 
Figure 56. Optimization of immobilization time of 3 different AuNPs/mL spotting 
concentration ..................................................................... ...................................... 142 
Figure 57. Optimization of spotting concentration of RPs ............................................. 143 
Figure 58. IRJS images acquired pre- and post- binding with the benchtop setup ......... 144 
Figure 59. Detection of AuNP labels bound to target using the IRJS bench top ............. 144 
Figure 60. Schematic ofPOC IVD allergy test.. ............................................................. 148 
XX 
LIST OF ABBREVIATIONS 
APTES 
AuNP 
BOE 
BSA 
CaFE 
CCD 
CRD 
DIH20 
DLS 
DMA 
DNA 
EDC 
EDTA 
ELISA 
FBS 
HCl 
HMDS 
IgE 
IgG 
IRIS 
IUPAC 
IVDs 
LED 
LLQ 
LOB 
LOD 
LOQ 
MAPS 
NA 
NaOH 
NaPB 
NAS 
PBS 
(3-Aminopropyl)triethoxysilane 
Gold nanoparticle 
Buffered oxide etch 
Bovine serum albumin 
Calibrated fluorescence enhancement 
Charge coupled device 
Component resolved diagnostics 
Distilled water 
Dynamic light scattering 
N,N - dimethylacrylamide . 
Deoxyribose nucliec acid 
1-Ethyl-3 -(3 -dimethylaminopropyl)carbodiimide 
Hydrochloride 
Ethylenediaminetetraacetic acid 
Enzyme linked immunosorbant assay 
Fetal bovine serum 
Hydrocholoric 
Hexamethyldisilazane 
Immunoglobulin E 
Immunoglobulin G 
Interferometric Reflectance Imaging Sensor 
International Union of Pure and Applied Chemistry 
In vitro diagnostic 
Light emitting diode 
Lower limit of quantitation 
Limit ofblank 
Limit of detection 
Limit of quantitation 
3(trimethoxysilyl) - propylmethacrylate 
Numerical aperture 
Sodium hydroxide 
Sodium phosphate buffer 
Ac1yloyloxysuccinimide 
Phosphate buffer saline 
XXI 
PCR 
PEG 
POC 
PSF 
SDS 
Si 
Si-Si02 
slgE 
Si02 
SPR 
sse 
Polymerase chain reaction 
Polyethylene glycol 
Point of care 
Point--spread·-fimction 
Sodium dodecyl sulfate 
Silicon 
Silicon-silicon oxide 
Allergen-specific lgE 
Silicon oxide 
Surface plasmon resonance 
Saline sodium citrate 
xxn 
Chapter 1 
INTRODUCTION 
1.1 Biosensors 
The function and survival of all living organisms depend on the numerous 
reversible biological interactions occurring within the cell. Binding kinetics between 
biomolecules such as proteins, nucleic acids, cells, viruses, etc. highly dictate 
physiological function and disease progression. To study and measure these interactions, 
scientists and engineers have developed biosensors, or analytical devices, to transform 
the signal of a highly specific molecular event, such as the pairing of a specific antigen to 
its specific antibody, into a quantifiable signal. One example of a commercialized 
biosensor is the blood glucose monitor, which uses glucose oxidase to digest blood 
glucose. Morever, these devices have been extensively investigated and utilized for early 
disease diagnostics and monitoring [1]. Biosensors have evolved into more reliable, 
sensitive, and quantitative tools delivering rapid results from microliter sample volumes 
due to advancements in micro- and opto- electronics since their first appearance as 
glucose concentration monitors in 1962 [2]. Biosensors traditionally have 3 components 
that are depicted in Figure 1: 
1. A biological recognition component that sensitively and specifically 
recognizes the analyte in question. 
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..... 
2. The transducer element that transforms the event of physiochemical 
interaction into another quantifiable signal. 
Electronics and a user interface that outputs the results in an easy, user-friendly way. 
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Figure 1. Principle ofBiosensors. Adapted from [3]. 
Electronics and 
User Interface 
Tissues, organelles, cells, enzymes, protein, nucleic acids, and/or microorganisms such as 
bacteria or viruses have been used as the biological recognition element. These biological 
elements are typically immobilized on a solid support, such as a glass substrate, and 
referred to as probes. The immobilized biological elements on the solid support are then 
incubated in a sample - buffer, serum, blood, saliva, etc. ~that potentially contains the 
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analyte, or target, to be detected. Whenthe target is captured specifically by its probe, the 
physiological change occurs and is transduced into a measurable signal. The transducer is 
typically an electrical, optical, or mechanical component that categorizes the biosensor. 
The measureable signal is then processed and outputted by a user interface. Electronic 
biosensors typically measure enzymatic catalytic reactions; thus, they are limited to 
detection of charged molecules only. Mechanical biosensors are thought to be the most 
sensitive of sensors; however, precise control of environmental factors- such as 
temperature and atmosphere - limit their practicability towards biological applications. 
The emergence of robust and versatile optical biosensors has revolutionized modem 
research and clinical decisions. This dissertation will focus on the development of optical 
biosensors for allergy diagnostics. 
1.1.1 High throughput biosensors 
Advancement in computer and information technologies over the last decades has 
enabled tremendous amounts of data to be available. The fields of biology and medicine 
have advanced due to high throughput genomic and proteomic technologies, which 
enables millions of biochemical tests to be performed in parallel with small sample 
volume and offers major economic advantages. The commercial success of DNA 
microarrays in drug discovery, genetic testing and discovery, disease diagnosis, and 
forensics sciences is an example of high demand and versatility of this technology. 
However, protein microarray technology has yet to be adapted widely and commercially. 
Proteins are unstable macromolecules with more complexity compared to nucleic acids. 
Preservation of functionality and biological activity of immobilized proteins on the 
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sensor surface is a huge challenge that is discussed more thoroughly in Section 2.3 .1. 
While a reliable and cost effective manufacturing process has yet to be universally 
developed for protein microarrays, the availability of recombinant allergen proteins has 
facilitated the growth of allergen rnicroarrays for allergy profile testing over the last 
decade and is outlined in Section 1.3.2. Despite these challenges, the demand for high-
throughput, multiplexed analysis is high and scientists and researchers continue to utilize 
protein microarray methods in biological and clinical research. 
Optical biosensors are powerful tools that offer sensitive, multiplexed detection 
and are utilized in biomedical, healthcare, pharmaceuticals, environmental monitoring, 
and security applications [4-9]. Two modalities are typically seen in optical biosensing: 
fluoresce-based detection and label-free detection. In fluorescence-based detection, 
secondary reporters are labeled with fluorophore tags; the intensity of the fluorescence is 
directly correlated to the number of target molecules. While fluorescence-based detection 
is a well-established technique and has demonstrated single molecule sensitivity [10], it 
.. ": . . 
suffers from labeling protocols, which may interfere with reaction kinetics. Furthermore, · 
fluorophores are significantly affected by time and environment, which limit real-time 
data acquisition and require positive controls for normalization procedures. 
For decades numerous efforts have pursued label-free technologies to provide 
direct measurements. A successful method oflabel-free technology has been throughthe 
use of common path interferometry on layered substrates [ 4, 11-13]. These optical 
interrogation techniques utilize a broadband or narrowband illumination source to probe 
the substrate's interference signature. As molecular binding events occur on the substrate, 
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an alteration to the interference signature is induced. These shifts are then characterized 
to the amount of bound mass in order to provide a sensitive, quantified method of direct 
detection [13]. 
Recently, numerous label-free detection systems for protein and DNA arrays have 
recently been developed to quantify mass accumulation on sensor surface through 
changes in optical path length, refractive index, or resonant frequencies of the sensor [14-
16]. While label-free biosensing has numerous benefits specifically in quantitative 
analysis and minimal assay complexity, the sensitivities of most label-free detection 
techniques are lower than fluorescence-based techniques. To improve upon fluorescence-
based techniques, nano and micro particle tagging methods have been developed to 
challenge sensitivity thresholds down to attomolar concentrations [17]. More detail on 
particle labeling technologies and applications in biodiagnostics is discussed in Section 
5.2. 
Nanoparticle research has accelerated understanding of biological processes at the 
nanoscale and has led to many novel applications in diagnostics and therapeutics. 
Development of detection and characterization techniques for nanoparticles will 
substantially impact the progress and utility of biological research from nanomedicine to 
nanotoxicology. Moreover, the throughput, speed, and reliability of nanoparticle 
detectors exhibit successful promise for utility in point of care (POC) applications [ 18]. 
Single nanoparticle detection has been accomplished via electrical, mechanical, and 
optical transduction mechanisms. The main challenge of nanoparticle detection for 
biological applications resides in the capability to distinguish nanoparticles in complex 
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biological samples, such as serum or whole blood; this requires detection mechanisms to 
be capable of nanoparticle classification based on size, shape, chemical composition, etc. 
A general overview of the recent progress in single nanoparticle techniques based on 
these mechanisms is thoroughly described by Yurt eta!. [19]. 
This dissertation focuses on the development of the Interferometric Reflectance 
Imaging Sensor (IRIS), initially a high-throughput, multiplexed, quantitative label-free 
biosensor developed in our group by Ozkumur et al. and later modified to detect single 
nanoparticles on a surface, for applications in allergy diagnosis [20, 21]. The working 
principle and design of IRIS for these two modalities is discussed in Chapter 2. Allergen-
specific IgE (sigE) is the primary indicator of allergic sensitization and its discrimination 
requires a secondary binding reaction. Conventional methods to detect sigE typically 
utilize a secondary antibody specific for IgE labeled to fluorophores. This mandate in 
conjunction with the sensitivity threshold (~ 1 Opg/mL) rule out the ability to detect the 
presence of sigE with current label-free biosensing platforms. Current sigE detection 
technologies and their limitations are discussed in Section 1.3. 
1.2 Background on allergy 
1.2.1 Immunology 
Allergy is a disorder of the immune system characterized by a maladaptive 
immune response to otherwise harmless environmental antigens (allergens). Allergic 
reactions occur when the immune system generates large quantities of immunoglobulin E 
(IgE). Upon first exposure to an allergen, plasma cells generate IgE antibodies, which 
attach onto mast cells. If the allergen is exposed again, the primed mast cells capture the 
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allergen and rupture. This causes a release of histamine and other mediators involved in 
the complement complex to circulate in the blood and instigate swelling and redness at 
the sight (Figure 2). 
1. Plasma cells 
release lgEs 
Figure 2. Allergic cascade. 
2. Primed mast cell 
3. Allergen re-exposure 
activates release of 
histamines and other 
mediators. 
4. Symptoms 
Although two antibodies participate in the event - lgE and immunoglobulin G 
(IgG) - lgE antibody is the primary indicator of allergic sensitization. Each IgE is 
specific to each particular allergen; for example, the body will produce one type of IgE 
for apple and another IgE for peanut. In contrast to other immunoglobulins, IgE 
concentrations are vety low, measuring less than lng/mL in blood. To compare, lgG 
concentrations are approximately 1 Omg/mL. Because both specific IgGs and lgEs bind to 
their particular allergen but only lgE pinpoints allergic sensitization, it is important to 
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differentiate and detect IgE levels in human samples. Most biosensing technologies 
discriminate against IgE by utilizing a labeled secondary antibody against IgE. In order to 
exploit IgG specificity, immunotherapy drugs for slgE commonly consist of increasing 
slgG levels in the body, thereby reducing or preventing allergy outbreaks [22-24]. 
However, the reliability of this method is unknown. 
1.2.2 Clinical problem 
The major clinical manifestations of systemic sensitization to allergens are 
allergic asthma, allergic rhinitis (hayfever) and food allergy. Approximately 20% of the 
US population is atopic (allergic) and 60% of adult asthma is allergic in origin: this 
percentage is higher in children [25, 26]. In the past decade the occurrence of food 
allergy has increased by 18.5%, with projected global market to reach $26.5B by 2017 
[25, 27]. At present, nearly 15M patients could benefit from a POC allergy diagnostic 
system in a primary care setting. At a modest $20 per patient annual price, the 
addressable market would reach $300M for a POC allergy test. Both prevalence and costs 
for care of asthma and allergies are predicted to continue to increase over the next 
decade. 
Because no cure for allergic asthma or food allergy exists, the cornerstones of 
allergy care are symptom relief and environmental trigger control. The first step in 
controlling allergen exposure in individuals with allergy is identification of allergen 
. sensitivity. The current standard of care to determine allergen sensitization is 
conventional skin testing. Including setup and the second round (from scratch to 
intradermal), this clinic-based procedure requires subspecialty referral and takes 
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approximately 1 hour. In some instances, primary care physicians order in vitro 
diagnostic (IVD) allergy testing; results take 3-5 days and may require interpretation by a 
specialist. Thus, the patient would save both time and money with the implementation of 
a POC allergy diagnostic test. The main limitation to bringing an IVD allergy test to the 
POC is automated sample preparation and handling; most tests require detection of 
analytes in serum, and in the US, it is not possible to separate serum from whole blood in 
the clinic due to regulatory issues. 
1.3 Conventional allergy diagnostics 
Allergists use three components to determine the diagnosis of an IgE-mediated 
allergic disorder of a patient: 
1. Allergen sensitivity through close analysis of clinical history is identified. 
2. Skin testing or in vitro testing validates the presence of slgE to the allergen. 
3. A causal relationship between allergen exposure and symptoms via clinical 
history or a challenge protocol is determined. 
This section will focus on Component 2 and discuss different methods used to determine 
the presence of slgE and the advantages and disadvantages of each technique. 
Many allergy platforms utilize allergen extracts, or complex mixtures of allergenic and 
non-allergenic compounds derived from the natural allergen sources that are not entirely 
standardized. These mixtures may contain cross-reactive allergen components, which are 
present in a variety of different allergens. Commonly referred to panallergens, these 
cross-reactive components create false positive results against numerous allergens and 
cause a challenge to determine the correct allergen sensitization. Component resolved 
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diagnostics (CRDs) specifically aim to test for individual specific allergen components 
and not crude extracts and is discussed later in this section. 
1.3.1 Skin prick testing 
The current standard of care to determine allergen sensitization is conventional 
skin testing. This test is a bioassay that detects the presence of slgE on mast cells (Figure 
2). 
__;,--- -~ 
~ 
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Figure 3. Skin prick testing 
Varied commercial extracts of common aeroallergens (e.g. pollens, molds, animal 
dander) and a control solution are applied to the skin with a scratching device and/or 
injected intradermally. When the allergen interacts with the primed mass cells, 
degranulation releases mediators, such as histamine. The histamine causes wheal and 
flare response. A positive clinical re.sult is determined by the degree of flare and wheal 
(Figure 3). Including setup and scratch to intradermal time, this clinic-based procedure 
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takes approximately 1.5 hours. Moreover, skin testing typically occurs on the second visit 
to a specialist since a majority of individuals with allergic symptoms (hayfever and/or 
asthma) are taking antihistamine medications that interfere with skin testing and must be 
discontinued for 10 days prior to skin testing. 
Two approaches to skin testing are followed. A focused approach occurs when the 
person's clinical history strongly suggests the specific allergen, and the patient is 
evaluated for that particular allergen in question. A more general approach occurs when 
the patient has recurrent rhinitis and/or asthma. This approach entails testing for slgE to a 
panel of allergens pertinent to the geographical region. The degree of wheal and flare are 
quantified and compared to that of control solution to determined if the individual is 
allergic to an allergen. 
The sensitivity and specificity of skin testing is limited by the particular allergens 
used. For example, the performance of airbourne allergen extracts to diagnosis allergic 
rhinitis is more reliable compared to the reliability of food allergen extracts. The 
sensitivity of food allergen extracts is generally low, thus, a positive skin prick result 
from a food allergen requires follow up testing to verify sensitization in parallel with 
clinical history confirmation. On the other hand, a negative skin prick test has very high 
predictive value with up to 95% accuracy [28]. 
1.3.2 Commercialized tests to detect allergen-specific IgE. 
Although skin prick testing is the conventional standard of care to diagnose 
allergen sensitization, it usually requires follow-up slgE testing using a commercialized 
platform to confirm positive results, especially regarding food sensitivities [29]. 
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Table 1. Comparison of skin and commercialized specific IgE testing 
Product Sample Measurement Time (hr) Range (kU/L) Sensitivity Specificity Test Location CRD 
Skin Test skin Degree of wheal < 1 n!a 50% Specialist No 
ImmunoCAP sponge 
serum Fluorescence enzyme 4 0.1- 1000 89% 91% Lab No (Phadia) 
(Immulite Siemen Health 
serum Fluorescence enzyme 1 0.1-1000 82-90% 98% Lab No Care Diagnostics) 
Turbo RAST (HYTECH-
288, Hycor Biomedical- serum Fluorescence enzyme 3 0.1 - 20 78-100% 66- 93% Lab No 
Agilent) 
AlaSTAT serum Enzyme 3 0.05-100 71% 87% Lab 
ImmunoCAP-ISAC serum Fluorescence 3 0.1- 1000 <CAP Lab Yes 
ImmunoCAP Rapid blood Fluorescence/ dyed .03 1-100 92% 97% Clinic Yes particles 
Luminex Corp (xMAP 
serum 
Fluorescently-labeled 3 0.1-80 82% 92% Lab Yes 
Technology) micro beads 
--
1.3.2.1 General specific IgE testing protocol 
Most commercialized slgE immunoassays follow a generalized protocol (Figure 
4). First, allergens are covalently linked onto a substrate, such as a microarray slide or 
cellulose membrane. The immobilized allergens are then incubated in serum, which 
contains slgE and slgG molecules that react with the allergens. After washing procedures, 
enzyme-labeled antibodies against IgE are introduced to form a complex. The unbound 
enzyme-labeled antibodies are removed from the solution and a developing agent is 
added. Once the reaction is stopped, fluorescence measurement is acquired to quantify 
4. Developing agent yields fluorescence 
3. Enzyme labeled antibody against lgE 
2. Serum (slgE + slgG) 
1. Allergen immobilization 
Figure 4. Generalized slgE testing protocol 
the amount oflgE in the serum sample; a higher signal equals more IgE in the sample. 
ImmunoCAP® sponge and Immulite ® technology utilize this protocol. ImmunoCAP® 
ISAC technology immobilizes allergens on a glass microarray substrate and combines 
step 3 and step 4 in Figure 4 by introducing a fluorescently-labeled antibody against IgE. 
The fluorescence is measured with a microarray scanner. ImmunoCAP® Rapid uses a 
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lateral-flow assay format and gold labeled antibodies against sigE. 
1.4 Limitations of conventional specific lgE testing 
Whether referred to a specialist or not, patients with skin disorders or who cmmot 
tolerate discontinuation of antihistamines (which interfere with skin testing) are not 
suitable candidates for skin testing. For these individuals, immunoassays that detect sigE 
in serum are the primary alternative to skin testing to characterize systemic allergic 
sensitization to allergen. Commercially available assays in the U.S. have key limitations: 
they 1) require a separate blood draw, 2) are sent out to reference laboratories with results 
returning in 3-5 days, and 3) primarily use crude allergen extracts to capture serum sigE, 
leading to detection of immunologic cross-reactivity that may not be clinically 
informative. We have also identified two specific technological shortcomings with 
current IVD technology. First, cunent microarray platforms (ImmunoCAP® ISAC 
biochip) require sophisticated fluorescent readers, which are not applicable to POC, to 
boost sensitivity. Second, the measurements are not quantitative- the allergen spots are 
not calibrated and have very high variability in mass of spotted protein, which affects 
specific IgE capture and quantization using fluorescence detection alone [31]. To 
summarize, there is a need for a calibrated, sensitive, and multiplexed allergy microarray 
platform that can operate in unprocessed finger-prick volumes of whole blood for a rapid, 
POC instrument. 
1.5 Point of care (POC) testing 
POC testing for the diagnosis and monitoring of diseases holds significant 
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promise to impact and change the course of health care and treatment. While major 
technological advances in the sensitivities of diagnostic platforms compete with 
conventional methods such as PCR and ELISA, the transition of these tools from the 
laboratory to clinical setting remains a challenge. To effectively implement a diagnostic 
test in the clinical setting, the tool must rival conventional sensitivity and specificity 
thresholds, exhibit robustness and portability, and be easily integrated into the financial 
and regulatory policies of the clinical setting [ 17]. Implementation of reliable and 
sensitive POC IVDs into the clinic will expedite decision-making processes and 
treatments. Data have shown that early detection and treatment of diseases, such as 
colorectal, breast, and prostate cancers, decrease mortalities by 80% [32]. In addition, 
determination of allergen sensitization has been shown to reduce anaphylaxis and asthma 
[33]. 
Biosensing platforms detect biomarkers by two mechanisms: 1) amplification of 
target - a technique used in PCR - or 2) amplification of the signal - a method used in 
ELISA. While the first technique has been favored compared to the latter method, recent 
introduction of nano and microscale material labels have proven to be powerful and 
sensitive in serum samples. However, these techniques i) utilize multiple step processes 
that increase the complexity ofthe assay, ii) require th<~:t the biomarkers of interest be 
within the dynamic range of the platform, and iii) involve blood preparation and handling 
prior to testing. Moreover, nanoscale and complex sensing elements may limit clinical 
applicability such as POC testing (34, 35]. 
While highly sensitive protein detection methods have been achieved in serum 
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samples, biomarker detection in unprocessed whole blood remains very challenging due 
to non-specific binding of cells and particulates to the sensor surface. One approach to 
perform biosensing in whole blood samples has been demonstrated by Stem et al., who 
have developed a micro fabricated microfluidic purification chip to process 1 O)..lL of 
whole blood in 20 minutes [36]. However, this teclmique only achieves 500pM 
sensitivity, which is 106 times less sensitive than the techniques established for detection 
in serum. Moreover, this level of sensitivity is not pertinent to most protein biomarkers, 
whose serum concentrations in healthy individuals range between 0.01-1 OOpM. 
While a variety of commercialized allergy assays (ImmunoCAP®, Siemens, Hycor 
Biomedical, Hitachi Chemical Diagnostics, Luminex Corporation) have been developed 
for diagnostics in the laboratory setting, the ImmunoCAP® Rapid System (Thermo-
Fisher Scientific) is the only commercialized sigE test that can operate with unprocessed 
blood samples. This assay uses a capillary blood draw of 100 microliters and totals 25 
minutes of testing while other commercialized assays take 1 hour of sample preparation 
in addition to over 4 hours of assay time [37, 38]. However, the Rapid System is limited 
to aeroallergens, has a narrow dynamic range, and requires professional interpretation of 
results because it is not quantitative. 
1.6 Overview of the dissertation 
There is an opportunity to develop the next-generation sigE detection platform. A 
new allergy diagnostic platform must demonstrate high sensitivity and specificity, 
provide large multiplexing ability, be high-throughput, cover a large dynamic range, 
deliver quantitative results, test for allergen components, require minimal calibration, 
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operate with unprocessed biological samples, and offer competitive advantages compared 
to commercialized allergy tests. 
In this dissertation we present multiple platforms to improve upon current 
commercialized sigE platforms. We primarily compare these systems to the 
ImmunoCAP® system because this company holds 70% of the global market share in 
allergy diagnostics. These platforms are not limited to allergy detection, but are relevant 
to a variety of clinically based applications with any known ligand-antigen pair. The 
following is a brief overview of the dissertation. 
• Chapter 2 discusses the Interferometric Reflectance Imaging Sensor (IRIS), an 
optical biosensor platform that offers label-free biomass quantification and 
single nanoparticle counting and size profiling. The importance of surface 
chemistry and the description of protein microarray fabrication is also 
reviewed. 
• Chapter 3 discusses design of a single chip for dual label-free and enhanced 
labeled measurements. This chip uses IRIS to optimize protein immobilization 
conditions in addition to providing sensitive fluorescence measurement. Such 
a chip has strong utility in assay design, optimization, and performance. 
• Chapter 4 discusses two microarray platforms that address the problem of 
protein immobilization variation and their application to allergy diagnostics. 
These platforms can be tuned to optimize fluorescence emission for a single or 
broad spectrum offluorophores(s) while maintaining ability to perform label-
free quantification. 
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• Chapter 5 discusses a microarray platform that detects highly sensitive protein 
targets in complex biological samples (serum, whole blood) using the IRIS 
single nanoparticle counting modality. The sensitivity, dynamic range, and 
repeatability of the platform are thoroughly characterized in human serum and 
whole blood samples. 
• Chapter 6 discusses the clinical utility of the platform developed in Chapter 5, 
focusing on its application as an allergy diagnostic system. 
• Chapter 7 discusses the preliminary design and fabrication of self-referencing 
substrates to facilitate automatic focusing and detection of nanoparticles on 
the IRIS substrates. 
• Chapter 8 discusses the implications and conclusions and outlines the futme 
direction of this work. 
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Chapter 2 
INTERFEROMETRIC REFLECTANCE IMAGING SENSOR (IRIS) 
Chapter 2 details the IRIS platform. IRIS operates in two modalities: 1) total 
biomass measurement and 2) single nanoparticle counting. The primary differences in the 
total biomass quantification and single nanoparticle counting modalities of IRIS are the 
magnification of the objective, the oxide spacer on the substrate, and the resulting 
information in the image acquired by the CCD array (Figure 5). The detection principles, 
data quantification methods, and software and hardware for both methods are outlined in 
detail. Furthermore, the surface chemistry used for sensor fabrication and optimization is 
described. 
Dual label-free and fluorescence measurements using the IRIS substrate is also 
introduced. Chapter 3 motivates the need for a single chip capable of dual measurements, 
and Chapter 4 discusses the characterization and optimization of dual measurement 
substrates and their advantages in allergy diagnostics. 
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a) Biomass c) 
measurement 
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5X objective 
Wavelength (nm) 
I 
Single 
nanoparticle 
counting 
50X objective 
Figure 5. Optical Setup of IRIS. a) biomass measurement and the c) single nanoparticle counting 
modalities. a) Four LEDS and a low magnification objective (SX) are used to illuminate the surface after 
antibody immobilization (B) and antigen incubation (C) and referred to a background (A) to quantify mass 
density accumulation. The intensity of the reflection from the top of the Si02 surface and Si-Si02 interface 
is recorded on to a CCD camera. b) A phase shift in the interference signature of the mass density modality 
is fused to determine the optical path length and biomass accumulation atop the Si02 film. c) One LED and 
a high magnification objective (SOX) are used to image the sample onto a CCD. Single nanoparticles are 
detected via the interference of the scattered field produced by the nanoparticle on the surface and the 
reflected field generated by the Si-Si02 interface. A forward model is useQ. to determine the size 
distribution of the nanoparticles and allows filtering and discrimination to remove background noise. 
2.1 Biomass measurement 
2.1.1 Detection principle 
2.1.1.1 Reflective interferometry 
The first modality measures biomass accumulation in microarray format on the 
surface and is described thoroughly elsewhere [39]. The principle of detection for IRIS is 
based on quantifying the shifts in the spectral reflectance signature to calculate the added 
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biomass by sampling it at specific wavelengths and measuring the characteristic 
reflection intensities using a CCD camera (Retiga 2000R from Qlmaging). The sensor 
surface is sequentially illuminated using an ACULED VHL surface-mount LED package 
(Perkin-Elmer), which has four independently driven LEDs with peak emission 
wavelengths of 455nm, 518, 598nm, and 635nm. The position of the LEDs' emission 
spectra with respect to the reflectance curve is critical for allowing the accurate 
measurement of the shift in this curve due to a change in the thickness (biomass 
accumulation) of the top layer. After acquiring images of the substrate for each of the 
four wavelengths each pixel of the CCD represents an individual measurement of the 
reflective interference intensity at each wavelength, forming a 3-dimensional array of 
data (pixel, wavelength, intensity) for the entire sensor. The data points for each pixel are 
fitted to a curve derived using well-known formulations (Fresnel equations- Equation 1), 
which govern the behavior of reflection from a semi-transparent hi-layered substrate [4]. 
To achieve repeatable measurements the intensity of the incident light must be 
monitored. Incident light is traditionally measured by using an external photodetector; 
however, to maintain the simplicity of the system an on-chip reference is utilized. The 
reference region is created by etching a bare silicon region on the substrate that is placed 
in the field of view to normalize for any fluctuations in the incident light intensity. After 
fitting every pixel in the image, the surface topography of the sensor's surface is 
presented in a grayscale i~age where brighter regions indicate greater thickness on the 
surface. To determine optical spot heights, the average value from pixels in an annular 
region outside of the spot (background) is subtracted from the average value of pixels 
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inside the spot. By using previously determined calibration factors, this information can 
be converted to mass densities at each spot location on the chip to determine binding. This 
technique has been demons1Tated to offer picogram/mm2 sensitivity, real-time ki:J;letics 
monitoring, and the binding of multiple analytes to immobilized probe molecules-all in 
a simple platform amenable to high-throughput screening [4, 13]. 
The reflection coefficient of a single oxide layer on silicon can be approximated by 
Equation 1 
where r1 and r2 are the Fresnel reflection coefficients of the air-Si02 and the Si02-Si 
interfaces. More specifically, the reflection coefficients can be calculated as: 
nox - nl d ns. - n 
'i= an r2=' ox Equation 2 
nox +~ ns; +nox 
and ¢ is the optical phase difference between the two reflections are defined as 
2nd 
n. = --n cos() '~' A. ox Equation 3 
In Equation 2, dis the oxide thickness, nox is the refractive index of Si02, /..,is the 
wavelength of the incident light, and () is the angle of incidence. Here, the angle of 
incidence is 0 because the light is illuminated perpendicularly to the substrate. In this 
model, the biomass accumulated on the surface is assumed to have a refractive index 
identical to the Si02. As the amount of molecular layers accumulate on the sensor 
surface, a change in optical thickness is measured by shifted intensity vs. wavelength 
curves (Figure 5b). Equation 1 is fitted to the spectral reflectance data to yield the optical 
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path difference at each image pixel and calculated as d to yield a surface profile image. 
2.1.2 Quantification of biomolecular mass by measuring film thickness 
Advantages oflabel-free quantification ofbiomolecular interactions compared to 
conventional chemiluminescence or fluorescence methods are discussed in Section 1.1.1. 
The significant advantage of label-free techniques is that the natural binding interactions 
between the molecules are observed in their native state. This eliminates the need for a 
standard curve to be generated for every set of experiments because there is no concern in 
the inconsistency of labeling protocols between trials. Generally, interferometric 
techniques assume a linear relationship between the optical path length difference and the 
accumulated biomass on the sensor surface. Some methods model the optical path length 
difference as a fixed-height layer with a varying refractive index [40, 41], and others 
describe the optical path length difference as a fixed-index layer with varying thickness 
[42, 43]. Comparison on each approach is discussed in Ozkumur eta! [13]. Because each 
model is an approximation, the system must be initially calibrated to correlate the known 
mass of the adsorbed layer to the signal and experimentally verify the theoretical 
calculations. 
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Figure 6. IRIS calibration relates the optical path difference to amount of deposited biomolecules on the 
surface . For valid comparison to total mass, the mean thickness was multiplied by the area of the deposited 
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spot that was used to measure the thickness. Ozkumur et al. obtain 1.21 ng/mm2/nm for BSA, 1.28 
ng/mm2/nm for IgG, and 0.8 ng/mm2/nm for DNA using a fixed-index ofn = 1.45. This figure is adapted 
from [3]. 
Ozkumur et al. quantitatively calibrated the optical path difference for the IRIS 
technique by measuring the optical path length difference of known concentration of 
proteins and DNA normalized by the area of the biomolecules. The total mass of the 
biomolecules was determined by measuring the deposition volume of precisely known 
concentration of biomolecules. Immobilization was done in deionized water so any mass 
left on the surface after water evaporation only consisted of biomolecules without any 
salt. By comparing the weighted sum of material thickness with the total mass of the 
biomolecules, Ozkumur et al. established the relationship between the effective spot 
height and surface concentration of different macromolecules [44] (Figure 6). For the 
remainder of the dissertation, 1.2ng/mm2 of surface density per nm measured IRIS 
response for protein is used to correlate optical path length difference to biomolecular 
mass measurement. 
2.1.3 Data processing 
A spot finding algorithm either manually or automatically selects circular regions of 
interest that generate four concentric dotted circles that represent the user-specified inner 
radius (green), the center and radius of the spot (yellow), and the boundaries of the 
background (red) (Figure 7). The user is able to tweak different parameters of the spot, 
such as the variance of the pixel intensities, to eliminate poor features within the analysis 
region. The thickness of the spot above the surface is reported as the mean thickness of 
the inner spot minus the mean thickness from the background. 
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(A) 
IRIS image 
(B) 
IRIS image 
Identified sensor 
Identified sensor 
Identified spot displaying 
pixels used in analysis 
Identified spot 
wi.th pixel elimination 
Figure 7. Spot finding algorithm. (A) The software easily identifies the spot by accumulating the vertical 
and horizontal lines throughout the image. The center and the radius of the spot are identified as indicated 
by the yellow dotted circle. The user denotes the radius inside sensor (green dotted circle) as well as the 
background area outside the sensor (red dotted circles). In this figure, a spot height of 1.440 nm was 
obtained by measuring the differential optical path length of the area defined by 80% of the sensor radius 
(green pixels) and the area defined by 120% and 160% of the sensor radius (red pixels). (B) A spot with a 
small area artifact, most likely caused by a piece of dirt is analyzed, which must be eliminated for accurate 
quantitative analysis. The identified spot height is 1.804 nm when this artifact area is included. However, 
when filtering out all pixels that bad fitting error of more than one standard deviation of the entire image, 
the reported spot height decreases by 19% to 1.463 nm. This value is similar to the spot height of a spot 
without any artifact (the right image from (A)). As seen in the right image, the artifact is not included, and 
only the green pixels are used in calculating the spot height. (Adapted from [7]) 
2.1A Evolution of IRIS 
As shown in Figure 8, we have demonstrated successful prototyping of the IRIS biomass 
measurement system. This first generation prototype was specified and designed within 
1 year from the first demonstration on the bench top. This process followed the 
established BU Photonics Center I ARL pipeline program. Zoiray Technologies 
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commercialized this prototype instrument (with a tunable laser) for protein microarrays. 
Four years ago, a graduate student team in the Unlii laboratory was able to replace the 
bulky/expensive tunable laser with discrete LED sources and reduce the size, cost, 
complexity, and power requirements of the instrument. 
Bench-top IRIS (2007) 18" 
Prototype system (2008) 
LEOs replace 
bulky/expensive 
tunable laser (201 0) 
Figure 8. Evolution of IRIS. On the left: First generation IRIS setup which used a tunable laser and spanned 
half of an optical table. In the center: A first generation prototype produced by Zoiray Technologies. On the 
right: A second generation IRIS prototype with multi-color LED sources. 
We currently have working instruments with LED illumination in the laboratories of our 
collaborators at CNR Milan (Chemistry), MITRE Corporation, and BU Medical School 
(Microbiology). These instruments are built using off-the-shelf components and our 
group assists in the operation. We also recently have been funded to build an instrument 
for the Junker group at McGill University. Currently, a senior design team is working 
towards a prototype IRIS biomass measurement tool that utilizes a microscope slide that 
will be easily adapted into the research community. The idea is a researcher or scientist 
can utilize the automated instrument as a quantitative assessment tool to account for any 
variation in immobilization density to acquire accurate, calibrated fluorescence read out 
(See Chapter 3 and Chapter 4 for motivation and data) [31]. 
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2.2 Single nanoparticle counting 
2.2.1 Detection principle 
2.2.1.1 Intederometl'"ic microscopy 
Imaging nanoparticles using a microscope typically involves illuminating the 
nanoparticles with a visible light source and detecting the light scattered or absorbed 
using objective lenses, and array/single element sensors. For a small spherical 
nanoparticle, the scattered intensity at a detector (Idet) can be equated by: 
2 
Equation 4 
where Esca and <Jsca are the scattered field and scattering cross-section, respectively. The 
dielectric index of the nanoparticle ( Ep), the surrounding medium (Em), the radius of the 
nanoparticle (R), and the illumination wavelength are the primary parameters affecting 
the scattered intensity. The strong dependence ofthe scattered intensity on the particle 
size causes small nanoparticles to be challenging to detect. Interferometric detection is 
one approach to this difficulty, which is carried out by mixing the weak scattered field 
with a stronger reference field (Eref): 
Equation 5 
where Brs corresponds to the phase angle difference between the reference and scattered 
fields. The first term becomes a constant background intensity, the second te1m 
approaches 0 due to the R 6 dependence, and the third term dominates the optical response 
due it its R3 scaling factor [19]. 
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Daaboul et al. initially demonstrated sizing capability of individual viruses on the 
IRIS platform by using a layered reflective substrate [21]. In this work, the layered 
substrate was designed with a 1 OOnm oxide on silicon to allow dynamic control over the 
optical response at a given illumination wavelength. This spacer layer was tuned for 
optimized detection and sizing of HlNl viruses and polystyrene nanoparticles 
immobilized on the substrate. The IRIS single nanoparticle counting modality enhances 
the contrast of a single nanoparticle on a bilayered substrate by interfering the scattered 
field produced by the nanoparticle on the substrate surface with the reflected field 
generated by the buried Si-Si02 interface of the IRIS chip. The CCD camera senses the 
individual nanoparticles on the IRIS chip as point objects, which are processed via 
custom software to extract size information (See Figure 5). 
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Figure 9. IRIS. (a) Schematic of the optical setup. The setup uses a 525nm LED source that is set up fin 
Kohler illumination using a 50 x 0.8NA objective. The sample is imaged using a CCD camera. (b) The 
close-up schematic of the object space where the reflected and scattered fields are shown. (c) IRIS and (d) 
SEM images of the immobilized virus on the surface with the same field of view. (e) The size distribution 
of single nanoparticles on different chips. (f) Size distribution of virus immobilized on the layered substrate 
measured with IRIS. Adapted from [4, 5]. 
In this dissertation, IRIS nanoparticle counting uses one discrete LED wavelength 
(525nm) to illuminate the sensor's surface using a high magnification objective (SOX, 
0.8NA) to detect, count, and size gold nanoparticles (AuNPs) of known size labeled to 
secondary antibodies and captured on the sensor surface through affinity binding 
reactions. 
2.2.2 Data processing 
2.2.2.1 Size-discrimination of single nanoparticles on the sensor surface 
IRIS nanoparticle counting software incorporates 3 elimination processes to 
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ensure that point objects detected in the image are AuNP-functionalized secondary 
antibodies (Figure 1 0). First, anomaly filtering disregards any irregular points caused by 
the morphology of the protein spot. Second, a point spread function (PSF) filter 
disregards any particles on the surface that do not exhibit the expected profile of the 
AuNPs; the profile of a AuNP takes form of the point spread function of the optical 
system that is known in advance. PSF filtering is crucial: spot morphologies often contain 
particulates that may be misconstrued as false positives; thus, it is important to utilize the 
expected PSF profile to ensure accurate AuNP detection. Third, the size-discrimination 
feature of IRIS nanoparticle counting eliminates any particulates outside of the size 
regime of the introduced AuNPs. 
iii) PSF filtering - Mean = 58nm, SD = 11 nm, Counts = 428 iv) Size-discrimination- Mean= 53nm, SD = 4nm, Counts= 332 
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Figure 10. IRIS size discrimination processes. A histogram of the size distribution of all particles in the 
image is constructed (i). After the 3 elimination processes - anomaly (ii), PSF (iii), and size discrimination 
(iv) - the profile of particles in the images becomes the anticipated size-distribution introduced by the user 
to detect targets in the sample. Figure reproduced from [45]. 
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Here, IRIS nanoparticle images were acquired after an immunoassay described in 
detail in Section 5.4.9 and processed with custom software. Briefly, 54nm AuNP labels 
on secondary antibodies specific for ~-lactoglobulin were detected on the sensor surface. 
IRIS software returns a histogram of the size distribution of nanoparticles in the image 
and uses 3 important elimination processes - anomaly filtering, point-spread-function 
(PSF) filtering, and size-discrimination - to ensure accurate and sensitive detection of 
labeled detection antibodies. Without filtering, the average size and standard deviation of 
the particles detected on the surface was 59±18nm corresponding to larger size than 
expected for the AuNP tags indicated that many of the "detected" particles are image · 
artifacts also indicated by the very large size distribution. After using IRJS elimination 
processes, the average size and standard deviation of detected nanoparticles was reduced 
to 53±4nm, which was the diameter of the functionalized AuNPs confirmed with 
dynamic light scattering (DLS). 
In a typical bioassay, which is described in detail in Section 5.4.9, IRJS pre- and 
post- particle incubation images are acquired. Background images of the captured target 
on the immobilized proteins take into account any particulates that are binned into the 
size distribution of the AuNP labels, which are then normalized by the detection area. 
This enables quantification of specifically bound AuNPs only introduced by the user by 
subtracting the signal from the background (Figure 11). 
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Figure 11. Single nanoparticle detection of protein in whole blood. AuNPs functionalized to secondary 
antibodies are incubated for 1 hour to detect captured protein from the incubation sample. In this example, 
target was spiked into bovine blood at 5pM for 2 hours. The black dot is an image artifact. 
2.2.3 IRIS prototype for single nanoparticle counting 
The IRIS single nanoparticle counting modality revolves around the enhanced contrast in 
the scattering signal from a particle on an interferometric substrate. The contrast 
enhancement allows the optics within the reflection mode microscope to be reduced to a 
lower magnification and numerical aperture without losing detection capabilities. This 
reduction enables a larger field-of-view and, therefore, higher throughput. Instrument 
design continues with the selection of the illumination wavelengths. The wavelength of 
illumination is selected based on the particle material and size of interest to maximize our 
size detection capability. For example, based upon Equations 4 and 5, a green LED 
(525nm center wavelength) is sensitive to sizing the radius of AuNPs between 15nm and 
40nm and polystyrene or virus particles between 45nm and 90nm. Understanding the 
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design interplay between these parameters has allowed us to develop a compact, self-
contained, and high-throughput prototype for multiplexed detection. 
12" X 8" X 4" 
(a) (b) 
IRIS Chip 
••• 
••• 
+- Target 
capture 
+- Negative 
control 
(c) 
Figure 12. IRIS prototype for single nanoparticle counting. (Top) a SolidWorks schematic of the prototype 
and IRIS spotting protocol. (a) Physical prototype. (b) IRIS chip is held by a stage and inserted into 
prototype for automated image and data acquisition. (c) IRIS image of captured viruses on a spot. 
The first version of the IRIS prototype (Figure 12) has been designed to 
demonstrate the technique's ease-of-use and low-cost. The instrument is constructed for 
under $20k from off-the-shelf components (optics and electronics) with a custom 
aluminum case for mounting. Wall power is stepped down to the needed 24VDC, 
12VDC, and 5VDC to power all internal electronics including a router, camera, LEDs, 
stages, and control circuitry. However, future versions of the prototype can use battery 
power for operation. 
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Once powered, data acquisition occurs with a click of a button. Using an 
automatic 3-axis stage and custom software, this prototype allows the user to serially 
insert samples for automated data acquisition and processing by interfacing a laptop via 
Ethernet or wireless connection. The inexpensive, compact, and automated nature of this 
instrument will empower users with little to no training to conduct sensitive and specific 
diagnostic tests outside of the laboratory [ 46]. With incorporation of a micro fluidic 
cartridge to minimize user exposure to the contagions, this prototype will be able to 
perform a complete bedside examination. 
2.3 Microarray fabrication 
2.3.1 Surface chemistry 
Surface chemistry dictates the success of a biosensor. In order to successfully 
probe minute amounts of target molecules over a large dynamic range in a sample using 
immobilized biomolecules on a solid support ("solid phase assay"), it is crucial to utilize 
a surface chemistry which minimally affects the affinity and the specificity of the target 
as well as the background noise caused by non-specific binding. A tremendous effort to 
develop superior surface chemistry for multiplexed biosensors has been in continual 
development. Cretich et a!. outline the criteria for successful surface chemistry [ 4 7]: 
1. Surface chemistry must allow a good control of capture probe density with 
homogeneous morphology for optimal binding capacity of the ligands. 
2. The biological activity of the probes must be retained upon immobilization. 
3. The probes. must be accessible to the target of interest. 
4. The surface must display a 'low degree of non-specific interactions. 
35 
One-dimensional coatings 
Two-dimensional coatings 
Three-dimensional coatings 
Dendrimeric polymers Gel and filter membranes 
Figure 13. Graphical representation of various forms of surface chemistry for solid phase assays. Figure is 
reproduced from [48] . 
Surface chemistries for solid phase assays can be categorized into 1-D, 2-D or 3-
D groups based on their architectures as shown in Figure 13 [ 48]. Cretich et a!. review 
various 1-D, 2-D, and 3-D surface chemistries for Si-SiOz slides and their advantages and 
disadvantages to immobilized protein conformation and specificity [ 49]. The degree of 
the conformational change of adsorbed proteins depends on the polarity of the surface, 
which includes the extent of hydrophobicity/hydrophilicity, and the environmental 
conditions, such as temperature, pH, and ionic strength of the solution. The influences of 
these factors on protein conformation and functionality are the primary reason why 
protein microanays are generally more difficult to fabricate than DNA microarrays. 
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Complex 3-D structures with polymeric matrix or gel and filter membranes have 
increased in popularity for fabricating protein microarrays. Hydrogels coated surfaces are 
developed to maximize the loading capacity and simulate an aqueous, native 
environment; however, these techniques are impractical because the gel-like structures 
tend to reduce the diffusion of the target of interest [48]. This problem is exacerbated 
when the target protein is in low concentration and requires a prolonged incubation time 
for detectable capture. Nitrocellulose film coatings are another popular 3-D surface 
chemistry method and are used in ImmunoCAP® technology. While the film coatings 
exhibit unprecedented loading capacity and long shelf-life, the non-specific interaction on 
the nitrocellulose surface is a significant problem limiting its use in highly complex 
biological solution such as whole blood [ 48]. In this dissertation, we will limit the 
discussion of the 3-D polymeric coating used in the presented studies. 
Professor Chiari's group at the CNR developed a 3-D polymeric matrix, N,N-
dimethylacrylamide (DMA) - acryloyloxysuccinimide (NAS) - 3(trimethoxysilyl) -
propylmethacrylate (MAPS)) (which will be referred as copoly (DMA-NAS-MAPS) or 
copoly polymer for the remainder of the dissertation) for initially immobilizing DNA on 
glass surfaces [50]. Later the group demonstrated its application to protein microarrays 
[51] and peptide arrays [52]. The 3-D polymeric matrix structures noticeably increased 
the loading capacity [50], reduced protein denaturation by maintaining an solution-like 
microenvironment for the probes, and displayed very low non-specific binding [51]. 
Copoly (DMA-NAS-MAPS) consists of three monomers with different functions (Figure 
14A). The copoly (DMA-NAS-MAPS) is covalently bound to the glass surface by the 
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condensation of MAPS monomers, and the binding is reinforced by the hydrogen bond 
interactions ofDMA monomer, the major constituent. NAS monomers react with primary 
amine groups of the biomolecules to covalently linlc the biomolecules to the substrate. 
(A) 
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Figure 14. Graphical representation of copoly (DMA-NAS-MAPS). (A) Molecular structure of copoly 
(DMA-NAS-MAPS) and its interactions to the glass surface is shown. The monomer concentration is as 
follows: MAPS (m) = 1, NAS (n) = 2, and DMA (p) = 97. (A) is adapted from [53]. (B) Graphical 
representation of copoly (DMA-NAS-MAPS) on a glass surface after hydration and antibody binding. The 
polymeric chains swell upon hydration to provide an aqueous microenvironment for the probes. (B) is 
reproduced from [51]. 
The coating is prepared by a "dip and rinse" approach immersing a silicon oxide 
substrate in an aqueous solution ofthe copolymer (lOmg/mL) at ambient temperature 
followed by washing with water. The coated substrates are then cured at 80°C for 30 min. 
When Si-Si02 wafers are immersed in the copolymer solution for 30 minutes, ultrathin 
films of the polymer were generated and characterized by Yalcin et a/. using Spectral 
Self-interference Fluorescence Microscopy (SSFM) [53]. SSFM measures the distance of 
fluorophores from the reflecting surface using interferometry. The swelling of copoly 
(DMA-NAS-MAPS) is obtained by measuring the height of the fluorophores tagged on 
the immobilized DNA on the surface in aqueous environment compared to the height in 
the dry environment. Figure 15a shows the height ofthe fluorophores fi·om the sensor 
surface from 10 DNA spots measured by SSFM. When the polymer is hydrated, the 
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fluorophore height increases by 7.5 run, indicating the copoly (DMA-NAS-MAPS) swells 
dramatically (Figure 15c). The same experiment was performed on epoxysilane surface 
(Figure 15b), and no change in fluorophore height was observed. The white light (WL) 
measurements determine the optical thickness of the polymer layer and the silane layer. 
No change in optical thickness for both cases was observed confirming that there was no 
change in mass of surface chemistry layers. 
In addition to these advantages, copoly (DMA-NAS-MAPS) does not alter the 
optical properties of the optimized Si02layers, thus allowing us to produce micro array 
supports characterized by a very low non specific background for interferometric 
detection [8] and for high sensitivity protein assays in array format [54, 55]. 
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Figure 15. Copoly (DMA-NAS-MAPS) swelling. Measured heights with white light (WL) and SSFM 
techniques for 10 independent spots on the same samples before and after hydration are shown. (A) Copoly 
(DMA-NAS-MAPS) coated sample shows increased fluorophore heights in wet environment. (B) the 
epoxysilanized sample shows no change. White light (WL) spectroscopy measurements for both samples 
show no change. (C) Graphical illustration of swelling of the copoly (DMA-NAS-MAPS) layer in aqueous 
solution. Figure is adapted from [53]. 
2.3.2 Protein immobilization 
The copoly (DMA-NAS-MAPS) coating has proven to be a versatile polymer for 
various IRIS applications, such as virus [21], protein [39], and DNA [39] detection. 
While previously synthesized in-house using the Chiari protocol, the polymer is now 
bought through Lucidant Polymers. Protein microarrays have been spotted on-chip using 
humidity and temperature control. All proteins were immobilized overnight on the sensor 
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surface using 45% relative humidity at 20 °C. The arrayed chip were washed on the 
following morning on a rotating shaker with 4 x 5 min 1X PBST (Phosphate buffer 
saline, 0.1% Tween), 4 x 5 min 1X PBST, and a final rinse with DI H20 (distilled water, 
filtered) prior to imaging. 
2.3.3 Improving spot morphology 
Protein microarrays are infamous for the large heterogeneity of immobilization 
between protein molecules compared to DNA microarrays [31]. This concern is discussed 
and addressed in Section 4.1. Uniform spot morphology is crucial to reduce intra- and 
inter- spot variability and acquire reproducible data. Spot smearing, ring-like spots, and 
ambiguity due to salt crystallization are commonly observed non-uniform spot 
morphologies as shown in Figure 16a. The custom software developed to detect single 
nanoparticles operates best if spot morphology is clean to minimize the possibility of 
binning a spot artifact in the size regime of the desired particle. After optimization (data 
not shown), it was decided 20mM trehalose would be added to the PBS spotting buffer to 
reduce spotting artifacts and improve homogeneity of the spotting protocol (Figure 16b ). 
This additive reduced spot diameter, substantially reduced inter- and intra-
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Figure 16. Controlling spot morphology using 20mM trehalose in PBS. Images were acquired with IRIS 
using a high magnification objective. 
experiment variability and has facilitated sensitive detection of target in serum and whole 
blood samples. Although the immobilization density was reduced with this additive, no 
reduction in binding signal was noted, suggesting that uniform spot morphology 
influences protein functionality compared to high density of probes. 
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2.4 Conclusions 
The materials in this chapter highlight the key concepts behind the IRIS biomass 
measurement and single nanoparticle counting modalities. The benefits of quantitative 
analysis and assessment of immobilized probe density and its effect on target capture 
suggests an important role in quality assurance and is explored more in Chapter 3 and 
Chapter 4. Moreover, discussion of the operating principles behind the IRIS single 
nanoparticle counting modality has high potential to directly impact healthcare as a 
diagnostic tool in the clinical setting. The versatility and reproducibility of copoly 
(DMA-NAS-MAPS) in IRIS applications was also reviewed. Adding 20mM trehalose to 
the spotting solution also controlled uniformity of morphology of protein micro arrays. 
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Chapter 3 
DUAL LABEL-FREE AND FLUORESCENCE DETECTION USING SILICON BIOCHIPS FOR 
IMPROVED PROTEIN MICROARRAY PERFORMANCE 
A new silicon chip for protein microarray development, fabrication, and 
validation is discussed in this chapter. The chip is made of two areas with oxide layers of 
different thicknesses: an area with a 500nm Si02layer optimized for interferometric 
label-free detection using IRIS and an area with a lOOnm Si02layer optimized for 
enhanced fluorescence measurement. The chip permits label-free imaging of arrayed 
protein probes using IRIS coupled with high sensitivity fluorescence detection in a single 
experiment. Dual detection on the same surface is of high practical utility during the 
assay development process to image arrays, check consistency and quality of the protein 
array, quantify the amount of immobilized probes, and detect fluorescence with high 
sensitivity compared to other bioassays. The text and figures in this chapter were 
primarily adapted from [55] and [ 49]. 
3.1 Introduction 
Multiplexed assays in microarray format have generated increased interest in the 
last decade for their ability to simultaneously detect multiple analytes in a sample by a 
specific molecular binding event at the surface interface [56]. Proteomic chips are 
becoming more appreciated for medical diagnostics due to the fast and highly parallel 
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analyses that can be performed with them and have been used for protein discovery, 
binding behavior characterization, and/or understanding of protein-protein complexes and 
interactions [57-59]. Protein microarrays consist of multiple proteins immobilized on a 
sensor surface that share the same superficial chemical environment regardless of their 
broad range of physicochemical properties and different binding affinities. This protocol 
may incorrectly assume that the entire panel of arrayed proteins is reproducibly and 
quantitatively immobilized on the probing surface. 
In-depth investigation on the absolute amount of surface bound probes of utmost 
importance for protein chips is crucial, especially regarding making clinical decisions 
derived from applications such as antibody profiling for allergy diagnosis, responses to 
infectious agents, diabetes or autoimmune disorders. Label-based methods to visualize 
printed slides have been developed for DNA microarrays spot quality control prior to 
hybridization [60-62]. Recently, a label-free imaging technique using photonic crystals 
for quantitative spot quality analysis was developed and applied to DNA microarrays 
without altering standard microarrays protocols [63]. While relevant, these techniques 
focus on quality control of printed arrays of nucleic acids, which are a class of chemicals 
with uniform physiochemical characteristics. In contrast, different proteins interact with 
surfaces quite distinctly, and spotting conditions must be carefully optimized to keep 
solubility and structure in order to yield favorable binding kinetics and a good spot 
morphology. Here we describe a silicon chip system that consists of dual interferometric 
and fluorescence reading for protein microarray development, fabrication, and validation. 
The system allows label-free imaging of the arrayed protein probes coupled with the 
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fluorescent detection of targets in a single experiment. 
We have already outlined the IRIS and its ability to quantify biomolecular mass 
accumulation on a surface [13, 39]. We have also recently reported on the use of silicon 
with. a silicon dioxide top layer of appropriate thickness for fluorescently enhanced 
microarray substrate. Accordingly, fluorescence is intensified on these slides due to the 
optical constructive interference between the incident and reflected light of the 
fluorescent radiation [31, 54]. 
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Figure 17. Concept design of dual label-free and label chip. (a) The IRIS platform consists of a silicon 
oxide surface on a silicon substrate, on which highly functional capture probes are immobilized. Biomass 
accumulation on the surface changes the optical path length difference between the two interfaces, resulting 
in a shift in the reflectance curve (b). The sample reflectance is recorded as an intensity image by a CCD 
camera by illuminating discrete wavelengths of LEDs, forming a reflectivity-vs.-wavelength curve at each 
pixeL (c) Optimizing substrates for dual detection: on the right, the thickness of the silicon dioxide layer is 
chosen to enhance the fluorescence yield of the fluorophore; on the left, the oxide used for IRIS is too thick 
and the silicon surface too distant to have maximal enhancing effect. 
Silicon technology and a proper modulation of the thermal oxide layer enable 
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precise, accurate dual measurements. In this chapter, we describe a silicon chip with two 
areas with oxide layers of different thicknesses: an area with a 500nm SiOz layer 
dedicated to interferometric label-free detection and quantification of proteins and an area 
with 1 OOnm Si02 providing enhanced fluorescence (Figure 17). This type of chip offers 
high practical utility during the assay development process to im~ge arrays of proteins, 
check consistency and quality of the spotted array, quantify the amount of immobilized 
probes, and detect fluorescence in bioassays. The microarray protocol is not altered in 
any way and provides pg/mL sensitivity. Awareness of real immobilization quantities for 
different proteins in distinct immobilization conditions facilitates the production of 
consistent protein chips. The absolute amount of immobilized material, the activity of the 
immobilized proteins, and the specificity of the secondary antibodies will ultimately 
determine the sensitivity" and reproducibility of proten;_ microarrays. 
This dual detection scheme is particularly effective for allergen chips, which 
suffer from large immobilization variability that may result in underestimation or failure 
of detection of captured targets [84,86]. To address protein microarrays reproducibility 
issues, the Calibrated Fluorescence Enhancement (CaFE) method, which integrates 
quantitative IRIS label-free sensing and enhanced fluorescence measurement, has been 
developed and is discussed in Chapter 4. 
3.1.1 Modulation of fluorescence intensity by the construction of optical 
interference on oxidized silicon substrates 
In field of molecular biology, fluorescence measurement of labeled secondary 
probes bound to targets is the primary method of detection for microarrays [3-6]. For 
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highly sensitive detection, this technique relies upon the difference in the absorption and 
emission spectrum of fluorophores called the Stokes shift. When a fluorophore absorbs a 
photon at a specific wavelength, the photon loses some energy and emits at a higher 
wavelength. Spectral isolation of the emission spectrum leads to a low background. With 
a minimized background, further advancement in sensitivity studies may be pursued 
through maximizing the collected signal. 
The strength of the collected signal is controlled by two factors: the emitted 
intensity and the collection efficiency. To improve the emitted intensity, a more powerful 
excitation source can be implemented to drive the fluorophores through more absorption 
and emission cycles. However, turning up the source intensity win offer limited 
improvement due to more rapid photo bleaching effects. The collection efficiency is 
limited by the collection optics, which only collect a fraction of the omnidirectional 
intensity emitted by fluorophores. 
The implementation of a reflective substrate to redirect the emitted photons 
typically lost in the glass substrate towards the collection optics has demonstrated an 
enhancement of the fluorescence signal [7-8]. A reflective substrate often includes a 
transparent spacer layer on the surface of the substrate to generate constructive 
interference of the excitation wavelength for · enhanced excitation [9, 1 OJ. Reflective 
substrates can also be crafted into a complex structure, such as a photonic crystal, to 
confine and direct the excitation and emission wavelengths for more than 100-fold 
enhancement of the fluorescence signal over than glass substrate [11-13] . These 
configurations prove that glass substrates for fluorescence micromTays are not the 
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optimized platform for sensitive detection. The selection of an alternative scheme, which 
is compatible with existing chemistries and processes, can provide immediate 
improvement to existing systems. 
A particularly promising replacement for glass slides is Si-SiOz substrates. This 
layered substrate configuration is widely available, inexpensive, compatible with 
established glass surface chemistries, and provides a tunable wavelength enhancement 
[14]. The optically transparent Si02 acts as a spacer to bring the fluorophore into the 
plane of constructive interference. By varying the thickness of the Si02 layer, the 
emission wavelength of any fluorophore of choice can be enhanced by constructive 
interference. Using the dipole emission model [9,15,16] to simulate fluorophore emitters 
as dipoles near a dielectric interface on a layered substrate, the structure can be designed 
and optimized for a range of wavelengths, which outlined in Section 4.3.1. Briefly, the 
total emission of a monolayer of random dipoles measured through an objective with 
maximum angle collection angle e;:,ax is calculated by integrating the emission intensity, 
ftotaf, over the objective: 
n/2 n: e::,:x 
!total= J J J 1(8,cp,(}em)sin(}em d(}em df/Jd8. Equation 6 
8=4J rp~O e ,m 
where <pis the azimuthal angle of the observation point, Bern, is the emission angle (or 
polar angle of the observation point), and(} is the polar tilt of the dipole in the x-z plane 
(Figure 18). The modeling software used to design substrates for emission enhancement 
is in Appendix A. 
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Preliminary experiments demonstrating the effect of oxide thickness and 
numerical aperture (NA) on fluorescence collection efficiency is shown in Figure 19. In 
these experiments, aminated Atto-655 fluorophores in DMSO (40 micrograms/mL) were 
immobilized on substrates (glass, silicon, 100nm Si02 on Si, 500nm Si02 on Si, 51-lm 
Si02 on Si, and 171-lm SiOz on Si) for 30 minutes using amine silanization chemistry (5% 
(3-Aminopropyl)triethoxysilane (APTES) in acetone dip-coated for 3 minutes, washed 
for 5 minutes, and dried with argon gas). Collection of emission intensity through a 5X, 
1 OX, 20X, and 50 X objective was measured with the SSFM using 632nm excitation. 
These results suggested that 1 OOnm Si02 on Si collected at high NA maximizes 
fluorescence emission and collection. More thorough discussion, modeling, and design of 
these substrates for enhanced fluorescence emission are outlined in Section 4.2. 
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Figure 19. Fluorophore emission signals measured on different substrates and collected with different NAs. 
3.2 Materials and methods 
3.2.1 Reagents 
TRIS, BSA, Tween 20, PBS tablets, SSC 20X, bovine milk casein, rabbit 
immunoglobulin G, carbonic anhydrase, bovine serum albumin, ovalbumin, 13-
lactoglobulin B, a-lactalbumin and lysozyme were purchased from Sigma (St. Louis, 
MO). Sheep anti-casein was purchased from Abnova (Taipei city, Taiwan), Rabbit anti 
B-lactoglobulin from Bethyl Laboratories (Montgomery, TX), goat anti- a-lactalbumin 
from GeneTex Inc (Irvine, CA) and rabbit anti-ovalbumin from AbCam (Cambridge, 
UK). Secondary antibodies (Cy3 labelled goat anti-mouse and anti-sheep IgG and mouse 
anti-goat IgG) were from Jackson ImmunoResearch (West Grove, PA). 
3.2.2 Silicon chip microfabrication 
The combination 500nm and lOOnm Si02 chips with bare silicon reference were 
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fabricated using photolithography patterning processes and wet etching. Wafers of 
500nm thermally grown Si02 on a silicon substrate were purchased from Silicon Valley 
Microelectronics (Santa Clara, CA). Acetone sonication for 10 minutes and oxygen 
plasma ashing at 300sccm and 500W for 1 Omins are used to remove organic residue on 
the surface. Hexamethyldisilazane (HMDS) and Shipley S1818 positive resist are spun 
onto the surface at 2krpm for 30 seconds. The chip is exposed for 30s at 15m W and then 
developed for 45 seconds in the SUSS Mask Aligner MA6 and Micro-Dev resist 
developer, respectively, to form the bare silicon reference pattern. The exposed region of 
the wafer is etched 500nm at 77nm/min when submerged in buffered oxide etch (BOE) 
6:1. 
With the bare silicon reference exposed, the wafer is again patterned following 
the same cleaning, spinning, and developing steps. The developed pattern exposes the 
Si02 which will be used for fluorescence enhancement while protecting the label-free 
measurement regions. Etching from 500nm to 1 OOnm is performed with BOE 6:1 diluted 
1:40 with DI to achieve an etch rate of 4nm/min. Finally, the resist is striped to reveal a 
chip with label-free and enhanced fluorescence Si02 regions. 
3.2.3 Detection setup 
IRIS was used to quantify immobilized protein on the surface and has been 
described in 2.1. Scanning for fluorescence evaluation was performed by a ProScanArray 
scanner from Perkin Elmer (Boston, MA); silicon slides were analyzed using 80% and 
90% Photomultiplier (PMT) and laser power. Fluorescence intensities of replicated spots 
were averaged. 
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3.2.4 Surface chemistry 
Silicon slides were coated with copoly(DMA-NAS-MAPS) as described in 2.3. 1. 
3.2.5 Protein microarray experiments 
An array of rabbit immunoglobulin G, carbonic anhydrase, bovine serum 
albumin, ovalbumin, ~-lactoglobulin B, a-lactalbumin and lysozyme at 1 mg/mL 
concentration was patterned using an SciFlexArrayer S5 spotter from Scienion. Every 
protein was spotted in three different buffers: PBS (pH 7.2), borate (borate/NaOH 50 mM 
pH 9) and acetate (6-EACA/acetate 20 mM pH 4.4). 
Printed slides were placed in a humid chamber and incubated at room temperature 
overnight. The slides were then blocked by 50mM ethanolamine in TRIS/HC11M pH 9 
for 1 hour, washed with water and dried by a stream ofNitrogen. Arrayed slides were 
then incubated in a humid chamber with 100J.!L of the solution of the specific antibody in 
incubation buffer (Tris/HCl 0.05 MpH 7.6, NaCl 0.15 M, Tween 20 0.02%) with 1% w/v 
BSA, for 2 hours at different concentrations of antibody (0, 0.001, 0.0075, 0.002, 0.075 
ng/mL). For casein experiments, slides were incubated with policlonal anti-casein sheep 
antibody (1 ng/mL) for 2 hours. 
Slides were then washed with washing buffer (Tris/HCl 0.05 MpH 9, NaCl 0.25 
M, Tween20 0.05%) for 10 minutes, rinsed with water and then incubated with lOOJ.!l of 
the solution of the specific labelled secondary antibody 1 J.lg/mL in incubation buffer for 1 
hour. Slides were then washed with PBS (1 0 min), rinsed with water and dried with a 
Nitrogen stream. 
After binding of proteins and blocking ofumeacted sites, the quarter of the chip 
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exhibiting the 500nm oxide layer is with IRIS and the amount of immobilized protein for 
each condition is quantified; the morphology and consistency of spots are also verified by 
visual inspection of the images generated by the IRIS setup. After IRIS quantifies the 
amount of surface immobilized probes, the chip undergoes a conventional fluorescence 
assay. The silicon biochip for dual label-free and fluorescence detection proposed can be 
of high practical utility during the microarray assay development process. Without 
altering the standard microarray protocol, the new tool can be implemented in a routine 
use as an internal quality control for protein array production. 
Scanning for fluorescence evaluation was performed by a ProScanArray scanner from 
Perkin Elmer (Boston, MA). 
3.2.6 Determination of the Limit ofDetection (LOD) 
In order to determine the minimum concentration of antibody that can be reliably 
detected (analytical sensitivity), the concentrations of antibody used were plotted versus 
the intensities of the corresponding detected fluorescence. We fitted the values with a 
linear regression and extrapolated the limit of detection (LOD) as the antibody 
concentration that exceed the mean fluorescence of the Ong/mL (blank) sample plus three 
standard deviations. 
3.3 Results and discussion 
3.3.1 Concept 
The concept of the new silicon biochip applied to allergen microarrays is 
illustrated in Figure 20. The chip is a 15x15 mm2 silicon slide divided into four quarters 
0 0 (Figure 20a), three regions ofthe chip exhibit a silicon oxide layer of lOOnm whereas one 
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region displays an oxide thickness of 500nm. Each quarter of the chip is printed with the 
same protein array within the same spotting session. After protein immobilization and 
blocking of unreacted sites, the quarter of the chip exhibiting the 500nm oxide layer is 
imaged using IRIS and the amount of immobilized protein for each condition is 
quantified [ 13] the morphology and consistency of spots are also verified by visual 
inspection of the images generated by the IRJS setup. After IRIS measurement, the chip 
undergoes the 
a 
Silicon chip consisting of areas coated by 
oxide layers with different thicknesses 
Composite image of fluorescence 
and label free imaging 
Figure 20. The silicon chip is a 15 mm x 15mm square silicon slide divided into four quarters (a), the three 
regions of the chip exhibit a silicon oxide layer of 1 OOnrn while one regions has an oxide layer of 500nrn. 
Each quarter of the chip is spotted during the same spotting session. The quarter of the chip with the 500nm 
oxide is imaged with IRIS to quantify immobilization density and the other three quarters are analyzed with 
a fluorescence scanner. (b) reports a combined image for the same allergen microarray before serum 
incubation (label-free detection and quantification of immobilized allergens) and after incubations with an 
allergic patient's serum and fluorescence secondary antibody. This figure was reproduced from [55]. 
conventional microarray experiment. Here we demonstrate utilize an allergen array as an 
example (Figure 20b ). First, the array is incubated with serum samples containing 
documented levels of slgEs and then exposed to fluorescently labeled secondaty 
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antibodies against slgE. The microarray is finally analyzed using a fluorescence scanner 
for quantification of fluorescent signals. Three sectors of the chip are dedicated to 
fluorescence detection to increase the number of replicates. Figure 20b reports a 
composite label and label-free image before the serum incubation and after incubations 
with an allergic patient's serum and fluorescent secondary antibody. The fluorescent 
signals obtained can be associated, allergen-by-allergen, with the amount of immobilized 
protein in order to implement an internal quality control into the microarray. This is 
particularly important if we consider that the allergens often experience problems of 
solubility and stability and may affect diagnosis. Thus, the proposed chip could therefore 
be a valuable tool to be used in the development, production and daily application of 
protein microarrays. 
3.3.2 Optimization of probe solubilization conditions 
To demonstrate the practical utility of the silicon biochip as a tool for protein 
microarray development, we studied the solubilization and binding of casein from bovine 
milk, an important food allergen whose solubility is pH and ionic strength dependent. 
The amount of casein immobilized on copoly(DMA-NAS-MAPS) coated Si-Si02 slides 
using buffers with different pH and additives was studied. In this experiment, 1mg/mL 
casein was added to PBS with 0.1% w/v SDS (1 ), PBS with 1% w/v SDS (2), PBS with 
0.01% v/v Tween (3), borate pH 9 with 0.1% w/v SDS (4), borate pH 9 with 1% w/v SDS 
(5), borate pH 9 with 0.01% v/v Tween (6), saline-sodium citrate (SSC) buffer (7), 
phosphate/NaOH 50 mM pH 8.5 buffer (8) and NaOH 10 mM (9) and allowed to dissolve 
under stirring overnight. The casein solutions were then filtered and spotted ( 4 replicated 
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spots for each conditions) on the silicon chip. After overnight incubation in a humid 
chamber, the surface was washed and the unreacted sites were blocked as reported in the 
experimental section. The surface was then imaged and the amount of immobilized 
protein quantified as described Protein microamiy experiments. In Figure 21a, the label 
free imaging of casein dissolved and spotted in different conditions (labeled from 1 to 9) 
is shown. The poor morphology of spots for conditions (2), ( 4 ), ( 5) and ( 6) can be 
observed; moreover we can notice that dissolution condition (3) led to absence of 
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Figure 21. (a) IRIS image of casein from bovine milk dissolved and spotted in PBS with 0.1% w/v SDS (1 ), 
PBS with 1% w/v SDS (2), PBS with 0.01% v/v Tween (3), borate pH 9 with 0.1% w/v SDS ( 4), borate pH 
9 with 1% w/v SDS (5), borate pH 9 with 0.01% v/v Tween (6), saline-sodium citrate (SSC) buffer (7), 
phosphate/NaOH 50 mM pH 8.5 buffer (8) and NaOH 10 mM (9). Dissolution of (3) led to absence of IRIS 
signal on the chip while (9) yielded the best immobilization. (b) Quantification of immobilized density of 
casein for all conditions. (c) Quantification of fluorescence after incubation with a polyclonal anti-casein 
antibody from sheep (lng/mL) followed by invuation with an anti-sheep IgG antibody labeled with Cy3 for 
fluorescence detection. As expected, (9) yielded highest fluorescence intensity. Figure reproduced from 
[55]. 
interferometric signal on the chip whereas condition (9) provided the highest signal with 
an acceptable spot morphology. The quantification of the amount of casein immobilized 
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in the different conditions (expressed as ng/mm2) is reported in Figure 21 b, showing that 
dissolving and spotting casein in NaOH 10 mM, condition (9), provided more than 
1ng/mm2 immobilized protein on copoly(DMA-NAS-MAPS) coated Si/Si02 slides. The 
array was then incubated with a polyclonal anti-casein antibody from sheep (lng/mL) 
followed by incubation with an anti-sheep IgG antibody labeled with Cy3 for 
fluorescence detection. The quantification of detected fluorescence signals is shown in 
Figure 21 c; as expected, condition (9) provided the highest fluorescence intensity 
confirming that, among the tested conditions, dissolution of casein in NaOH 10 mM 
yields the highest amount of protein available in spotting solution and an efficient 
immobilization environment. 
3.3.3 Optimization of protein immobilization conditions 
Broad ranges in physiochemical properties between proteins cause various ideal 
conditions, such as optimal pH to favor binding, use of detergent or additives to optimize 
spot morphology and to keep structure and /or activity, for immobilization. The absolute 
amount of immobilized protein provides critical, though not sufficient, information 
during the development of an assay based on a protein array and also valuable 
information when checking the consistency of the derived data. The amount of protein 
immobilized on copoly(DMA-NAS-MAPS) coated Si-Si02 slides using spotting buffers 
with different pH values was studied. In Figure 22a, an IRIS image of different proteins 
bound to the surface is shown. In these experiments rabbit IgG, carbonic anhydrase, 
bovine serum albumin, ovalbumin, ~-lactoglobulin B, a-lactalbumin and lysozyme were 
spotted at a concentration of 1 mg/mL in borate pH 9 buffer, PBS pH 7.2 and EACA-
58 
acetate pH 4.4 buffer. After one night of incubation in a humid chamber, the surface was 
washed and the unreacted sites were blocked as reported in the experimental section. The 
surface was then imaged and the amount of immobilized protein quantified. The amount 
of protein immobilized in each pH condition (expressed as ng/mm2) is shown in Figure 
22b. Reproducibility of protein binding within the same buffer condition is in line with 
microarray typical result variability. Alkaline conditions (borate buffer pH 9) gave the 
highest yield of immobilization and reproducibility for each of the seven proteins used in 
this study; this is probably due to the fact that in basic pH the reaction between the 
protein amino groups and the N-hydroxysuccinimide ester of the polymeric coating is 
favored. In general, immobilization in neutral (pH 7 .2) conditions provided higher yield 
and binding reproducibility than in acidic ones. 
59 
a 
b 1•1,00 
12,00 
10,00 
N 8,00 
E 
E 
0, 
c: 
6.00 
4,00 
2.00 
0,00 
1 Rabbit lgG 
2 Carbonic anhydrase 
3BSA 
40valbumln 
5 Beta-lactoglobulin 
6 Alpha-lactalbumin 
7 Lysozyme 
1 2 
• pH 4,4 
3 4 5 6 
A buffer pH 9 
B PBS, pH 7.2 
C buffer pH 4.4 
7 
Figure 22. (a) IRIS imaging of the 500nm oxide island spotted with various proteins immobilizated in 
different buffers. (b) Quantification of immobilized protein (ng/mm2). Alkaline buffer yielded optimal 
immobilization for all proteins. Figure reproduced from [55]. 
Investigation of the LOD for three of the seven food allergens ( ovoalbumin, f3-
lactoglobulin B, a-lactalbumin) was also studied. The aim of this label free/fluorescence 
assay was to relate the activity of the antigen upon immobilization with its actual amount 
on the surface. The data facilitates estimation of the fraction of proteins that are 
recognized by their solution target. This fraction depends on how proteins are exposed 
and their structure maintained. The chips were incubated with different concentrations of 
anti-ovoalbumin, anti-f3-lactoglobulin Band anti-a-lactalbumin policlonal antibodies 
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followed by incubation with a fluorescent secondary antibody. A calibration curve 
reporting the fluorescent intensities obtained upon incubation with the specific antibodies 
in the picogram/mL range was built for each protein. The minimum concentration of 
specific antibody tested was 2ng/mL for anti-!3-lactoglobulin Band anti-a-lactalbumin 
and 4 ng/mL for anti-ovoalbumin. For each protein, the specific antibody LOD was 
extrapolated from the fluorescent value corresponding to the blank sample plus three 
times the standard deviation. For all the specific antibodies tested we obtained very low 
LODs (in the picogram/mL range) due to the fluorescence enhancement of the 1 OOnm 
silicon oxide layer. The values ofLOD for each antibody, depending on the 
immobilization conditions of the capture protein, are reported in Table 2. 
Table 2. LOD determined for specific antibodies (pg/rnL). Reproduced from [55] . 
Limit of detection (LOD) determn1ed for protein specific antibodies in pg/mL 
Immobilized proteins Immobilization conditions 
pH4.4 pH 7.2 pH9 
13-Lactoglobulin B 6 3 60 
a -Lactalbumin 67 57 232 
Ovoalbumin 25 37 28 
Despite the higher amount of immobilized protein at pH 9, alkaline 
immobilization produces a less sensitive LOD for f3-lactoglobulin Band a-lactalbumin 
specific antibodies compared to neural or acidic immobilization. This is because higher 
fluorescence is measured in the blank samples, which is caused by nonspecific interaction 
of the fluorescent secondary antibody when proteins are immobilized in alkaline 
conditions. In sandwich assays, specificity of the secondary antibody is of great 
importance in determining the actual LOD of an assay because it directly influences the 
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signal provided by the blank samples. 
3.4 Conclusions 
Awareness of the actual immobilization yield for different proteins in distinct 
immobilization conditions facilitates development of consistent protein chips. The 
absolute amount of immobilized material is valuable information when developing 
protein microarrays; together with activity of the immobilized proteins and specificity of 
the secondary antibodies it will ultimately determine the sensitivity and reproducibility of 
protein microarrays. We also briefly discussed the ability to increase bioassay sensitivity 
by designing layered substrates to enhance fluorescence emission compared to glass 
substrates based on the dipole emission model. 
The new silicon biochip for dual label-free and fluorescence detection proposed 
here can be of high practical utility during the microarray assay development process. It 
allows, in a single experiment, performed on the same surface chemistry, to check 
spotting consistency, to optimize solubilization and binding conditions for the different 
proteins and to relate these data to the fluorescence of the final bioassay with sensitivity 
in protein detection down to the pg/mL range. Without altering the standard microarray 
protocol, the new tool can be implemented in a routine use as an internal quality control 
for protein array production. 
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Chapter 4 
CALIBRATED FLUORESCENCE ENHANCEMENT (CAFE) METHOD TO QUANTIFY 
ALLERGEN-SPECIFIC IGE 
Some of the text is reproduced with permission from M. Monroe, A. Reddington, 
A. Collins, C. LaBoda, M. Cretich, M. Chiari, et al., "Multiplexed Method to Calibrate 
and Quantitate Fluorescence Signal for Allergen-Specific IgE," Analytical Chemistry, 
vol. 83, pp. 9485-9491, 2011 [31]. Copyright 2011 American Chemical Society. 
Using a microarray platform for allergy diagnosis allows for testing of specific 
IgE sensitivity to a multitude of allergens, while requiring only small volumes of serum. 
However, variation of probe immobilization on microarrays hinders the ability to make 
quantitative, assertive, and statistically relevant conclusions necessary in 
immunodiagnostics. To address this problem, this chapter describes a calibrated, 
inexpensive, multiplexed, and rapid protein microarray method that directly correlates 
surface probe density to captured labeled secondary antibody in clinical samples. We 
have identified three major technological advantages of our Calibrated Fluorescence 
Enhancement (CaFE) technique: (i) a significant increase in fluorescence emission over a 
hroad range of fluorophores on a layered substrate optimized specifically for 
fluorescence; (ii) a method to perform label-free quantification of the probes in each spot 
while maintaining fluorescence enhancement for a particular fluorophore; and (iii) a 
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calibrated, quantitative technique that combines fluorescence and label-free modalities to 
accurately measure probe density and bound target for a variety of antibody-antigen 
pairs. In this paper, we establish the effectiveness of the CaFE method by presenting the 
strong linear dependence of the amount of bound protein to the resulting fluorescence 
signal of secondary antibody for IgG, ~-lactoglobulin, and slgEs to Ara h 1 (peanut major 
allergen) and Phl p 1 (timothy grass major allergen) in human serum. 
4.1 Irreproducibility of protein micro arrays 
The main advantages of these microarray in vitro diagnostics resides in the 
inherent capability to quantify slgE using only 10-100 ml of serum per test and to better 
characterize allergen sensitization by measuring specific IgE to the component major 
allergens of a crude allergen extract ( CRD) [ 64]. However, two specific shortcomings 
exist with this technology. First, the typical microarray chips utilize assays with probes 
placed directly on a simple glass slide. In this configuration, the presence of a high index 
solid substrate (glass) in the immediate vicinity of the fluorophores reduces the 
fluorescence yield. Simple layered structures offer an inexpensive alternative to 
overcome the limitations imposed by glass slides and provide significant signal 
enhancement [54]. Second, the more important limitation is related to the difficulty in 
obtaining quantitative results in conventional fluorescence based microarray tests. This 
difficulty arises from the variability in the amount of immobilized allergens that affects 
specific IgE capture and quantitation [64-66]. As a result, fluorescence detection on 
typical glass (Si02) slides- the "gold-standard" technique used in microarrays - has 
limited sensitivity and may yield inaccurate results. These inadequacies can cause 
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underestimation or failure of detection for captured targets [62] and concurrently yield 
unreliable clinical results [ 67 -69]. 
Variability in microarray technology in general has become an essential concern 
in producing reliable data not only due to the technical variation, such as array printing, 
sample processing, analytes, plate, or person, but also due to the inherent nature of 
proteins themselves [70-72]. Label-based procedures have been developed to account for 
this variation in probe deposition and binding to the surface in order to visualize the 
printed slides prior to experimentation [60, 73]. Although these techniques verify the 
presence ofuniformly bound probe, they may negatively affect the activity of the probe, 
fail to quantify amount of bound probe on surface, and alter physiochemical properties. 
Recently, an approach that utilizes a photonic crystal biosensor surface and a high 
resolution label-free imaging detection instrument to formulate prehybridization images 
of spotted nucleic acid array was recently reported as a sensitive method of quality 
control [63]. Aside from being demonstrated only for DNA microarrays, this quality 
control method merely bins the spot as being suitable or unsuitable for analysis and does 
not offer the quantified amount of bound probe relative to secondary antibody (i.e. 
fluorescence). Although a variety of techniques have attempted to advance quality 
assurance of micro array technologies, a need for quantitative assessment providing 
calibrated microarray measurements still remains. 
To address these issues, we have integrated our label-free technology, the IRIS-
a quantitative, high-throughput, simple, robust, and versatile technology used for 
multiplexed detection of DNA and proteins with high sensitivity comparable to SPR 
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(Surface Plasmon Resonance) [20, 7 4-7 6] - with a new enhanced fluorescence 
technology to develop the Calibrated Fluorescence Enhancement (CaFE) method [77]. 
By combining the sensitivity of fluorescence with the quantitative nat-ure of IRIS, the 
CaFE method addresses microarray reproducibility issues by (1) quantifying the probe 
amount with IRIS, (2) measuring the enhanced fluorescence signal generated by labeled 
secondary antibodies, and (3) calibrating the fluorescence signal utilizing the quantitative 
assessment of the spots by IRIS. While this technique is broadly applicable to a variety of 
ligand-analyte based microarray platforms, it is particularly effective for allergy chips. 
Detection of slgE molecules necessitates the use of secondary antibodies to distinguish 
them from the large amount of physiologic slgG molecules that bind to the probe but are 
not indicative of allergic sensitization. The additional quantification challenge imposed 
by the large variability of immobilized probe density makes in vitro allergy diagnostics a 
perfect candidate for the demonstration of CaFE technology proof-of-concept. 
4.2 Design of a platform for enhanced fluorescence emission and calibration 
measurement for intra- and inter- chip variability 
A variety of layered structure designs could be used to achieve fluorescence 
enhancement for DNA and protein microarray applications [78-82]. In this paper, we 
choose to implement a simple oxide on Si structure due to its low-cost and well-
established characteristics. Our primary design parameters include wavelength range for 
fluorescence enhancement and label-free detection accuracy. We have designed two 
types of sample platforms for enhanced fluorescence and label-free protein sensing. For 
design optimization we used the dipole emission model [43, 83] to simulate fluorophore 
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emitters near a dielectric interface on a layered structure. Details of modeling for the 
label-free sensing by IRJS technology can be found in Daaboul et al. 2011 and Chapter 2. 
Platform-·1 consists of two areas of SiOz, one optimized specifically for label-free and the 
other optimized for fluorescence sensing (500nm for IRJS and 100nm for enhanced 
fluorescence [75, 77, 84]), and has been designed to enhance a broad emission range of 
fluorophore wavelengths. Recently, this combined chip was shown to be of high practical 
use during the assay development process [55]. Label-free sensing was utilized to image 
arrays prior to incubation with labeled antibodies to assess the robustness of the array and 
to quantify the amount of immobilized probes. Via this method, fluorescence 
measurements on the same chip yielded calibrated bioassay results in a single experiment 
[77]. However, this platform relies on uniformity and repeatability within a chip since 
label-free and fluorescence measurements are performed on two separate parts of the 
same chip. Platform-2 consists of a silicon chip with a single oxide thickness optimized 
for single spot enhancement of a particular fluorophore(s) and label-free analysis. In this 
new configuration, each spot is measured with both fluorescence and label-free 
modalities, and hence calibrated, effectively accounting for spot-to-spot variation 
commonly reported in microarrays. For both platforms, regardless of having single or 
multiple regions, the top layer is oxide and thus chemical surface preparation is identical. 
This feature allows the use of specialized polymeric coatings (copoly(DMA-NAS-
MAPS) [13, 85] to covalently link capture agents to the surface, while maintaining high 
functionality and preventing non-specific binding. Therefore, the self-calibrated CaFE 
platform offers an opportunity for quantitative assessment of allergy chips which uses 
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labeled secondary antibodies to detect captured IgE by integrating both label-free and 
fluorescence measurements. 
4.3 Materials and methods 
4.3.1 Platform design simulations 
Structure optimization is defined as the oxide thickness on Si that yields intensity 
enhancement across fluorescence emission wavelengths of interest and performs label-
free sensing with high accuracy. These simulations address two goals regarding oxide 
thickness design and optimization: (1) Platform-! (called CaFE chip) should yield 
emission enhancement for maximum coverage of wavelengths while performing label-
free sensing on a separate spot on the same chip and (2) Platform-2 maintains emission 
enhancement for a limited wavelength range (covering 1 or 2 fluorophores) while 
allowing for accurate calibration of the same spot using IRIS. Platform design for Cy3 
and Cy5 emission enhancement was chosen due to their extensive use in microarrays to 
study the ratio of expression of genes from two sources [86-90]. 
To investigate the effect of oxide thickness on fluorescence intensity, the dipole 
emission model [43, 83] was used to simulate fluorophore emitters near a dielectric 
interface on a layered Si02-Si structure. Simulations were carried out for oxide 
thicknesses ranging from lnm to 1 OOOnm over the entire visible wavelength range to 
select the optimized oxide thickness for each of the two platforms described above. In 
Figure 23a, we plot the wavelength dependence offluorescenc e intensity for two specific 
oxide thicknesses in comparison to a glass substrate along with typical spectra of 
fluorophores that are commonly used as labels in bioassays (Alexa Fluor®359, Alexa 
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Fluor® 488, Cy3 dye, Cy5 dye, and Alexa Fluor® 647). The initial optimization is 
performed assuming a collection angle of0.7. For a practical fluorescence collection 
system the numerical aperture (NA) is large (typical values around 0.5 to 0.7) [91] and 
hence the theoretical enhancement calculations should consider the dependence on NA. 
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Figure 23. (a) Simulations model the theoretical fluorescence of lOOnm oxide, 320nm oxide, and glass at 
normal incidence as a function of emission wavelengths. From left to right, the emission spectra of 
commonly used fluorophores (Alexa Fluor® 359, Alexa Fluor® 488, Cy3 dye, Cy5 dye, and Alexa Fluor® 
647). (b) Fluorescence emission enhancement ofCy3 for lOOnm and 320nm oxide is two-fold compared to 
glass at NA=0.7. (c) Normalized reflectivity curves for 500nm oxide and 320nm oxide are fitted to 
illumination wavelengths used in IRIS. (d) The CaFE method is performed and compared for both chip 
platforms. Reproduced from [31]. 
In Figure 23b, the NA dependence of emission enhancement of Cy3 is plotted and the 
two optimized designs are compared at typical NA values. 
The CaFE verification of fluorescence measurement is described in Supplemental 
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Materials and details on label-free detection using IRIS have been described [75]. As 
previously reported, 500nm oxide on Si is optimal for IRIS sensing because the spectra of 
three of the LEDs (455nm, 525nm, and 632nm) sample the linear region of the curve 
while the yellow LED (598nm) helps determine the amplitude of the curve over one 
period. Because the linear region falls on the inflection point of the curve, any small 
change in height, or biomass accumulation, will be detected. To check for label-free 
sensing capability for the oxide thickness chosen for emission enhancement of Cy3/Cy5 
fluorophores (goal-2), we generated an additional reflectivity curve at this oxide 
thickness as a function of illumination wavelengths and compared it to the curve 
produced from 500nm oxide (Figure 23c). 
Figure 24. CaFE chip with immobilized proteins. 
Finally, to verify the results of the simulations with experimental data, platform-1 (CaFE) 
chips and platform-2 (320nm) chips were fabricated as seen in Cretich and Reddington, et 
al., 2011 (Figure 24) [55]. An experiment described inJgG Calibration was performed on 
each platform to validate the accuracy oflabel-free detection and enhancement of 
fluorescence (Figure 23d). 
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4.3.2 Reagents and equipment 
TRIS, BSA, Tween 20, PBS tablets, rabbit immunoglobulin G, carbonic 
anhydrase, bovine serum albumin were purchased from Sigma (St. Louis, MO). Rabbit 
anti-~-lactoglobulin was purchased from Bethyl Laboratories (Montgomery, TX), goat 
anti- a-lactalbumin from GeneT ex Inc (Irvine, CA) and AbCam (Cambridge, UK). 
Secondary antibodies (Cy3-labelled goat anti-mouse IgG and mouse anti-goat IgG) were 
purchased from Jackson ImmunoResearch (West Grove, PA) and anti-IgE was purchased 
from BDBioscences. Allergens Bet v la (Bet v 1.0101), Phl p 1 (Phl pl.0101), Phl p 5 
(Phl p 5.0101) and Alta 1 (Alta 1.0101) were recombinant allergens from Biomay, 
(Vienna, Austria) and allergens Bet v 2 (Bet v 2.0101), Phi p 7, nDer p 1, nDer p 2 and 
nFel d 1 were recombinant (or native, when prefix ''n" is used) allergens from Indoor 
Biotechnologies Ltd (Warminster, UK). · 
4.3.3 Si/Si02 coating by copoly(DMA-NAS-MAPS) 
Si/Si02 slides were immersed for 30 minutes in a solution of copoly(DMA-NAS-
MAPS) at 1% wN concentration in a solution of deionized water and 20% saturated 
ammonium sulphate. Slides were washed with water and dried at 80°C for 15 minutes. 
This polymeric coating was chosen for our CaFE chips due the feasibility and 
reproducibility of its synthesis and coating process. This particular polymeric coating 
does not change the optical properties of the setup. 
4.3.4 Proof of concept of CaFE using lgG and P-lactoglobulin 
To demonstrate the universal application of the CaFE method, we have performed 
the quantification and conelation of captured IgG and ~-lactoglobulin probe to 
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fluorescence signal of Cy3-labeled-secondary antibody. For these experiments, we utilize 
the CaFE chip platform to optimize for all fluorophores and achieve maximum sensitivity 
on the IRIS device. IgG and ~-lactoglobulin proteins were chosen due to their well-
established spotting protocols and reliable spotting morphologies. 
4.3.4.1 IgG Calibration 
As proof of concept, 20 replicates IgG of varying concentrations (0.015, 0.03, 
0.063, 0.125, 0.25, and 1 mg/ml) were spotted onto 2 CaFE chips. After overnight humid 
chamber incubation, the chips were washed with 50 mM ethanolamine in TRIS/HC11 M 
pH 9 for 1 hour, rinsed with water, dried with a stream of argon gas, and then measured 
using IRIS. They were then incubated with 100 Jll of specific labeled antibody in 
incubation buffer (Tris/HCl 0.05 MpH 7.6, NaCl 0.15 M, Tween 20 0.02%) with 1% w/v 
BSA for 1 hour at 1 Jlg/ml. Another IRIS measurement was taken after washing with 
PBS for 10 min, rinsing with water, and drying with argon. 
Fluorescence evaluation was performed by a fluorescence scanner using 40% PMT and 
33% laser power for maximal fluorescence value without saturation. Mean fluorescence 
intensity and standard error from all 20 spots is depicted. 
4.3.4.2 p-Iactoglobulin calibration 
To model a sandwich assay similar to the allergen immunoassay and to 
demonstrate the versatility of the CaFE method, 20 replicates of ~-lactoglobulin of 
varying concentrations (0.015, 0.03, 0.063, 0.125, 0.25, and 1 mg/ml) were spotted onto 3 
CaFE chips, and after overnight humid chamber incubation, the CaFE chips were washed 
with 50 mM ethanolamine in TRIS/HCI 1 MpH 9 for 1 hour, washed with water, dried 
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with a stream of argon gas, and then measured using IRIS. The chips were then 
incubated with 100 m1 of specific antibody in incubation buffer with 1% w/v BSA, for 2 
hours at 10 ng/ml. Slides were then washed with washing buffer (Tris/HCl 0.05 MpH 9, 
NaCl 0.25 M, Tween20 0.05%) for 10 minutes, rinsed with water, and dried with argon 
gas. The chips were then incubated with 100 J..ll of the solution of the specific labeled 
secondary antibody 1 J..tg/mL in incubation buffer for 1 hour. Slides were then washed 
with PBS for 10 minutes, rinsed with water, dried with argon, and measured with IRIS. 
Fluorescence evaluation was performed using 90% PMT and 90% laser power for 
maximal fluorescence value just below saturation. Mean fluorescence intensity and 
standard error were plotted for the 20 replicate spots. 
4.3.4.3 CaFE Implemented as an Allergy Testing Platform 
To evaluate CaFE as a clinical diagnostic platform, 2 major allergens (peanut 
(Ara h1), timothy grass (Phi p1) were spotted in replicates of3 at 4 concentrations (0.25 
mg/ml, 0.5 mg/ml, 0.75 mg/ml, and 1.0 mg/ml) on 2 CaFE chips. In addition, PBS and 
IgG were spotted as negative and positive control parameters. After overnight humid 
chamber incubation, the chips were washed with 50 mM ethanolamine in TRIS/HCI 1 M 
pH 9 for 1 hour, washed with water, dried with a stream of argon gas, and then measured 
using IRIS. The chips were then incubated with 100 ul of patient serum with documented 
allergy to peanut (specific IgE 19.40 kU/L, Phadia ImmunoCAP) and timothy grass 
(positive allergen skin prick test) in incubation buffer with 1% w/v BSA, for 2 hours at 
10 J..tg/ml. (Subject recruitment was approved by the Boston University Medical Campus 
Institutional Review Board, Protocol H-29428). Slides were then washed with washing 
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buffer for 10 minutes, rinsed with water, and dried with argon gas. After incubating with 
1 ng/ml anti-IgE labeled with Cy3, the chips were washed with PBS (10 min), rinsed with 
water, dried with argon, and measured with IRIS. 
Scanning for fluorescence evaluation was performed. CaFE slides were analyzed 
using 90% PMT and laser power to maximize the signal-to-noise ratio without pixel 
saturation. Mean fluorescence intensity is depicted. 
4.4 Results and discussion 
4.4.1 Platform Design Simulations 
After running the radiation model of emitters near a dielectric interface, a 1 OOnm 
oxide thickness yielded emission enhancement for maximum coverage of wavelengths, 
and a 320nm oxide thickness yielded enhancement for emission wavelengths of Cy3 and 
Cy5 fluorophores (Figure 23a). This enhancement effect is a result from the interference 
of the emission wavelength reflected at the oxide-silicon interface and the air-oxide 
interface. The oxide thickness serves as a spacer in which emitted light is reflected at the 
air-oxide interface and refracted through the oxide layer. The refracted light travels 
through the spacer layer and is then reflected by the silicon layer. Depending on the 
wavelength of the emitted light, the thickness of the spacer will determine which 
wavelengths undergo constructive or destructive interference. Using this method, we 
designed two layered structures: (1) a 100nm Si02layer on Si that yields enhancement 
for maximum coverage of wavelengths and (2) a 320nm Si02layer on Si that maintains 
fluorescence enhancement for Cy3 and Cy5 fluorophores . 
In Figure 23b, the NA dependence of emission enhancement of Cy3 is graphed 
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and the two optimized designs are compared. At low NA, a 1 OOnm oxide thickness yields 
a greater enhancement effect compared to a 320nm oxide layer. As the collection angle 
increases, the enhancement effect decreases because higher angles do not tmdergo 
complete constructive interference due to the increase in optical path length through the 
spacer region. The enhancement values converge as a greater percentage of the reflected 
emission is collected. When comparing the platforms at the typical NA used in 
fluorescence scanners (NA=0.7), both platforms yield a two-fold emission enhancement 
of Cy3. Furthermore, the enhancement produced by 1 OOnm Si02 is only 1.04 times 
greater than the enhancement yielded by 320nm Si02. Based on these results, designing a 
chip with 1 OOnm oxide on Si would enhance all wavelengths of commonly used 
fluorophores and constructing a chip with 320nm oxide on Si would maintain 
enhancement for Cy3 and Cy5 fluorophores. 
In Figure 23c, normalized reflectivity curves as a function of illumination 
wavelength are generated for both platforms and compared. Because the rate of change 
with wavelength is slightly slower in the 320nm oxide compared to the 500nm oxide, the 
illumination wavelengths intersect the curves at slightly different locations. As a result, 
the spectra of the LEDs now sample the 320nm reflectivity curve close to the minima and 
maxima regions. Although none of the LEDs fall directly on the inflection point of the 
graph, the green and yellow LED sample above and below the linear region, helping to 
define the slope of the curve and determine the reflectivity profile of a 320nm oxide on 
Si. These reflectivity comparisons suggest that IRIS measurements on a 320nm oxide are 
feasible; however, a reduction in level of detection and sensitivity may occur. 
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Fluorescence simulations and IRIS reflectivity curves facilitated the design of two 
platforms: (1) a CaFE chip with one area of lOOnm oxide on Si for fluorescence 
enhancement coverage over all visible wavelengths and au area of 500nm for sensitive 
label-free biosensing and (2) a 320nm oxide on Si chip that maintains fluorescence 
enhancement of Cy3 and Cy5 fluorophores and operates with IRIS. These designs were 
tested and compared by conducting the IgG calibration experiments on each platform 
(Figure 23d). As expected, the CaFE chip yields a higher fluorescence signal and slightly 
better sensitivity compared to the 320nm oxide chip. Standard deviation is also higher on 
the 320nm oxide chip, and the measurement was not able to detect the lowest spotting 
concentration (0.015 mg/ml). Based on this data, the radiation model of emitters and IRIS 
reflectivity curves helped design two dual modality platforms that optimize for enhanced 
fluorescence of one or more wavelengths and quantify biomass accumulation, label-free. 
' . 
4.4.2 Proof of Concept of Quantification and Calibration of CaFE using IgG and 
P-lactoglobulin 
Images of both label-free measurements (Figure 25a) and fluorescence 
measurements (Figure 25b) show a gradient that correlates with varying concentration of 
immobilized rabbit IgG and captured Cy3-anti-rabbit IgG. The fluorescence enhancement 
of the 1 OOnm oxide islands is noticeable when compared to the 500nm oxide island. 
Similar effects are seen in the P-lactoglobulin array but are not shown. 
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Figure 25. Label-free IRIS image of varying concentrations of rabbit IgG on a 500nm island of Platform-
l(CaFE) chip. (b) Fluorescence image of spotting array on CaFE chip for varyi.ng concentrations of 
captured Cy3-anti-rabbit IgG. CaFE measurement for rabbit IgG (c) and 13-lactoglobulin (d) . Error bars 
represent the standard deviation of 20 spots. For IgG calibration of Chip 3, two quadrants (Ql and Q2) 
analyze on chip variability. Results show that CaFE platform yields calibrated, linear responses from chip-
to-chip for a variety of proteins. Adapted from [31]. 
Theoretically, each chip should bind the same probe density on surface. However, 
IRIS measurements show that both lgG and ~-lactoglobulin showed a large 
immobilization variation between chips resulting in varied fluorescence measurement of 
secondary antibody. Quadrant-to-quadrant variation on chip was also present in the lgG 
data. The CaFE method was then applied to fluorescence and IRIS data in order to 
quantify and calibrate specific secondary antibody for both IgG and ~-lactoglobulin 
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systems (Figure 25c and Figure 25d). In these plots, all error bars correspond to spot-to-
spot variability, while each subset shows chip-to-chip variability. In both cases, each of 
the proteins demonstrates a calibrated, str ong linear response (R2 ~ 90%) between 
fluorescence and probe density despite chip-to-chip variability. Because each protein has 
different finite binding capacities, the slopes of the CaFE curves differ. This capacity also 
may result in possible saturation point at higher concentrations. Overall, these results 
suggest that the CaFE method will be an effective and versatile platform to quantify and 
correlate bound probe to secondary labeled antibody and has potential application in 
immunodiagnostics. In addition, on-chip variation could be addressed by implementing 
Platform-2, which would assess each spot individually. 
4.4.3 CaFE Implemented as an Allergy Testing Platform 
The performance of the two chips, defmed by fluorescence signal of secondary 
IgE, varies between the allergens because different levels of IgE in serum for each 
particular allergen are present. This is confirmed with the ImmunoCAP® results (Figure 
26). When analyzing the fluorescence signal of anti-IgE in the fashion of typical ELISA 
and microarray assays, measurement variation of sigE of the same allergen between chips 
is present, particularly in Phl pl allergen (Figure 27a). The degree of chip-to-chip 
variation between allergens most likely occurs due to the physiochemical properties of 
the allergens themselves (i.e. affinity to immobilize to the surface) and technical variation 
(ie. spotting). While only slight chip-to-chip fluorescence variation is seen for Ara hl 
allergen (R2 of0.88), a significant chip-to-chip fluorescence variation is seen for Phl pl 
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Figure 26. Bar graph shows IRIS measured optical height (1nm~1ng/mm2) after allergen immobilization 
(1mg/ml) (blue), serum incubation (red), and anti-IgE (green) incubation. The table values above the bar 
graph compare bound serum (lgG+IgE) molecules (defined as allergen immobilization height subtracted 
from serum incubation height) with IRIS, fluorescence, and lmrnunoCAP ® results for each allergen. 
Agreement between CaFE (IRIS+ fluorescence) and lmrnunoCAP® is confirmed. Note: Ara h 1 anti-lgE 
bar line decreases due to probe loss. Adapted from [31]. 
allergen (R2 of0.24), despite the same conditions, reagents, and serum samples used in 
this single experiment. Based upon fluorescence data alone, it is unknown as to why Phl 
p 1 allergen chips yield different fluorescence responses. 
To account for this deviation, the CaFE method is applied to collected 
fluorescence and IRIS data. As a result, a calibrated, linear response between sigE and 
amount of allergen immobilized on surface emerges (Figure 27b ). In both Ara hl and Phl 
pl examples, the R2 value increases to at least 90%, demonstrating the higher degree of 
correlation between fluorescence signal and immobilization density compared to spotting 
concentration. Although the CaFE method only slightly improves upon Ara hl allergen 
data, the effects of including label-free IRIS measurement are dramatically seen in the 
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Phl pl data. Most importantly, use of the CaFE method clarifies that higher 
immobilization density of Phl p 1 allergen on Chip 2 results in higher fluorescence signal, 
indicating that any variation in immobilization density will affect the amount of IgE 
captured. In accordance with the literature, this data supports that high variation in 
allergen immobilization microarrays is a concerning issue. The strong linear correlation 
between fluorescence and immobilization density demonstrates the value of the CaFE 
method as an opportunity for calibrated quantitative assessment of serum slgE, and 
should improve accuracy in predicting clinical reactivity in susceptible individuals. 
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Figure 27. (a) The standard 'calibration ' of secondary antibody for diagnosis of allergy is measured as the 
degree of fluorescence as a function of spotting concentration is shown for Ara h 1 peanut allergen (left) 
and Phl p l timothy grass allergen (right) for two chips. Using the self-calibration method provided by 
CaFE (b), results show calibrated, linear responses for allergy testing analysis compared to traditional 
"semi-quantifiable" analysis in (a) . Adapted from [31 ]. 
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Finally, in order to verify that the CaFE method differentiates between allergic and non-
allergic samples, five allergens were arrayed in replicates of 3 onto a CaFE chip. This 
chip was incubated with characterized serum in which there was selective slgE. Results 
were compared to ImmunoCAP® or skin test characterization (Figure 26). 
4.5 Effect of substrate design on fluorescence enhancement 
Fluorescence enhancement on a layered Si02-Si substrate compared to 
conventional glass substrates was shown to be tunable for 1) user-specified flourophore 
emission wavelength and 2) NA in Platform Design Simulations (Figure 23a and Figure 
23b ). Figure 28 shows the effect of oxide thickness on silicon on fluorescence intensity 
normalized by the fluorescence intensity calculated for glass substrates for Cy3 and Cy5 
fluorophores. This figure shows that 11 Onm and 320nm oxide will yield maximum 
constructive interference compared to glass substrates for these two fluorophores. Similar 
simulations can be constructed for any fluorophores, as described in Platform Design 
Simulations. 
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Figure 28. Effect of oxide thickness on silicon substrate compared to glass substrate on Cy3 and Cy5 
emission (NA=0.7). Simulations used the dipole emission model to generate figure. 
4.6 A dual label and label-free microscope to self-calibrate fluorescence 
microarrays 
In this chapter we have motivated the need for a quantitative and calibrated 
method to account for variation in fluorescence protein microarrays. The CaFE method 
was successfully shown to use the IRIS biomass measurement in conjunction with a 
fluorescence scanner to address this concern; however, it uses two separate instruments 
which may be unsuitable in the clinical setting. The combination of IRIS and 
fluorescence microscopy creates an opportunity to reduce microarray variability by 
calibrating the signal to immobilized probe in a single instrument. In this section, a 
platform for sensitive and calibrated microarray measurements is introduced. This dual 
modality platform performs CaFE measurements by merging an IRIS and a wide-field 
fluorescence microscope. 
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Figure 29. The CaFE instrument combines IRIS and fluorescence microscopy in a single instrument. 
The instrumental design and operation are out of the scope of this dissertation and 
are currently being finalized. 
4. 7 Conclusions 
We have designed two platforms- (1) a chip with multiple sections to optimize 
label-free measurement and fluorescence over a broad range of wavelengths and (2) a 
silicon chip that has been engineered specifically for the enhancement of a particular 
fluorophore and is operational in the label-free modality and allows for calibration of the 
same spot - to create a calibrated fluorescence enhancement, or CaFE, method that 
improves upon quality and quantity control in microarrays. In our experiments, we utilize 
one of the two platforms, the CaFE. chip, to demonstrate that the correlation between the 
fluorescence signal and immobilized probe density is linear despite chip-to-chip variance. 
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We also show that these experiments are repeatable on a single oxide thickness platform. 
Without the ability to quantify the amount of capture probes (major allergens), the typical 
assay quality control would be limited to controlling the spotting conditions, i.e., the 
intended concentration of the probes. Thus, the CaFE method is an effective, self-
calibrated, multiplexed and sensitive platform and offers technological advances that are 
not currently or readily available. 
4.7.1 Future work 
A self-calibrated fluorescence enhancement platform would enable laboratories to 
greatly enhance the value of their growing protein microarray segment. Currently no 
solution of technique exists that explicitly offers solutions for quality assurance in protein 
microarray manufacturing. Current quality control methods employed by protein 
microarray manufacturers use a fluorescence-based, multi-step process with a 
representative sacrificial microarray from each batch. In order assess the fabrication 
quality of every microarray without sacrificing reagents and resources, it is necessary to 
utilize a label-free detection method to analyze the immobilized probe density on the 
surface. The CaFE method offers these advantages by providing quality control on every 
microarray slide 1) without additional resources and reagents and 2) not compromising 
the functionality of the slide. 
While this system improves quality control standards in the laboratory setting, it 
is not applicable as a POC allergy diagnostic because it only operates in serum and 
utilizes fluorescence labels to detect specific IgE. The use of fluorophores for antigen 
detection has failed at the POC setting due to its 1) 'sticky' properties which cause it to 
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non-specifically attach to various components in whole blood [35] and 2) variation in 
microarray technology. In order to deliver a platform that will be feasible for a variety of 
clinical applications, including POC, the diagnostic platform must utilize a strategy that 
will detect targets in unprocessed whole blood samples, requiring zero sample 
preparation. Furthermore, the platform must be fully integrated, automated, and deliver 
an accurate, reliable, easy-to-interpret readout. Chapter 5 and Chapter 6 approach these 
concerns by discussing assay development to detect slgE in unprocessed whole blood 
using gold nanoparticle labels attached to secondary antibodies. 
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Chapter 5 
SINGLE NANOPARTICLE DETECTION FOR MULTIPLEXED PROTEIN DIAGNOSTICS WITH 
ATTOMOLAR SENSITIVITY IN SERUM AND UNPROCESSED WHOLE BLOOD 
Some of the text is reproduced with permission from M. R. Monroe, G. G. 
Daaboul, A. Tuysuzoglu, C. A. Lopez, F. F. Little, and M.S. Unlu, "Single nanoparticle 
detection for multiplexed protein diagnostics with attomolar sensitivity in serum and 
unprocessed whole blood," ed. Analytical Chemistry, Vol. 85, No.7, 2013, pp. 3698-
3706 [45]. Copyright 2011 American Chemical Society. 
Although biomarkers exist for a range of disease diagnostics, a single low-cost 
platform exhibiting the required sensitivity, a large dynamic-range and multiplexing 
capability, and zero sample preparation remains in high demand for a variety of clinical 
applications. In this chapter, IRIS was utilized to digitally detect and size single gold 
nanoparticles to identify protein biomarkers in unprocessed serum and blood samples. 
IRIS is a simple, inexpensive, multiplexed, high-throughput, and label-free optical 
biosensor that was originally used to quantify biomass captured on a surface with 
moderate sensitivity. Here we demonstrate detection of B-lactoglobulin, a cow's milk 
whey protein spiked in serum (> 10 orders of magnitude) and whole blood (>5 orders of 
magnitude), at attomolar sensitivity. To our knowledge, this level of sensitivity over a 
large dynamic range has not been previously demonstrated. 
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IRIS offers four main advantages compared to existing technologies: it i) detects proteins 
from attomolar to nanomolar concentrations in unprocessed biological samples, ii) 
uuambiguously discriminates nanoparticles tags on a robust and physically large sensor 
area, iii) detects protein targets with conjugated very small nanoparticle tags ( ~40nm 
diameter), which minimally affect assay kinetics compared to conventional microparticle 
tagging methods, and iv) utilizes components that make the instrument inexpensive, 
robust, and portable. These features make IRIS an ideal candidate for clinical and 
diagnostic applications. 
5.1 Clinical need for high sensitivity biomarker detection over a large dynamic 
range in unprocessed whole blood 
Highly sensitive, quantitative, and multiplexed biomarker detection is a crucial 
focus for the technological development of next generation diagnostics [92]. Biomarkers 
are successful identifiers of diagnosis and prognosis in a variety of diseases from cancer 
to allergy. For example, nearly an 80% total decrease in cancer mortalities for colorectal, 
female breast, and prostate cancer have been largely due to improvements in early 
detection and treatment [32] : Likewise, determination of systemic sensitization to specific 
allergens has been established as the primary method to guide trigger avoidance [33, 93]. 
Although protein biomarkers are known for a range of diseases, current multiplexed 
protein biosensors are subject to limitations: i) the absence of a large dynamic range 
assay to accurately detect all clinically relevant concentrations of a variety of biomarkers 
[94] (See Table 3 for a partial list which expands over 5 orders of magnitude), ii) the 
inability to screen for a panel of biomarkers, versus a single biomarker, for reliable 
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disease detection and monitoring [95, 96], iii) the challenge of maintaining sensitivity 
and specificity in unprocessed whole blood or minimally prepared serum samples [18], 
and iv) the need for the biosensor platform to be robust, portable, and versatile [17]. 
Table 3. Partial list of healthy levels of protein biomarkers in serum [1, 94]. Figure reproduced from (45]. 
I I 
Prostate cancer PSA 29.4 
IL-8 22.5 
Breast cancer IL-8 22.5 
HER-2 57.1 
VEGF 2.14 
Oral cancer IL-6 129.3 
Head/neck carcinomas p53 6.6 
Lung, thyroid, kidney, VEGF 2.14 
bladder, ovarian cancers 
Pancreatic, uterine, CEA O.ol 
stomach cancers 
Allergen sensitization Total IgE 949.4 
5.2 Conventional detection techniques to detect biomarkers in biological 
samples and their limitations 
Biomarkers in serum have been detected using a variety of transduction and 
amplification mechanisms, such as electrochemical [97, 98], mechanical [99, 100], or 
optical [101, 102] techniques; micro/nanoparticle tagging and single molecule detection 
methods are often used to achieve very high sensitivity. One particular sensing approach 
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termed the bio-barcode assay developed by Stoeva et al. uses AuNPs as secondary probes 
to detect protein targets. Once bound, the tags are additionally stained with silver to 
amplify the signal to achieve high sensitivity from the attomolar to picomolar range in a 
multiplexed format [102, 103]. Furthermore, single molecule quantification has been 
demonstrated by detecting binary events to achieve digital sensing [104, 105]. For 
example, Rissin et al. have developed a single-molecule ELISA method to detect proteins 
at subfemtomolar concentrations over 4 orders of magnitude in serum [1 05]. These 
techniques requiTe that the biomarkers of interest be within the dynamic range of the 
platform and that whole blood samples must be processed prior to testing. Moreover, 
nanoscale and complex sensing elements used in these single particle detection 
techniques may limit clinical applicability such as point of care testing [34, 35]. 
Protein detection at attomolar sensitivity in serum has also been achieved by using 
microparticles with diameters between 1-200~m attached to secondary antibodies [106]. 
While the large size of these microparticles allows for visibility in a conventionally 
acquired image, they are known to severely reduce the diffusivity (~3-4 orders of 
magnitude (Figure 30)) and thus require external force fields [107]. Moreover, once the 
microparticle tag exceeds 3 ~min diameter, the particle will settle out of solution and only 
undergo 2D diffusion and may cause the assay outcome to be inaccurate [106, 107]-. To 
maintain native kinetics of the particle-probe complex, it is crucial that the particle tag be 
on a similar size scale as the target. 
While highly sensitive protein detection methods have been achieved in serum 
samples, biomarker detection in unprocessed whole blood remains very challenging due 
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to non-specific binding of cells and particulates to the sensor surface. One approach to 
perform biosensirig in whole blood samples has been demonstrated by Stern et al., who 
have developed a microfabricated microfluidic purification chip to process 1 0~-tL of 
whole blood in 20 minutes [36]. However, this technique only achieves 500pM 
sensitivity, which is 106 times less sensitive than the techniques established for detection 
in serum. Moreover, this level of sensitivity is not pertinent to most protein biomarkers, 
whose serum concentrations in healthy individuals range between 0.01-lOOpM (Table 3). 
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Figure 30. The Einstein-Stokes equation was used to estimate the diffusivity constant of a native detection 
antibody (diameter~IOnm) conjugated to particles of various sizes. Microparticles reduce the diffusivity of 
the detection complex by 2 or more orders of magnitude and require the use of external force, which affects 
the outcome of the assay. The ability to size-discriminate nanoparticles as small as 35nm with the IRIS 
platform allows the particle tag to be on the same size scale as the target protein. Here we report secondary 
antibodies functionalized to 50nm particle tags, which only affect the diffusivity of the detection complex 
by half that of the native protein. Figure reproduced from [45]. 
5.3 IRIS single nanoparticle detection of biomarkers in biological samples 
In this chapter, we demonstrate the ability of IRIS to perform discrete detection of 
biomarkers in unprocessed whole blood samples with negligible non-specific binding 
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from the attomolar to picomolar range by discriminating 40nm AuNP tags, with 
negligible effect on binding kinetics, functionalized to secondary antibodies over a 
physically large and robust sensor surface. The IRIS technique has been first 
demonstrated for label-free, and quantitative measurements ofbiomass captured on the 
sensor surface [13, 39] and recently modified to detect single nanoparticles across a large 
sensor surface using only basic optical components: a simple, inexpensive, silicon-silicon 
oxide (Si-Si02) substrate; commercially available LEDs; and a CCD detector [21]. 
Typical optical sensors designed to detect single nanoparticles utilize micro-
fabricated devices with small surface areas [108, 109]. IRIS uses a simple planar surface 
that is easy to multiplex and does not require micro-fabricated features. Instead, IRIS 
benefits from enhanced visibility due to interference of optical field scattered from 
captured nanoparticles interfering with the reference reflection from the layered surface. 
In this imaging sensor modality, each diffraction-limited spot creates the opportunity to 
detect a single binding event on the IRIS substrate effectively yielding as many as 1 06 
parallel sensing elements with discrete detection capability [19]. 
To review, the primary differences in the total biomass quantification and single 
nanoparticle counting modalities of IRIS are the magnification of the objective, the oxide 
spacer on the substrate, and the resulting information of the image acquired by the CCD 
array (Figure 5). The first modality (low magnification) ofiRIS quantifies biomass on a 
surface by converting the intensity value of each pixel in the CCD array into an average 
optical height measurement. The second modality (high magnification) of IRIS detects, 
size discriminates and counts individual AuNP. The resulting discrete detection of 
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nanoparticle tags provides the ability to distinguish the specific binding events in 
complex solutions allowing for detection in serum and whole blood with high sensitivity. 
However, discrete detection requires that the density of nanopmi icles on the surface is no 
more than one per diffraction limited spot and thus has an upper limit in detection 
concentration. In practice, for unambiguous discrimination of individual AuNP tags from 
the background a relatively low density on the surface, less than 104 particles/mm2 is 
desirable imposing a limit on the dynamic range. While the discrete detection saturates ~t 
the high target protein concentration, the sensitivity of the low-magnification modality of 
IRIS would become sufficient and thus provide label-free total biomass quantification. 
5.4 Materials and Methods 
5.4.1 Reagents and equipment 
Bovine serum albumin (BSA), B-lactoglobulin, Tween 20, high purity 
poly( ethylene glycol-8K) (PEG), Ethylenediaminetetraacetic acid (EDTA), Heparin and 
PBS tablets were purchased from Sigma (St. Louis, MO). Rabbit anti-B-lactoglobulin was 
purchased from Bethyl Laboratories (Montgomery, TX). 40nm carboxylated gold 
nanoparticles (AuNPs) were purchased from Cytodiagnostics (Ontario, Canada). MES 
buffered saline packs, EDC (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
Hydrochloride), and Sulfo-NHS (N-hydroxysulfosuccinimide) were purchased from 
Thermo Fisher Scientific (Rockford, Illinois). Copoly(DMA-NAS-MAPS) [51] was 
purchased from Lucidant polymers. The Bio-Rad Calligrapher (Bio-Rad Laboratories, 
Inc.) was used for protein printing on chips. Fetal Bovine Serum (FBS) was purchased 
from America Type Culture Collection. Bovine and human blood was purchased from 
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Innovative Research. 
5.4.2 Substrate fabrication 
Silicon chip fabrication is described elsewhere [55]. Briefly, chips consisting of 
region of a bare silicon reference region, an oxide of 500nm, and an oxide of 1 OOnm were 
used for optimized IRIS biomass measurement (500nm) and single AuNP counting 
(lOOnm). Each oxide spacer was engineered and optimized to a specific thickness in 
order to maximize the contrast for both biomass measurement (500nm) and nanoparticle 
counting (lOOnm) on Si-Si02 substrate [19, 39]. 
5.4.3 Surface functionality 
The surface of the silicon chip was functionalized with copoly(DMA-NAS-
MAPS) [51] due to the feasibility and reproducibility of its synthesis, coating process, 
and antifouling properties. Details of the coating process is outlined in 2.3.1. 
5.4.4 Optical detection 
Two modalities of IRIS were employed in this work. The differences between the 
.. 
two IRIS modalities (total biomass measurement vs. single nan~part!Cle counting) are i) . 
the magnification of the optical imaging system, ii) the oxide spacer (500nm vs. lOOnm) 
on the Si substrate, and jii) the forward models used to interpret the response detected by 
the CCD camera. The biomass measurement and single particle modality are detailed in 
Chapter 2. The second modality of IRIS uses one discrete LED wavelength (525nm) to 
illuminate the sensor's surface using a high magnification objective (SOX, 0.8NA) to 
detect, count, and size nanoparticles ofknown material located on the Si02 surface and is 
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thoroughly described elsewhere [19, 21]. Briefly, this modality of IRIS enhances the 
contrast of a single nanoparticle on a bilayered substrate by interfering the scattered field 
produced by the nanoparticle on the substrate surface with the reflected field generated 
by the buried Si-Si02 interface of the IRIS chip. The CCD camera senses the individual 
nanoparticles on the IRIS chip as point objects, which are processed via custom software 
to extract size information. 
The optical setups of each modality of IRIS are detailed in Figure 5. 
5.4.5 Gold nanoparticle functionalization of secondary detection antibodies 
·To functionalize the AuNPs to the detection antibody, the purchased carboxylated 
40nm AuNPs were diluted to a solution containing ~ 1010 particles/mL. The particles were 
then incubated in 2:1 EDC/NHS in 0.1 MES buffer (pH 6) for 30 minutes. The particles 
were then spun down, the supernatant was removed, and the particles were exposed 
overnight to the detection antibody at 1 OJlg/mL in PBS buffer. The functionalized 
particles were then washed with 1 %BSA w/v in PBS, 0.02% Tween in PBS, and stored in 
0.1% BSAw/v, 0.1 %w/v PEG in PBS. T}lis ensemble is refered to as the detection 
complex. 
5.4.6 Verification of the size of detection complex 
The diameters of the carboxylated AuNPs pre- and post- anti-B-lactoglobulin 
functionalization were verified with Dynamic Light Scattering (DLS) technology 
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manufactured by Malvern Instruments Ltd. DLS reported the carboxylated AuNPs to be 
51nm in diameter prior to antibody functionalization and 54nm after antibody 
functionalization. To discriminate AuNPs against particulates in the IRIS images, only 
AuNPs 53±10nm were quantified as labeled secondary antibody to its target. 
5.4. 7 Protein immobilization 
Twenty IRIS chips were functionalized with the polymeric coating. Ten chips 
were printed with 8 replicates of anti-~-lactoglobulin (positive control) and BSA 
(negative control) at 1mg/mL and stored overnight at room temperature in a humid 
environment and used for testing undiluted serum. The remaining 10 chips were printed 
with 4 replicates of anti-~-lactoglobulin (positive control) and BSA (negative control) at 
lmg/mL and stored overnight at room temperature in a humid environment and used for 
testing whole blood. The chips were then washed 3 times each for 5 minutes in PBST 
and PBS buffers, rinsed with DI water, and dried with a stream of argon gas. Probe 
immobilization was then quantified with the IRIS biomass measurement. 
5.4.8 Choosing an anticoagulant for whole blood assays 
Anticoagulants are substances that prevent coagulation, or clotting, of blood. In 
these experiments, we considered EDT A and heparin as options to be used in 
experiments. Heparin is a natural biological substance which blocks thrombin from 
clotting blood and has been demonstrated to be successful in blood cloting prevention 
both in vivo and in vitro in or on medical devices. EDTA chelates Ca2+ ions, the main 
player in the coagulation cascade and has been extensively used in IVDs [11 0]. Figure 31 
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shows immobilized protein incubated in unprocessed whole blood incubated using 5mM 
EDTA and heparin anticoagulants. Based on these results, and others (data not shown), 
5mM EDTA was chosen as the anticoagulant for all unprocessed whole blood 
experiments to reduce non-specific binding. This is the concentration recommended by 
the International Council for Standardization in Hematology [110]. 
Figure 31. EDTA and heparin anticoagulants used for whole blood incubations. Images were acquired with 
IRIS using high magnification. EDT A was the chosen anticoagulant due to minimal non-specific binding of 
cells on the surface. Black dot is an image artifact. 
5.4.9 Detection of P-lactoglobulin targets spiked in undiluted serum or 
unprocessed whole blood 
5.4.9.1 Optimization of incubation time for detection complex 
To determine optimal time of incubation oflabeled secondary antibodies, 
lOOng/mL ~-lactoglobulin in serum was incubated on 4 chips printed with 1mg/mL anti .. 
~-lactoglobulin and 1mg/mL BSA (negative control) in replicates for 2 hours. 
Background images were scanned and analyzed using IRIS and custom software. Next, 
the detection complex was incubated at 1% AuNPs/mL in PBS/1% BSA for 8 for 15, 30, 
60, and 120 minutes to understand kinetics. Post incubation images were scanned using 
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IRIS and custom software detected amount binding (Figure 32). Based on these results, 
saturation of the detection complex occurs approximately at 1 hour. This time was used 
for future experiments using 1% AuNPs/mL. Occasionally 5% of 10% AuNPs/mL were 
used to 
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Figure 32. Time study for optimizing incubation of functionalized secondary antibodies specifc for B-
lactoglobulin. 
quicken experiment time. However, more characterization needs to be performed on 
these concentrations. 
5.4.9.2 Dilution curves for P-lactoglobulin in undiluted serum or unprocessed whole 
blood 
After quantification of probe immobilization density, each chip was incubated in 
lmL volume ofundiluted serum (bovine) or unprocessed whole blood (human and 
bovine) spiked with ~-lactoglobulin target antigen at 5.4fM (O.lpg/mL), 54fM (lpg/mL), 
97 
540fM (lOpg/mL), 5.4pM (100pg/mL), 54pM (lng/mL), 5.4nM (100ng/mL), and 54nM 
(1J.Lg/mL) for 2 hours. Three chips were incubated in pure undiluted serum as blanks to 
quantify any unspecific particle binding as background noise or false detection. Chips 
were then washed with PBST buffer for 10 minutes (5mM of EDT A was added for whole 
blood samples), rinsed in water, and dried with a stream of argon gas. IRIS biomass 
measurements were then taken to observe any changes in mass accumulation on chip. 
The chips were then incubated in~ 108 functionalized AuNPs/mL in 5%w/v BSA/PBS for 
1 hour, washed in PBS for 10 minutes, rinsed in water, and dried with a stream of argon 
gas. The chips were finally scanned with the IRIS single particle modality to quantify 
bound AuNPs. 
5.4.10 Elimination processes to ensure accurate detection of gold nanoparticles 
with IRIS 
IRIS nanoparticle counting software incorporates 3 elimination processes to 
ensure that point objects detected in the image are AuNP-functionalized secondary 
antibodies. First, anomaly filtering disregards any irregular points caused by the 
morphology of the protein spot. Second, a point spread function (PSF) filter disregards 
any particles on the surface that do not exhibit the expected profile of the AuNPs; the 
profile of a AuNP takes form of the point spread function of the optical system that is 
known in advance. PSF filtering is crucial: spot morphologies often contain particulates 
that may be misconstrued as false positives; thus, it is important to utilize the expected 
PSF profile to ensure accurate AuNP detection. Third, the size-discrimination feature of 
IRIS nanoparticle counting eliminates any particulates outside of the size regime of the 
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introduced AuNPs. 
5.4.11 Determination of limit of detection 
The LOD of the IRIS platform, in accordance with all measurements acquired 
with the single nanoparticle counting modality, is defined as the LOD per mm2 in serum 
and whole blood. Three chips incubated in blank serum or blank whole blood were 
grouped as a single experiment to yield 24 tests for serum (8 spots per chip) or 12 tests 
for whole blood (4 spots per chip). The background signal (AuNPs per spot) of the tests 
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' Figure 33. The normal probability plot of the background signal per test, or spot (AuNPS per mm2). The 
cumulative distribution function (CDF) of the standardized background signal is plotted against 
the standard normal distribution for each data set. The background signal for both serum and whole blood 
exhibit a high correlation to the CDF plot (R2serum = 0.98, R2whole-blood = 0.95). This whole blood data is from 
2 bovine samples and 1 human sample. Figure reproduced from [ 45]. 
on the blank chips follows a normal distribution (Figure 33); therefore, we can combine 
the 3 chips as a single experiment. We measured each test, or spot consisting of 
immobilized probes, to be a sensor area consisting of 0.0855mm2. The numbers of 
detected AuNPs on each test were taken in combinations from 1 (0.0855mm2) to 9 
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(0.7695mm2) spots to study the effect of increasing effective sensor size on the LOD per 
mm2• Because the whole blood chips consisted of less spots, combinations from 1 to 6 
spots were taken. The average of the AuNPs per mm2 plus 3 times the standard deviation 
was determined as the background signal (AuNPs per mm2) for the defined sensor area. 
Note, the average always stays constant; however, the standard deviation changes with 
the sensor size, n, by a factor of n-0·5 . Thus, the data was fitted withy= A *n"-0.5 + B 
using linear regression and 95% confidence bounds to determine the dependence of the 
background signal on the sensor area (Figure 34a). The background signal was then used 
to extrapolate a target concentration using the linear regression described by the log-log 
plot of AuNPs per mm2 versus target concentration (Figure 34b ). 
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Figure 34. a) The mean of detected AuNPs on probes incubated in blank serum or whole blood plus 3 times 
the standard deviation was defined as the background signal (AuNPs per mm2) as a function of sensor size 
(spots). Different areas were accounted for by taking the combinations of 1 to 9 spots from the chips 
incubated in blank serum (24 total spots) and 1 to 6 spots from the chips incubated in blank whole blood 
(12 total spots). The results were fitted to y = A *n·o.s + B using a linear regression with 95% confidence 
intervals. b) A linear regression for target detection in serum and whole blood was determined by plotting 
the log-log of the response (AuNPs per mm2) versus target concentration. The background signal from a) 
and the respective linear regression were used to extrapolate the minimum target concentration that is 
capable of being detected with IRIS nanoparticle counting. This target concentration is defined as the limit 
of detection (Figure 37). This whole blood data is from 2 bovine samples and 1 human sample. Figure 
reproduced from [ 45]. 
This section has focused on analyzing the LOD of IRIS by defining it as the 
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average signal of the blank plus 3 times the standard deviation. This calculation was 
chosen because it is commonly used by other techniques and commercialized products. 
However, the Clinical and Laboratory Standards Institute (CLSI) has published the 
guideline, Protocols for Determination of Limits of Detection and Limits of Quantitation 
[111], to provide a standard method for determining the limit ofblank (LOB), LOD, and 
limit of quantitation (LOQ) [112]. The LOB is defmed as the mean signal of the blank 
plus 1.645 times the standard deviation of the blank. As defmed by EP 17, the LOD is 
calculated by using the LOB measurement and test replicates of a sample that contained a 
low concentration of analyte [ 111] so that it will be determined by LOB plus 1.645 times 
the standard deviation of a low concentration sample. The LOQ may be equal to or 
greater the LOD. 
5.4.12 Determination of the lower and upper limits of quantitation 
A number of different "detection limits" may be used to characterize the 
minimum and highest concentration reliably measured by an analytical procedure. 
Typically, the LOD is calculated to report the minimum concentration of the analyte that 
can be detected with less than 1% false positive error. The lower limit of quantification 
(LLQ) and the upper limit of quantification (ULQ) are calculated when a higher degrees 
of confidence is desired, such as in commercialized clinical assays. The LLQ was 
calculated as described in the Determination of the Limit of Detection methods section; 
however, while the LOD was calculated using 3 times the standard deviation from the 
mean, the LLQ was calculated using 1 0 times the standard deviation from the mean. 
The ULQ was defined as the target concentration at which linear regression of the 
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dilution curve became less than R2 = 0.90 fori) serum and ii) unprocessed whole blood 
samples. Target concentrations from 5.4fM to 5nM were fit over 4, 5, and 7 orders of 
magnitude (Figure 42) for serum and unprocessed whole blood samples to determine 
when the linear correlation between the signal and target concentration fell below R2 = 
0.90. 
5.5 Results and discussion 
This report focuses on the single nanoparticle counting modality of the IRIS 
platform. The novel, yet straightforward, features of this modality have facilitated the 
design of a highly sensitive (attomolar), large dynamic range (attomolar to nanomolar), 
quantifiable, and multiplexed immunoassay in both serum and whole blood using 40nm 
AuNPs functionalized secondary antibodies. The unique ability to detect single 
nanoparticles over a large sensor area with the IRIS platform allows the use of 
nanoparticle tags that are in the size regime of the target molecules without sacrificing the 
kinetics of the reaction. Moreover, the platform maintains the ability to detect target at 
attomolar quantities in unprocessed whole blood. Discrimination ofnanoparticle tags [19, 
113] and a large sensor size contribute to the low limit of detection (LOD) of the assay. 
5.5.1 Quantification and verification of bound AuNPs using elimination processes 
on IRIS 
IRIS nanoparticle images were acquired and processed with custom software. 
IRIS software returns a histogram of the size distribution of nanoparticles in the image 
and uses 3 important elimination processes- anomaly filtering, point-spread-function 
(PSF) filtering, and size-discrimination - to ensure accurate and sensitive detection of 
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labeled detection antibodies (Figure 35c, Figure 36). Figure 35c and Figure 36 
demonstrate the importance of eliminating particles in the image that are not the 
functionalized AuNPs. used specifically for target detection. 
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Figure 35. a) Detection schematic of P-lactoglobulin using anti-P-lactoglobulin functionalized 40nm 
AuNPs as the detection complex. The mean final diameter of the detection complex after functionalization 
was measured to be 5lnm with dynamic light scattering (DLS). BSA was used as a negative control. b) 
IRIS images before and after detection complex incubation to detect 5pM of 13-lactoglobulin spiked in 
unprocessed whole blood. c) Histograms of detected particles on the sensor area of anti-B-lactoglobulin 
probes and the mean, standard deviation (SD), and counts using i) no filtering, ii) anomaly filtering, iii) 
point spread function (PSF) filtering, and iv) size-discrimination. The size and distribution of the 
functionalized AuNP diameters agree with the sizes measured by DLS and distribution specs provided by 
the distributor. Figure reproduced from [ 45l 
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Figure 36. Insets are the log-log plot of each measurement and display the effects of point-spread-function 
(PSF) filtering on the correlation of the signal to target concentration in undiluted serum. Without PSF 
filtering, the sensitivity drops from the attomolar to picomolar regime and the dynamic range decreases by 
4 logs of magnitude. Standard deviation from the mean also increases without PSF filtering because 
particulates in the image were falsely detected as gold particles. Finally, correlation of AuNPs per mm2 to 
dilution is reduced from 0.99 to 0.40 without implementing PSF filtering. Figure reproduced from [ 45] . 
Without filtering, the average size and standard deviation of the particles detected 
on the surface was 59±18nm corresponding to larger size than expected for the AuNP 
tags indicated that many of the "detected" particles are image artifacts also indicated by 
the very large size distribution. After using IRIS elimination processes, the average size 
and standard deviation of detected nanoparticles was reduced to 53±4nm, which was the 
diameter of the functionalized AuNPs confirmed with dynamic light scattering (DLS). 
Likewise, the dynamic range of the assay was improved by 4 orders of magnitude after 
applying the elimination processes (Figure 36). Because aberrations in the image may 
affect the calculated particle size, AuNPs 54±10nm in diameter were analyzed to quantify 
the number ofbinding events during dilution experiments. 
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5.5.2 Attomolar detection of P-lactoglobulin in undiluted serum and unprocessed 
whole blood 
IRIS single particle counting digitally detected ~-lactoglobulin spiked in lmL of 
undiluted serum or unprocessed whole blood and improved upon the dynamic range and 
sensitivity of the IRIS biomass platform (Figure 37). Analysis of the nanoparticle 
counting data resulted in a 107-fold increase in repeatable sensitivity from the nanomolar 
to the attomolar regime in unprocessed biological samples (Figure 37a). Post AuNP 
incubation images of immobilized anti-~-lactoglobulin and BSA probes incubated with ~-
lactoglobulin at various dilutions are presented in Figure 38. Protein microarrays are 
notorious for inconsistent or poor morphologies and a detection platform must not be 
compromised because of these intrinsic, and often unavoidable features [61, 73]. 
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Figure 37. a) The response determined by the signal minus the limit of detection of either IRIS nanoparticle 
counting or total biomass measurement. Results demonstrate comparable responses of target detection by 
nanoparticle counting in serum (N=8) and whole blood (N=4). Correlation was determined by taking the 
power-log of the response and target concentration of single nanoparticle data (Rscrum2 = 0.99, Rwhole-blood2 = 
0.98) . When the nanoparticle counting measurement reaches its upper limit, total biomass measurement 
becomes sensitive. Error bars refer to the standard deviation of the mean. b) The response determined by 
the signal minus the limit of detection (LOD) for 2 serums and 2 whole bloods experiments. The 
correlation between the mean of each data point (16 total points from 4 experiments) is 0.88. Error bars 
correspond to the standard deviation between the mean CNscrum = 8, Nbtood = 4). Figure reproduced from 
[45] . 
Furthermore, serum and whole blood contain non-homogenous particulates and 
cells that may affect detection sensitivity and range. Thus, the ability to discriminate 
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against any false signal and/or non-specific binding caused by these features is crucial for 
reducing noise of the assay. The ability to automatically discriminate AuNPs from non-
specific particles provides IRIS with a method to reduce the biological noise associated 
with the use of complex samples. Overall, this feature of the nanoparticle counting 
modality is key to producing reliable, sensitive detection of target in serum and 
unprocessed whole blood. Figure 38 includes examples of poor immobilization of anti-~-
lactoglobulin and BSA probes. It is crucial that the non-homogeneity of the spot does not 
affect nanoparticle quantification. By instituting the IRIS elimination processes, only 
AuNPs introduced by the user are detected in the image. Likewise, the biomass 
measurement was previously shown to correct variation in allergy chips and is reported 
elsewhere [31]. . 
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Figure 38. Anti-P-lactoglobulin and BSA spot images acquired with the IRIS nanopmticle counting 
modality to digitally detect P-lactoglobulin at varying concentrations in undiluted serum. The green circles 
encompass detected single particles after anomaly and PSF fi ltering. Poor morphology seen in the anti-P-
lactoglobulin probes and artifacts seen on the BSA probes do not affect go ld nanoparticle detection. After 
anomaly and PSF filters are applied, a histogram is produced to faci litate size-discrimination. Poor spot 
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morphology and artifacts do not affect particle detection due to these 3 processes. Figure reproduced from 
[45]. 
A schematic of the assay and the signal minus the LOD of each modality are 
shown in Figure 37a. Repeatability of the assay is shown in Figure 37b. Anti-~-
lactoglobulin probes were used to capture target from the complex solution. BSA probes 
were used as a negative controL The LOD of the nanoparticle counting modality was 
calculated to be ~60aM in undiluted serum and ~500aM in unprocessed whole blood. 
Using fluorescently labeled secondary antibodies, the LOD of the same protein system 
was found to be 163-tM in PBS [55]. As the response ofnanoparticle counting saturates, 
the biomass (low magnification) measurement in serum becomes sufficiently sensitive at 
2nM and linearly increases. Unfortunately, the biomass measurement fails in whole blood 
due to non-specific binding of cells to the sensor surface. This causes the dynamic range 
of the platform to be reduced from 10 orders of magnitude in serum to about 5 orders of 
magnitude in whole blood. 
Although attomo1ar sensitivity has been matched by other methods [114, 115], 
these techniques currently have not reported the ability to perform highly sensitive 
detection of biomarkers over a large dynamic range in unprocessed, complex biological 
samples. Furthermore, these techniques require microparticle tags, multiple amplification 
steps, nanoscale elements, and/or expensive instrumentation that may not be suitable for 
clinical applications, such as POC testing. With improved sensitivity and dynamic range, 
IRIS can be implemented as a single, simple instrument to quantifY a wide range of 
biomarkers of varying concentrations in undiluted serum and unprocessed whole blood in 
a single test. 
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5.5.3 Advantages of increasing biological sensor area to improve assay sensitivity 
Multiplexing capacity is a desirable criterion for biosensors developed for clinical 
applications. High--throughput platforms generally perform multiple tests in a minimum 
of 3 replicates to calculate a mean and standard deviation of each test. These tests run a 
'blank' sample in parallel to compute the LOD (mean plus 3 times the standard deviation) 
ofthe assay. When we calculate the IUPAC (International Union ofPure Applied 
Chemistry) LOD for the IRIS platform, we determine that the LOD in serum is lfM and 
in whole blood is 3fM (Figure 39a). Equal sensitivity in serum and whole blood has not 
previously been reported in the literature. In addition, this level of sensitivity is 1-2 orders 
higher than common IVD tests, which are restricted to serum samples only (Figure 39b ). 
The capability to detect similar low levels of analyte in serum and whole blood is directly 
related to the ability of IRIS to discriminate sizes of nanoparticles in the image. 
The number of wells or the sensor area usually limits the total number of tests a 
platform may perform. Thus, a compromise between the number of tests and the number 
of replicates of each test must be determined in order to collect meaningful data that will 
contribute to the detection of multiple biomarkers with potentially different sensitivity 
thresholds; for example, an increase in multiplexing capability results in a decreased 
ability to replicate each test because the available sensor area is dedicated to 
multiplexing. The effect of sensor size per test is studied as a function of sensor area to 
highlight these considerations (Figure 39c). 
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Figure 39; a) The limit of detection (LOD) as defined by the IUPAC is lfM in serum (left) and 3fM in 
whole blood (right) using a sensor area of 0.03mm2• b) The LOD ofiRIS is 1-2 orders in magnitude higher 
than current IVD tests, which are restricted to serum samples only. c) The LOD per~ as a function of 
sensor size for serum and whole blood. At a sensor area of 0.684mm2 (8 spots of immobilized probe), the 
LOD is 62aM for serum and 507aM in whole blood. Serum results are from FBS and blood results are from 
a pool of2 humans and 1 bovine blood samples. Figure reproduced from [45] . 
The occurrence of independent and random binding events becomes discrete 
when sufficiently low numbers of target molecules are in solution and may be maximized 
by increasing the sensor area [116]. Similarly, ,a larger sensor area reduces the variance of 
stochastic noise of the system such as non-specific binding. Here, the surface area of 
immobilized probes on the IRIS substrate describes the sensor area, n. The LOD per mm2 
as a function of sensor size for serum and whole blood samples on the IRIS platform is 
shown in Figure 39. The LOD per mm2 is defined as the average signal (AuNPs/mm2) of 
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a defined sensor size plus 3 times the standard deviation from the mean. Standard 
deviation is a function of sample size, n, which scales by 1 f...;r;: As expected, an increase 
in sensor size causes the LOD per mm2 to decrease by 1 j ...{ii and level off at a constant 
value representative of the mean (R2 = 1.0) for both serum and whole blood 
measurements (Figure 39). At a sensor area of0.684 mm2 (approximately 8 spots of 
immobilized anti-~-lactoglobulin probes), the LOD per mm2 is 62aM in serum and 
507aM in whole blood. Conventional tests utilize 3 replicates to calculate the LOD of 
their platform. Based on our measurements, if we utilized a sensor area of a single spot 
(area~ 0.0855mm2), the LOD per mm2 is 322aM in serum and 46fM in unprocessed 
whole blood. Theoretically, if sensor area were infinite in size, the LOD per mm2 for both 
serum and whole blood would approach 1 OaM. Although an order of magnitude of 
sensitivity is lost in whole blood samples when a sensor area of0.684mm2 (~8 spots) is 
used, this level of sensitivity in unprocessed whole blood samples is, to our knowledge, 
unmatched by other technologies that sense single molecular targets in unprocessed 
whole blood. Because a single nanoparticle can be detected on the IRIS substrate, the 
primary limitation of the platform becomes the ability to increase the capture efficiency 
of molecules in solution. 
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Figure 40. Repeatability ofLOD using human samples. 
Repetition of the LOD in a pool of 3 human blood samples was repeated to assess 
the repeatability of the LOD ofiRIS (Figure 40). Previous data used only 12 spots to 
calculate the LOD in blood. This round 24 spots were used to calculate the LOD. The 
data was collected and analyzed as previously described in Section 5.4.9. Bloodl data is 
collected 3 human samples. Blood2 data is collected from 2 bovine and 1 human samples 
and was the data used for Figure 39. The lines begin to diverge after an area of~ 0.7mm2 
but this may be due to more data collected in the second batch of experiments. These 
curves suggest that replicates of 6-8 spots should be used in order to achieve sub-
femtomolar sensitivity. 
When we utilize this EP 17 standard defined by the CLSI, the LOD of IRIS 
becomes 550aM in serum and 17fM in unprocessed whole blood for an area of 
0.0855mm2. Previously, we utilized an area of 0.684mm2 to determine the LOD. Because 
the low concentration sample consisted of only 8 replicates (the CLSI requires 20 
replicates minimum for laboratory studies and 60 replicates for clinical studies [112]), the 
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EP17 calculation was determined using the smallest sensor area. In Figure 39, the LOD 
ofiRIS was determined to be 332aM in serum and 46fM in unprocessed whole blood 
when the sensor area was 0.0855mm2• These results are similar to the EP17 standard, and 
a similar trend would be expected as the sensor area increased. 
5.5.4 Determination of the lower limit of quantitation (LLQ) and upper limit of 
quantitation (ULQ) 
The LLQ per mm2 for the ~-lactoglobulin assay was 260aM in serum and 30fM in 
unprocessed human whole blood using a sensor area of0.684 mm2 (Figure 41). 
Commercialized sigE assays, such as ImmunoCAP® (Phadia), Immulite (Siemens), and 
- ... Tui-b~o RAST (Hycor Biomedical), that detect sigE are typically carried out in ELISA 
format. Luminex Corporation recently commercialized an allergy assay with xMAP 
Technology (Luminex Corp). An analytical comparison of the two assays demonstrated 
the LLQ of ELISA to be ~600fM and the LLQ ofxMAP MAGPIX Technology to be 
~100fM when running a TNFa MAGPIX assay [37, 38]. These commercialized assays 
are limited to only serum samples and small sensor areas. IRIS technology is 1000 times 
more sensitive in serum and 10 times more sensitive in unprocessed whole blood 
samples. The ULQ for the ~-lactoglobulin assay in serum was determined to be 100pM in 
serum and whole blood samples using IRIS single nanoparticle counting (Figure 42). 
ELISA and xMAP MAGPIX assays each have aULQ of ~100pM, respectively [37, 38]. 
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Figure 41 . The lower limit of quantitation (LLQ) per mm2 as a function of sensor size for unprocessed 
whole blood is plotted. At a sensor area of 0.684mm2 (8 spots of immobilized probe), the LLQ is 30fM in a 
pool of 3 human whole blood samples. The reported LLQ for ELISA is 600fM and xMAP is 1 OOfM. 
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Figure 42. The upper limit of quantitation (ULQ), defined at where the linear conelation between signal 
and concentration becomes less than R2 = 0.90, was determined to be lOOpM for both serum and 
unprocessed whole blood samples. Y-axis values are the log of the signal (AuNPs per mm2) at each 
concentration and scaled to see each individual regression line. Figure reproduced from [ 45]. 
5.6 Conclusions 
We have demonstrated highly sensitive, multiplexed biomarker detection over a 
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large dynamic range in unprocessed biological samples with IRIS, a simple instrument 
with potentially broad clinical impact, by implementing the advantages of nanoparticle 
tagging, single nanoparticle discrimination, and a large surface area, robust sensor. As 
proof of concept, ~-lactoglobulin, a cow's milk whey protein, was detected against 
negative controls at a detection limit of ~60aM in serum and ~500aM in whole blood. 
The upper limit was calculated to be ~ 1 OOpM. This sensitivity and dynamic range in 
biological media with no sample preparation are direct results of the ability of IRIS to i) 
eliminate all nanoparticles not specific to the assay and ii) detect single nanoparticles 
over a large sensor surface. Currently IRIS requires no time for sample preparation and 3 
hours for assay time, which may potentially be reduced with the incorporation of 
micro fluidics [ 117]. The elimination of sample preparation would reduce total assay time 
by 1 hour and permit the test to be performed outside of laboratory environments and 
therefore improve the utility of the system. The use of LEDs, simple optics, and 
inexpensive substrates to quantify multiple targets in complex samples establish IRIS as a 
promising platform for diverse clinical purposes. 
5.6.1 Future directions 
These characterization parameters were used for assay development for an allergy 
diagnostic platform that operates in serum and unprocessed whole blood and is discussed 
in Chapter 6 . 
In order for this assay to be conducted for a broad range of clinical applications, 
such as the POC, these assays will need to be conducted in an enclosed cartridge that is 
easily integrated into the IRIS automated platform. Furthermore, incubations times will 
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need to be optimized outside of the petri dish setting. One approach to reduce assay time, 
outside of microfluidics, involves capturing the target in solution directly to the detection 
complex [107]. This homogenous complex is this incubated on chip to reduce the 3-step 
sandwich assay to effectively 2 steps. Two preliminary experiments tested incubation 
times of the homogenous complex for capture on chip. 1mg/mL anti-B-lactoglobulin in 
20 mM trehalose/lX PBS (n=8) and 1mg/mL BSA in PBS were immobilized onto 5 
chips over night, blocked, and washed according to standard protocol discussed in 
Chapter 2. Background images were taken with IRIS high mag to account for any spot 
morphology artifacts. 30pg/mL B-lactoglobulin was then incubated in serum spiked with 
10% AuNP/1 %BSA/mL for 30 minutes. The homogenous complex was then incubated 
on chip for 5, 10, 20, 45, and 60 minutes. Samples were washed with lXPBST for 10min, 
rinsed with DI water, and dried. Post incubation images were taken to quantify binding. 
Preliminary data is shown in Figure 43. These results are quite exciting because they 
suggest detection of 30pg/mL in 6 minutes compared to 1 hour. This time was calculated 
by referring to the signal measured by 30pg/mL in the traditional 3-step sandwich assay 
(~540 AuNPs/mm2), plugging in the value from Figure 37, and extrapolating the time to 
achieve 540 AuNPs/mm2. Future work needs to investigate optimal target/AuNP solution 
binding time and generation of a dilution curve. 
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Figure 43. Detection of target in serum using homogenous capture in solution. 30pg/mL target was 
incubated in serum and 10% AuNPs/mL for 30 minutes. The complex was then incubated on chip for 
various times. 
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Chapter 6 
DETECTION OF ALLERGEN-SPECIFIC IGE USING IRIS SINGLE NANOPARTICLE COUTING 
IN UNPROCESSED WHOLE BLOOD 
Reproduced with permission from M. R. Monroe, G. G. Daaboul, A. Tuysuzoglu, 
C. A. Lopez, F. F. Little, and M.S. Unlu, "Single nanoparticle detection for multiplexed 
protein diagnostics with attomolar sensitivity in serum and unprocessed whole blood," ed. 
Analytical Chemistry, Vol. 85, No.7, 2013, pp. 3698-3706 [45]. Copyright 2011 
American Chemical Society. 
In this chapter, we demonstrate the clinical utility of IRIS by detecting sigE from 
microliters of characterized (ImmunoCAP®) human serum and unprocessed whole blood 
samples. Fluorescence tags were replaced with 40nm AuNP labels, which facilitate single 
molecule detection in unprocessed whole blood without sacrificing reaction kinetics and 
are not influenced by environmental conditions. Four human samples were succesfully 
tested with IRIS, fluorescence, and ImmunoCAP®, and the results were compared to 
validate IRIS as a potential diagnostic platform. Texts and figures are adapted from [45]. 
6.1 Clinical need for an allergy diagnostic platform that can operate in 
unprocessed blood samples 
We utilize IRIS technology to detect slgE in finger-prick volumes of 
characterized patient serum and whole blood samples. The clinical need for an allergy 
diagnostic platform that can function using unprocessed whole blood samples was 
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outlined in Section 1.5. Briefly, currently only one commercialized POC allergy test is 
available; however, it is not quantitative, and thus requires expert interpretation, and is 
restricted to aeroallergens. 
6.2 Materials and Methods 
6.2.1 Reagents and equipment 
40nm carboxylated gold nanoparticles (AuNPs) were purchased from 
Cytodiagnostics (Ontario, Canada). MES buffered saline packs, EDC (1-Ethyl-3-(3-
dimethyl-aminopropyl)carbodiimide Hydrochloride), and Sulfo-NHS (N-
hydroxysulfosuccinimide) were purchased from Thermo Fisher Scientific (Rockford, 
Illinois). Copoly(DMA-NAS-MAPS) [51] was purchased from Lucidant polymers. The 
Bio-Rad Calligrapher (Bio-Rad Laboratories, Inc.) was used for protein printing on chips. 
Anti-IgE was purchased from BDBioscences. Allergens Der p 1, Phi p 1, Ara h 1, Ara h 
2, Bet v 1, Mal d 1, and Phl p 1 were purchased from Indoor Biotechnologies Ltd 
(Warminster, UK). Cy3 labeling kit was purchased from GE Healthcare. 
6.2.2 Substrate fabrication 
Substrates were fabricated as discussed in 5.4.2. 
6.2.3 Surface functionality 
The surface was functionalized as described in 5.4.3. 
6.2.4 Optical detection 
Optical detection was carried out as described in 5.4.4 
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6.2.5 Gold nanoparticle functionalization of secondary detection antibodies 
Secondary antibodies specific for human IgE were functionalized to AuNPs according to 
the protocol described in 5.4.5. 
6.2.6 Verification of the size of detection complex 
This protocol is described in 5.4.6. 
6.2. 7 Multiplexed allergen immobilization 
Three CaFE chips were functionalized with copoly (DMA-NHS-MAPS) as 
described in 2.3 .1. The chips were printed with 4 replicates of 8 allergens - Der p 1, Phi p 
1, Ara h 1, Ara h2, Bet v 1, Mal d 1, and Phi p 1 - at 1mg/mL and stored overnight at 
room temperature in a humid environment. The chips were then washed 3 times each for 
5 minutes in PBST and PBS buffers, rinsed with DI water, and dried with a stream of 
argon gas. Probe immobilization was then quantified with the IRIS biomass 
measurement. Chips were then blocked to inactivate remaining functional groups on the 
polymer with 50mM ethanolamine 150mM NaCl pH 8.5 for 45 minutes prior to serum 
and blood incubations. 
6.2.8 Detection of allergen-specific lgE in characterized patient serum and whole 
blood 
After quantification of probe immobilization densi~;, 2 chips were incubated in 
50J.!L volume of serum and 1 chip was incubated with 50J.!L whole blood anticoagulated 
with EDTA for 2 hours . The amount of slgE to a variety of allergens in the serum and 
blood samples was quantified by ImmunoCAP (Phadia). The chips were then washed 
with washing buffer (Tris/HCI 0.05 MpH 9, NaCl 0.25 M, Tween 20 0.05%) for 10 
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minutes (5mM of EDT A was added to the washing buffer for whole blood samples), 
rinsed in water, and dried with a stream of argon gas. One chip incubated with serum and 
the chip incubated in whole blood were then incubated in ~108 anti-IgE-functionalized 
AuNPs/mL in 0.5%w/v BSA/PBS for 1 hour. The third chip was covered to and 
incubated in Cy3-anti-IgE in 0.5%w/v BSA/PBS (lng/mL) for 1 hour. The 3 chips were 
then washed in PBS for 10 minutes (5 mM EDTA was added to the chip incubated in 
blood), rinsed in water, and dried with a stream of argon gas. The chips were finally 
scanned with the IRIS single particle modality to quantify bound AuNPs. GenePix 4000B 
was used to quantify fluorescence. Comparison of the ImmunoCAP®, fluorescence, and 
IRIS protocols are displayed in Figure 44. 
Low magnification images of the allergen arrays before and after human serum or 
blood incubation were taken using IRIS to assess immobilization density of allergen 
probes and any nonspecific binding from serum and whole blood incubations (Figure 45). 
Images show consistent spot morphology for allergens 1-5 and low immobilization for 
allergens 6-10. This may be caused to the small molecular weight of these allergens or 
sensitiveness to humidity or temperature during immobilization. 
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Figure 44. Comparison of lmmunoCAP® ISAC, fluorescence, and IRIS protocols and imaging modalities 
to detect allergen-specific IgE. IRIS is 106 -fold more sensitive than the fluorescence-based assays and can 
operate in both serum and unprocessed whole blood samples. ImmunoCAP® is restricted to serum samples. 
6.2.9 Elimination processes to ensure accurate detection of gold nanoparticles 
with IRIS 
This protocol is described in 5.4.10. 
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Figure 45. Four replicates of 10 allergens (listed) were printed onto the CaFE chip for dual label 
(fluorescence or AuNP detection) and label-free measurements. Intensity images of allergen array were 
acquired with IRIS before and after charactetized human serum or blood incubations. Fluorescence image 
on 1 OOnm oxide island after serum and secondary antibody against IgE is also shown. AuNP detection 
against IgE images for all allergens are not shown here. 
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Figure 46. Multiplexed assay to detect specific IgE to 8 allergens. a) Fluorescence measurement was used 
as a control to validate nanoparticle counting detection (R2 = 0.97 for serum both and whole blood 
samples). Human sample was characterized with Phadia ImmunoCAP® or skin prick testing (SPT): (+) 
reflects a positive result. Error bars correspond to the standard deviation from the mean (n=4). *Results not 
determined. Figure reproduced from [45]. b) Repeatability. Serum and whole blood was tested two times 
each and the IRIS and fluorescence measurements correlated at 90% (N=26). 
6.3 Results and discussion 
6.3.1 Quantification of allergen-specific lgE in characterized serum and whole 
blood using IRIS nanoparticle counting 
The multiplexing capability and clinical applicability of IRIS nanoparticle 
counting was determined by detecting slgE in 50f..LL characterized patient serum and 
unprocessed whole blood against a panel of 8 purified major allergens immobilized in 
quadruplets. Ara h 6 and Fel d 1 results were disregarded because of poor immobilization 
density and/or spot morphology in one ofthree chips. Fluorescence detection ofslgE in 
serum was used as a control to validate IRIS nanoparticle detection of specific IgE in 
serum and whole blood. The average and standard deviation (N=4) of fluorescence and 
nanoparticle counting measurements were confirmed with Phadia ImmunoCAP® (Figure 
46). The nanoparticle counting measurements were correlated to the fluorescence results 
to validate the assay (Rserum2 = 0.97, Rwholc-bloo/ = 0.97). The standard deviations of the 
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fluorescence measurements were larger than the standard deviations of the nanoparticle 
counting measurements in serum and unprocessed whole blood. This is a direct result of 
the ability to detect discrete binding events on immobilized probes; spot-to-spot 
morphology inconsistencies, which are notoriously present in protein microarrays, were 
averaged in the fluorescence measurement and contributed to larger deviation. Although 
the fluorescence and nanoparticle counting measurements detected minimal IgE bound to 
Bet v 1 (birch), the ImmunoCAP® reports slight elevated levels of slgE (slgE -
Fluorescence: 16±11 SNR, Nanoparticle counting: 4±7 AuNPs/mm2, ImmunoCAP®: 
0.69 kU/L). This low signal is most likely due to low immobilization of Bet v 1 probes 
that has been quantified by the IRIS biomass measurement on the sensor surface [31]. 
Furthermore, measurement of lgE to Ara h 2 (peanut) and Bet v 1 on the whole blood 
chip was not reported due to spotting inconsistencies (Figure 47). The ability to quantify 
immobilization density of each spot in the array highlights the need of an instrument to 
be capable of quantitative assessment to guarantee reliable, accurate test results and has 
been demonstrated elsewhere [31]. This is one example ofthe two modalities ofiRIS 
complement each other. 
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Figure 47. Pre and post anti-IgE functionalized AuNPs incubation images acquired with IRIS. Black spots 
are-due to aberrations in optical path. Irregular morphologies of Ara h 2 are present in both the blood chip 
and serum chip. However, probes immobilized on the serum chip consist of a flat, high-density region. 
Image processing confirmed that binding was only distinguishable in this region. Because the blood chip 
did not have a high-density region for target binding, the data was ignored. Figure reproduced from [ 45]. 
The repeatability of detection of specific IgE in serum and whole blood in the 
same patient is seen in Figure 46b. As the AuNP density increases, the fluorescence 
measurement also increases accordingly (R2 = 0.90, N=26). These results are very 
exciting because it demonstrates the working ability of IRIS to repeatability measure IgE 
biomarker not only in serum, but also in whole blood with minimal loss in accuracy. 
Second, these results suggest minimal calibration or normalization procedures will be 
required with the IRIS measurement, in contrast to fluorescence data. 
Other patient samples were characterized, and results are displayed in Figure 48a. 
The goal of this work is to validate IRIS as an alternative for ImmunoCAP® testing. To 
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show feasibility, we plotted the IRIS signal vs. the ImmunoCAP® levels for the allergens 
with documented sensitization between these patients (Figure 48b ). These results suggest 
that there is a linear con-elation (R2 = 0.90) between IRIS and ImmunoCAP® 
measurements between patients. While these results are very encouraging, more samples 
need to be run in order to further justify the adva?tages of IRIS allergy clinical testing 
compared to ImmunoCAP® standards. 
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Figure 48. (a) Four patient serum and blood tested for sensitization against 8 allergens using fluorescence 
and IRIS platforms. Each data point is the average IRIS or normalized fluorescence measurements (N=4). 
Fluorescence values were normalized by highest signal for the particular patient. The highlighted data point 
means that the ImmunoCAP® value was reported for that allergen. (b) IRIS vs. lmmunoCAP® values are 
plotted for different patients and a high linear correlation is present (R2 = 0.90). 
One of the main challenges of allergy testing is conespondence between sigE and 
skin prick tests. It has been reported that sigE tests generally con-elate with skin testing 
but never greater than 90-95% of the time [118]. Figure 49 shows results from a tested 
patient sample, which chosen for IRIS testing because of its 4.5 ImmunoCAP® score for 
Der p 1 allergen. However, IRIS and the skin prick test came back negative. These sorts 
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of discrepancies, especially regarding food allergens, are frequently reported in the 
literature. For example, different methods agree in 55-6% of the cases. Moreover, 
differences in one class are generally 20-30% and differences in more than two classes 
are 5-10% [118]. These differences are mainly attributed to different populations ofigE 
antibody are measured in each serological IgE assay or differential expression of the 
epitopes on the allergen in each othese assays [119]. 
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Overall, IRIS data corresponds well to the ImmunoCAP®. These results 
demonstrate the ability of IRIS to perform multiplexed allergy testing in unprocessed, 
finger-prick volumes of whole blood. Utilizing the biomass measurement modality of 
IRIS aides in quantitative assessment of the allergy array. IRIS results correlated with 
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fluorescence controls at 97% and overall agreed with the IrrumnioCAP® result. 
Furthermore, when multiple characterized human samples were tested, a correlation 
between AuNPs/rrun2 and ImmunoCAP® value was high. 
6.5 Future directions 
Although IRIS has been shown to detect targets in blood with no sample 
preparation (a huge barrier to technologies trying to make it to the POC), translation of 
the IRIS biosensor into a POC instrument requires developing an automated focusing 
(preliminary results are discussed in Chapter 7) and microfluidic sample incubation 
platforms. The automated microfluidic system must be designed to 1) integrate 
connections between the disposable microchip and other systems (fluidic, electrical, 
optical), 2) dispense and control fluid's flow sequence, duration, and rate, 3) require 
minimal user interaction, and 4) maintain compatibility with disposable use and high 
throughput manufacturing. 
The primary challenges to overcome in the development of a cartridge for the 
primary care setting are i) maintaining consistent binding efficiency after translation of 
the immunoassay from a bulk (tube/petri dish) setting to a high surface area 
(microfluidic) environment, and ii) design and fabrication of an optically-compatible 
incubation cartridge. The first challenge will involve an extensive characterization study 
on the binding kinetics and optimization of the surface chemistry to maximize analyte 
capture, while the second challenge will require redesign of the IRIS optical imaging 
system. Although IRIS measurements are traditionally performed on dry samples, this 
approach has been proven sub- optimal in the context of a sealed micro fluidic cartridge, 
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as the highly hydrophilic sensor surface prevents clean and reliable drying of the 
microchannels. Additionally, the presence of several reflective interfaces between the 
sample and the optical path further reduces optical resolution via iilcree:.sed background 
reflection. 
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Chapter 7 
ACCURATE SIZING OF UNKNOWN PARTICLES USING GOLD REFERENCE PARTICLES 
This chapter outlines further development of IRIS into an automated, calibrated 
instrument for potentially broad clinical applicability. Here we design substrates with 
embedded reference nanoparticles (RNPs) for automatic and accurate sizing of single 
nanoparticles on the sensor surface. We have developed two methods for embedding RPs 
on the surface and discuss how the RNPs may reduce the variability in instrumental 
design. While this chapter shows that embedded RNPs improve image acquisition speed 
by 67%, the main goal of this work is to demonstrate accurate sizing ofunknown 
particles on the sensor .surface by improving the ability to focus with these easy-
fabricated reference substrates. 
7.1 · Introduction 
POC diagnostic devices must be fully automated and integrated devices that 
require no additionallaboratory equipment of medical infrastructure [17, 18, 92]. 
Although various biosensing platforms have been developed for clinical applications and 
are discussed throughout this dissertation, very few successfully translate from the 
laboratory setting to the clinic nor have replaced traditional ELISAs due to variety of 
reasons discussed in Section 1.5. Lab-on-a-chip systems as alternatives to ELISAs have 
been developed to integrate fluid-handling and detection in an automated format [ 120-
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123]. However, these technologies are relatively complex, expensive, and have low 
multiplexing capacity. Yang eta/. describe one approach to automate ELISA as a 
potential POC system that utilizes 96-well ELISA plates to detect pai:hogens with 
1 OOpg/mL sensitivity. However, the system still requires many wires and components 
that may complicate user operability. Moreover, any broadly applicable clinical 
diagnostic device must be robust to inherent manufactured variation. 
Prototyping of the IRIS single nanoparticle counting modality is currently in 
development (See section 22.3). Currently the instrument automatically focuses and 
sizes single nanoparticles on the surface. However, the automatic foc"~Jsing algorithm 
currently takes over 120s per spot on the array, which is too long for any practical clinical 
application that requires 100 spots in the array. In addition, the sizing algorithm depends 
on the optical design, oxide thickness, and focus, which may vary instrument to 
instrument. Thus, IRIS must ensure rapid focusing and robust sizing in order to be 
suitable for the clinical setting. 
We are approaching this engineering problem by integrating gold reference 
nanoparticles (RNPs) of known size (70nm) onto the IRIS substrate using a generic 
blanket coating method and spotting method. Briefly, the blanket coating is fabricated by 
dispersing the reference nanoparticles in the polymer solution prior to coating. The 
spotting method immobilizes the reference particles into an array on the substrate. 
Preliminary data supports improved focus acquisition time, ease and repeatability of 
fabrication, and ability to not interfere with the affinity/binding reaction of immobilized 
probe, target, and labeled secondary antibodies. 
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7.2 Materials and methods 
7.2.1 Reagents and equipment 
40nm carboxyla:;ed and 70nm aminated gold n.anopsri:icles (Au1\TPs) vrerc 
purchased from Cytodiagnostics (Ontario, Canada). MES buffered saline packs, EDC (1-
Ethyl-3-(3-dimethylarninopropyl)carbodiimide Hydrochloride), NaPB (sodium phosphate 
buffer), and Sulfo-NHS (N-hydroxysulfosuccinimide) were purchased from Thermo 
Fisher Scientific (Rockford, Illinois). Copoly(DMA-NAS-MAPS) [51] was purchased 
from Lucidant polymers. The S3 FlexArrayer (Scienion AG) was used for protein 
printing on chips. 
7.2.2 Substrate fabrication 
For silicon oxide on silicon substrates, a thickness of 1 OOnm has been selected to 
maximize the phase angle term [ 15]. Silicon chips with thin layers of silicon oxide, 
fabricated by SVM Inc. (Santa Clara, CA), were designed to be used with a reusable 
loading holder. Fiduciary patterns enable the use of an automatic spot detection 
algorithm, in addition to providing contrast for autofocusing algorithms. The dimensions 
of the chips are lOmm x lOmm x 0.5mm, with a 2.3mm x 2.3mm active center region for 
spotting capture probes. Small, periodic etched squares (15Jlm x l5Jlm every 143Jlm) in 
the capture probe area ensure that regions of high contrast are present in the field of view 
for coarse focusing, independent of the precise location of each capture probe spot. 
Presence of these small high contrast regions on the surface had no effect on copoly 
(DMA-NAS-MAPS) coating and protein spotting. 
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7.2.3 Surface functionality 
The surface was functionalized as described in 5.4.3. 
7.2.4 Embedding reference nanoparticles (RNPs) onto substrate 
7.2.4.1 RNP Blanket coating and characterization 
The surface functionalization coating was performed on 9 chips according to 
usual protocol until copoly (DMA-NAS-MAPS) was in solution. One chip followed the 
standard coating protocol as control. The other 8 chips were coated with 1010 AuNPs/mL 
spiked into the polymer solution at various times. The aminated AuNPs react and 
covalently bind to the to NHS groups in the polymer. The AuNPs were incubated in the 
polymer solution on a shaker for 1, 2, 4, 8, 10, 12, 16, and 24 hours and sonicated for 1 
minute once the respective incubation time was complete. The coating process was then 
continued according to standard protocol. 
0 0 0 0 AuNP 
0 
0 0 0 
0 0 0 0 
0 °000 08 
OG)~ 000 0 8 0 0 0 0 
0 0 0 
0 0 
Figure 50. Blanket coating of70nm AuNPs with immobilized probe 
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Because the RNPs, like the probe molecules, react with the NHS groups in the 
polymer coating, it is important to determine if probe density, target capture, or labeled 
secondary antibody binding is affected by RNP. After quantification of R'JlP density on 
the chips and standard blocking and washing procedures, 1mg/mL anti-P-lactoglobulin 
and 1mg/mL BSA (N=6) probes were immobilized on the surface according to Figure 50. 
The IRIS biomass measurement was used to quantify the average immobilization density. 
Next, 100pg/mL p -lactoglobulin in serum was incubated for 2 hours on the chips. 
Finally, 1% 40nm AuNP labeled to secondary antibodies specific for p -lactoglobulin 
were incubated for 1 hour. Binding was measured with IRIS single nanoparticle counting. 
All measurements were compared to the control (polymer coated with no RNP). 
7 .2.4.2 RNP Spotting and characterization 
Immobilization of 70nm aminated AuNPs was optimized using different spotting 
concentrations (109, 1010, 1011 AuNPs/mL), times (1, 2, 3, 4, 5, 20 hours), and buffers 
(lX PBS, 150mM NaPB pH7.5, 150mM NaPB pH8.5). Immobilization was performed 
using the S3 FlexArrayer in the schematic shown in Figure 51. After optimized 
immobilization time, the surface was washed and dried. Protein probes were then 
immobilized off-set to immobilized AuNPs for minimal immobilization interference. 
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Figure 51. Spotting schematic for probe and 70nm AuNPs 
1mg/mL anti-~-lactoglobulin and 1mg/mL BSA (N=5) probes were immobilized on the 
surface of all chips. Next, 1 OOpg/mL ~-lactoglobulin in serum was incubated for 2 hours 
on the chips. Finally, 1% 40nm AuNP labeled to secondary antibodies specific for ~ -
lactoglobulin were incubated for 1 hour. Binding was measured with IRIS single 
nanoparticle counting prototype and benchtop systems. 
7 .2.5 Optical detection 
The high magnification modality of IRIS was used to measure the RNP density and 
nanoparticle tags. Mass density measurements were performed with the low 
magnification modality ofiRIS. Details of optical detection are described in 5.4.4. 
7 .2.6 Gold nanoparticle functionalization of secondary detection antibodies 
Secondary antibodies specific forB-lactoglobulin were functionalized to AuNPs using 
EDS-NHS chemistry. The procedure is described in 5.4.5. 
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7 .2. 7 Verification of the size of detection complex 
The size of the detection complex was performed with DLS. This protocol is described in 
5.4.6. 
7.2.8 Faster image acquisition time of IRIS prototype 
Biological testing using the ~-lactoglobulin model frequently discussed in this 
dissertation was measured using the IRIS benchtop and IRIS prototype systems. While 
the biological tests were performed on the benchtop, image acquisition time was 
performed on the prototype using two image acquisition processes. Acquisition time and 
detected AuNPs per mm2 were compared for both acquisition methods. Briefly, the first 
process focused on the AuNP labels using the entire field of view. The second process 
- focused on the AuNPs using only 1/161h the field of view. A crucial RNP per mm2 in the 
field of view must be met to effectively shorten focusing time and image acquisition. 
This density was determined by studying when the automated focusing algorithm failed 
to improve initial focus time. Results of the minimum density requirement were 
determined and instituted for only the RNP spotting schematic because the blanket 
coating data was already acquired at the time. 
7.3 Results and discussion 
7 .3.1 RNP blanket coating and characterization 
7.3.1.1 Time of incubation 
Quantification of mean RNP density and standard deviation of 6 areas on the 
substrate is shown in Figure 52. At 1 hour of incubation time, initial density is 5xl 03 
AuNPs per mm2. This level stays constant until around 5 hours of mixing time. Density 
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continues to increase until about 10 hours of incubation time to ~3x104 • The blanket 
coating was repeated again for 3 samples at 4, 6, 8, and 10 hours and imaged at 9 
different areas systematically throughout the chip (Figure 53). Based on this data, AuNPs 
are not coated onto the substrate homogeneously. Depending on the density required for 
the IRIS prototype to expedite analysis, this may or may not be a concern. Despite 
variability discrepancies, the blanket coating is very simple and does not require any 
extra commitment or expertise for fabrication. 
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Figure 52. RNP Blanket coating as a function of incubation time. Images are sample areas of 1 of 6 
acquired using IRIS single nanoparticle counting modality. RNP (green circles) density is plotted against 
time of incubation with polymer solution a priori to substrate coating. Data points are the mean and 
standard deviation of 6 randomly acquired areas on the substrate. Images are 500x500 pixels2 . 
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Figure 53. Repeatability ofRNP blanket coating for 3 samples at 4, 6, 8, and 10 hours. This data suggests 
that the blanket coating has large variation between groups and an alternative reference coating be explored 
in case IRIS requires low variation for optimal performance. 
7.3.1.2 Biological testing 
After the substrates were blanket coated with the AuNP-spiked copoly solution at 
various times, two proteins were immobilized to study the effects of the embedded RNPs 
on immobilization density (Figure 54b ). Although the RNPs reaCt to the active groups in 
the polymer, these results suggest that immobilization density of protein is not affected. 
The immobilization height slightly decreases for the 24 hour AuNP-copoly incubation 
(~3x104 AuNPs/mm2), but more investigation to determine if this is a result of spotting or 
the RNPs is required. 
The effects on RNP on target capture were also studied using this platform. 
Because characterization of the required particle density for automatic detection was not 
yet determined, the chips incubated in AuNP-spiked copoly for 1 hour were chosen for 
this study. Figure 54c shows the results of detection of 1 OOpg/mL target in serum and 
RNPs using copoly coated and spiked copoly substrates. Quantification revealed little to 
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negligible effect of the blanket coating on target detection. 
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Figure 54. (a) IRIS images of control (copoly) polymer coating and 1 hour of incubation with 70nm AuNPs 
(~3000 AuNPs per mm2) (spiked copoly). (b) There is negligible effect of spiked copoly on protein 
immobilization. (c) There is negligible effect of AuNPs spiked into copoly on target detection. 
7.3.1.3 Faster image acquisition 
Implementation of the RNPs allows IRIS software to focus on a small area region 
of the chip and therefore crop the small area region to potentially expedite focusing time. 
Cropping an area 1/161h the field of view reduced the acquisition time per spot from 
> 120s to 75s on average or by 67%. After a more thorough analysis (Appendix B) the 
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main limitation in decreasing the focus time was determinedto be the number of 
iterations of the stages required for pinpointing the focal plane. Furthermore, it appears 
that the focal plane failed when the number of AuNPs dropped below 30 AuNPs in a 350 
x 3 50 pixels2 crop area ( ~ 1.1 x 104 AuNPs per mm2) (Appendix B). In order for this 
density to be achieved with the blanket coating method, AuNPs would need to be 
incubated in the copoly solution for a minimum of 5 hours. Biological characterization 
would need to be repeated to determine feasibility. 
7.3.2 RNP spotting and characterization 
7.3.2.1 Buffer optimization 
Three different spotting buffers (1X PBS, 150rnM NaPB pH 7.5, and 150rnM 
NaPB pH 8.5) were examined to optimize AuNP immobilization for different periods (1, 
2, 3, 4, 5, 20 hours). Results are shown in Figure 55. Aminated AuNPs in PBS evaporated 
and the immobilization could not be quantified (data not shown). The 150rnM NaPB pH 
8.5 buffer facilitated a more homogenous spotting morphology and higher density than 
the 150rnM NaPB pH 7.5 buffer solution. This may occur because the reaction between 
the amino groups and the NHS ester in the polymer coating is favored in the alkaline 
environment. Based on these results, immobilization in 150rnM NaPB buffer for 1 hour 
was chosen as the spotting protocol. 
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Figure 55. Three different spotting buffers (IX PBS, 150mM NaPB pH 7.5, and 150mM NaPB pH 8.5) 
were examined to optimize AuNP immobilization for different periods (1, 2, 3, 4, 5, 20 hours). The 150mM 
NaPB pH 8.5 buffer facilitated a more homogenous spotting morphology and higher density than the 
150mM NaPB pH 7.5 buffer solution. Immobilization in 150mM NaPB pH 8.5 buffer for 1 hour was 
chosen for the remainder of the immobilization characterization studies. The dashed line refers to the 
minimum RNP density for improved focusing time and image acquisition. 
7.3.2.2 Time 
Three concentrations of AuNPs were immobilized in 150mM NaPB pH8.5 buffer 
according to the layout seen in Figure 51 for 1, 2, 3, 4, 5, and 20 hours in a humid 
chamber. IRIS single nanoparticle counting quantified immobilization density (Figure 
56). Points represent the average and standard deviation of each sample (N=5). Purple 
dashed line represents minimal density required for faster acquisition time. Results 
suggest we can achieve greater than 1.1x104 AuNPs/mm2 with 1 hour of incubation time. 
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Figure 56. Optimization of immobilization time of 3 different AuNPs/mL spotting concentration. Points 
represent the average and standard deviation of each sample (N=5). Purple dashed line represents minimal 
density required for improved acquisition time. Results suggest we can achieve greater than 1.1 x 104 
AuNPs/mm2 with 1 hour of incubation time. 
7.3.2.3 Concentration optimization 
Inter-chip and intra-chip variability was determined by spotting 5 concentrations 
of 70nm AuNPs in alkaline pH for 1.5 hours. First, repeatability on-chip was determined 
by diluting the stock concentration (1x1012 AuNPs/mL) by 1:10, 1:20, 1:50, 1:100, and 
1:200 fold. Immobilization was quantified using IRIS (Figure 57 a). Results are repeatable 
and indicate that immobilization is highly dependent on spotting concentration. 
Furthermore, results indicate that the lower limit required for quicker image focusing and 
acquisition (dashed purple line) is achieved at 1x1010 AuNPs/mL. Intra-chip variation 
was determined by measuring two chips for 4 spotting concentrations ( 1 x 108, 1 x 1 09, 
1x1010, and 1x1011 AuNPs/mL) and measuring immobilization density with IRIS (Fi~e 
57b). In order to achieve the minimal requirement of 1x104 AuNPs/mm2, spotting 
concentration must be at a minimum concentration of lx1010 AuNPs/mm2 . 
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Figure 57. a) Stock concentration (lx1012 AuNPs/mL) was diluted to five spotting concentrations in order 
to determine which concentration exceeds the minimum density requirement of lx104 AuNPs per mm2 
(purple dashed line in (a) and (b)). Each concentration was spotted 5 times on a single chip to assess inter-
chip variability. b) Intra-chip variability was determined by spotting 5 replicates of 4 concentrations. All 
immobilization was performed in 150mM NaPB pH 8.5 buffer for 1.5 hours. 
7.3.2.4 Preliminary biological testing 
A sandwich assay using the ~-lactoglobin model was performed using the 
schematic depicted in Figure 51. IRIS benchtop images were acquired pre-binding and 
post-binding to compare immobilization density and repeatability (Figure 58). Presence 
ofRNP had negligible effect on capturing target particles (Figure 59). Column 1 shows 
negligible binding on negative control. Columns 2-7 show comparable binding and 
detection of target bound to probe. Columns 2 through 6 vary with RNP density, which 
were diluted according to the dilutions discussed in Spotting concentration. Column 7 
had no RNP immobilized in the spot. IRIS prototype images were also acquired pre-
binding and post-binding using 2 different processes (entire field of view vs. 1/16th field 
of view) to compare the acquisition time and target particle counts. The second process 
agreed with initial studies (Section 7.2.8) and was shown to increase acquisition time by 
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25 seconds (Appendix B). 
Post bind 
Figure 58. IRIS images acquired pre- and post- binding with the benchtop setup 
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Figure 59. Detection of AuNP labels bound to target using the IRIS benchtop. Column 1 is negative control 
(BSA). The mean and the standard deviation (N=5) are plotted. 
7.4 Conclusions and future direction 
This chapter presented a potential solution to further develop IRIS for broad 
clinical applications, such as the POC. We developed a substrate with embedded RNPs 
using two methods: 1) the blanket coating and 2) the spotting method. We characterized 
each of the coatings and determined inter and intra sample variability. Although the 
blanket coating is a simpler method, immobilizing localized RNPs proved to be more 
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repeatable. Preliminary biological testing with each RNP method did not seem to be 
affected by the presence of the RNPs in the polymer coating. Finally, we showed that 
using Ri'JPs decreases image acquisition by 67%. Fmiher biological testing and 
characterization and faster data acquisition needs to be performed to validate repeatability 
of focusing and sizing the RNPs. Furthermore, the upper limit of the system needs to be 
determined to defme the dynamic range of the platform. Finally, the ability to show 
accurate sizing of unknown particles using the RNPs needs to be validated. 
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Chapter 8 
CONCLUSIONS AND FUTURE DIRECTIONS 
8.1 Conclusions 
Successful implementation of a low-cost biosensing platform exhibiting the 
required sensitivity, a large dynamic-range, high multiplexing capability, and zero sample 
preparation would advance healthcare and clinical decision making. We examined a 
plethora of optical biosensors and assay designs, and discussed the challenges they face 
as broadly applicable clinical tools. Mainly, we focused on improving current methods in 
slgE detection by developing multiple calibrated, sensitive, multiplexed platforms using 
the IRIS system and validating the platforms with characterized patient samples. 
We have improved conventional allergy IVD technology with the following 
accomplishments. First, we discussed IRIS biomass and single nanoparticle detection 
modalities to quantify biomolecule binding, and we discussed the importance of surface 
chemistry, immobilization ofbiomolecular probes, and spot morphology in biosensing 
applications. Second, we designed a chip with dual label and label-free sensing capability 
in a single experiment to aide in the microarray assay development. We found that this 
combination chip holds valuable information to determine the amount of immobilized 
proteins on the surface and improve the sensitivity and reproducibility of the assay. 
Third, we designed and characterized two calibrated platforms to control for 
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immobilization variation frequently seen in allergy chips. The first platform consisted of 
two regions of oxide on silicon optimized for label and label-free measurement that 
would enhance fluorescence emission of all fluorophores . The second platform consisted 
of one region tuned to enhance only Cy3 and Cy5 fluorophores and perform label-free 
calibration on the same spot. In our experiments, we utilize one of the two platforms, the 
CaFE chip, to demonstrate that the correlation between the fluorescence signal and 
immobilized probe density is linear despite chip-to-chip variance. We also show that 
these experiments are repeatable on a single oxide thickness platform. Third, we showed 
that the high magnification (nanoparticle counting) modality in conjunction with low 
magnification of IRIS in a combined instrument offers four significant advantages 
compared to existing sensing technologies: IRIS i) corrects for any variation in probe 
immobilization, ii) detects proteins from attomolar to nanomolar concentrations in 
unprocessed biological samples, iii) unambiguously discriminates nanoparticles tags on a 
robust and physically large sensor area, iv) detects protein targets with conjugated 
nanoparticle tags ( ~40nm diameter), which minimally affect assay kinetics compared to 
conventional microparticle tagging methods, and v) utilizes components that make the 
instrument inexpensive, robust, and portable. This platform was tested on characterized 
patient serum and blood samples and results were validated by ImmunoCAP® standards. 
Fourth, we showed that embedded RNPs into the polymeric coating on the IRIS substrate 
decreased image acquisition by 67%. Moreover, we hope these RNPs will prove 
successful in the automatic sizing of unknown nanoparticles in the image. Overall, these 
features make IRIS an ideal candidate for clinical and diagnostic applications, such a 
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POC testing. 
8.2 Future directions 
This dissertation focuses on assay and substrate development of sensitive, 
calibrated, multiplexed slgE detection platforms. Sensitive, accurate results in 
unprocessed microliter volumes of whole blood samples suggest potential clinical 
applications such as the point of care. Although automation of the instrument has been a 
current work in process, the assay itself must also become automated. Thus, the future 
direction of this project will be to establish IRIS as a POC IVD test that can determine 
and monitor the presence of biomarkers, such as slgE, in less than 25~1 of whole blood in 
less than 1 hour. 
l 20min 
Figure 60. Schematic ofPOC IVD allergy test. 
A general schematic of an allergy diagnostic test for POC is shown in Figure 60: 
(1) incubation of finger-prick volume of unprocessed whole blood using enclosed, 
disposable cartridge, (2) automated detection of specific IgE using AuNPs to determine 
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allergen sensitization, and (3) automated delivery of results. First, assay materials 
(calibrated printed allergen chip and functionalized to antibodies specific for IgE) must 
be optimized for functionality and storage. Next, an enclosed, single-use cartlidge 
containing a specifically calibrated, printed allergen chip must be developed an integrated 
into the IRIS platform. Finally, an extensive clinical study to validate IRIS as a POC IVD 
test to determine allergen sensitization will need to be carried out. Finger-prick volumes 
of whole blood from patients with characterized levels of IgE (Phadia ImmunoCAP® 
and/or skin testing) will be used as the standard for validation. Each of these potential 
future studies is outlined below. 
8.2.1 Stabilized referencing substrates and detection antibodies up to 4 weeks 
Allergen microarrays are notorious for variation in immobilization density. IRIS 
technology has demonstrated capability to account for and correct this inherent feature. 
To develop a reliable assay for the POC, a calibrated, printed allergen chip that is stored 
in the clinic and facilitates automated readout must be developed. First, calibration 
features will be embedded into the chip to promote automation of AuNP detection. 
Second, the lifetime of the functionality of the enclosed printed allergen chip will be 
determined and maximized by studying the effects of storage atmosphere, buffer, 
additives, etc. Detection antibodies must also be at the site of the test. Currently, labeling 
detection antibodies to AuNPs is a simple, overnight process and is stable for up to 4 
weeks at 4°C. Furthermore, antibodies are usually stable for up to 3 months. This aim will 
work on further methods to potentially discriminate labels form the background (ie light 
polarization). These components will be delivered as an assay kit to the clinic. 
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Benchmark will occur when assay materials are stable and functional at the 4-week mark. 
8.2.2 Development of a single-use cartridge for rapid detection of allergen-
spedfic IgE in mnderr <'!.0 mimrm'ies 
An enclosed, flow-cell is currently under development. This flow cell will be 
translated into a single-use cartridge for automation and ease-of-use. To demonstrate 
proof of concept, a serial dilution from 1 OaM to 1nM in spiked bovine blood using the 
cartridge will be performed and the outcome will be compared to existing results. 
Incubation times and flow rates will also be studied to achieve best sensitivity and 
specificity. After design optimization, the cartridge will be used for specific IgE detection 
and the results will be compared to the ImmunoCAP® standard. Benchmark will occur 
when assay time is less than 40 minutes and sensitivity and accuracy are maintained. 
8.2.3 Integration of the cartridge into the IRIS platform 
The implementation of a cartridge into the instrument will require consideration 
for loading and imaging. Sample loading is achieved by a custom chip holder snapping 
into the instrument via magnetic beads. The chip is then brought into focus using an 
automated XYZ translational stage. Inserting a cartridge into the system only entails the . 
correct placement of the magnetic beads. Furthermore, embedding calibration features 
into the chip will facilitate autofocusing. Careful consideration of imaging inside of the 
carttidge and particle sizing within a solution will be studied. 
8.2.4 Clinical validation of IRIS as a POC IVD allergy test 
An extensive clinical study will be carried out with IRIS to test for a variety of 
common food and airborne allergens. To quantify and compare inter-assay variability, 
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sera and whole blood from 80 subjects with a range representative of geographical 
allergies and 40 non-allergic subjects' serum and whole blood will be used to clinically 
validate IRIS. Results will be compared to serum levels of sigE to food and aiibornc 
allergens by Phadia ImmunoCAP ® (in vitro standard) and allergen skin testing from 
individuals with documented.allergy. 
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Appendix A 
DIPOLE EMISSION SIMULATION CODE 
I=O; 
thetal_ max=asin(sin(theta _ max*pi/180)/nl ); 
n2=polyval([2.36993E-11,4.15146E-7,1.44454],a); %-silicon oxide 
%n3=polyva1([2.77285E-13,-7.96149E-9, 1.15738E-4,2.94558],a); %-silicon 
%k3=polyval([7.17232E-14,-2.50635E-9,3.14916E:·5,-0.1354],a); %-silicon 
n3 = polyval([2.36993E-11,4.15146E-7,1.44454],a); %use this and lOmm for thickness 
to simulate glass slide 
k3 = polyval([0.0005e-5,0.3886e-5],a); 
start=O; 
stop= I; 
for m=start:O.OO 1/thetal_ max:stop 
thetal =thetal_ max*m; 
if ~theta1, theta1 =.00 1; end % to avoid division by zero if gamma= O 
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theta2=asin( sin(thetal )*nl./n2); 
theta3=asin(sin(thetal )*nl./n3); 
· theta'-metal; 
Nl_ TE=nl. *cos(thetal ); Nl_ TM=nl./cos(thetal );. 
N2 _ TE=n2. *cos(theta2); N2 _ TM=n2./cos(theta2); 
N3 _:_ TE=(n3+ li*k3). *cos(theta3); N3 _ TM=(n3+ li*k3)./cos(theta3); 
phase_incidence=exp(4*1i*d*pi*nl *cos(thetal).*(a)/10000);% dis in micrometers 
got rid of (-) sign 
phase=2*D*pi*n2. *cos(theta2). *(a)/1 0000; 
cosphase=cos(phase ); 
sinphase=sin(phase); 
% D is in micrometers 
Y _ TE=(li *N2 _ TE. *sinphase+N3 _ TE. *cosphase )./(cosphase+ 1i *N3 _ TE. *sinphase./N2 _ 
TE); 
Y_TM=(li*N2_TM.*sinphase+N3_TM.*cosphase)./(cosphase+li*N3_TM.*sinphase./N 
2_TM); 
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TE=(Nl_TE-Y_TE)./(Nl_TE+Y_TE); %reflection coeffs for stack of mirrors 
TM=(Nl_ TM-Y _ TM)./(Nl_ TM+ Y _ TM); % calculated by matrix method 
gammaphi(l,:)=0:0.05:90; %gamma integration for random dipoles 
gammaphi(2,:)=0:0.1:180; %phi integration 
if dipole_tilt < 91, gammaphi(1,:)=dipole_tilt; end %if not random dipoles, then 
gamma = dipole tilt; no integration for gamma 
gammaphi(1 ,:)=gammaphi(l,:). *pi/180; 
gammaphi(2,: )=gammaphi(2,: ). *pi/180; 
Ete=sin(gammaphi(2,:) ). *sin(gammaphi(1 ,: ) )+ TE. *phase_ incidence; % was 
sin(phi) *sin(gamma) * ( 1 + TE. *phase_ incidence); 
Etmdir=cos(theta1).*cos(gammaphi(2,:)).*sin(gammaphi(l,:))-
sin(theta1 ). *cos(gammaphi(1 ,:)); 
Etmrefl=TM. * (cos( theta1 ). *cos(gammaphi(2,:)). * sin(gammaphi( 1,:) )+sin( theta1). *cos(g 
ammaphi(1,:))); 
Etm=Etmdir+Etmrefl. *phase _incidence; 
I=I+sum((abs(Ete)."2+abs(Etm)/'2)).*sin(theta); %This is Itot because I is integrating 
after each loop 
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%if dipole_tilt < 91, break, end % not random dipoles -- stop gamma integration 
end 
155 
FASTER IMAGE ACQUISITION USING REFERENCE PARTICLES 
Summary: 
'"' · · .: · - - ---- ~8Afhe limiti:ng factor in acquisition time is now the number of iterations and the stages. I 
can continue shaving off time by maximizing the focusing iterations but the real issue is 
becoming when the stages are unable to pinpoint the specified z-plane. They can lock up 
to 20-40s. On one spot it occurred multiple times. When measuring a 2x5 array, this 
occurred ~5-7 times. Raising the average time from 75s to 11 Os. 
Goal: 
1min/spot which is equivalent to experienced manual user 
Current timing· 
Process #of images Full ROI 
Focus Coarse focus 30 57s 
Offset Corner detection 9 16s 
---
Ref Region Med/Fine focus Variable 76-100s 
~ Feedback Focus I 17/iteration I · 1 1---- ·----- ------·-----------,_ -----·---------~-----~----.. - ----- ------~---- ··---·-·· ·--------------- -----~--~ ~ 1 Move Stages · I 0.6s j L _______ .. ____ ---------------- "--------·"·--------- _______ ,. ______ ·------·-·--------- ----- . ------------------ ---·---------- ----·-
!_ ·-" ___ ------ -----'--~~~ll~:.e _______ J ~-?~a~e_s ____ 1~ -3s __ ___ _ J 
focus Max: 20 med 
50 fine 
---~--_,.,_...,...,__ ..,., " _ ____________ v.---~-,.-.~-~.., .. ..-,.,_ 
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Processing 3.2s 
Summary ~49s /iteration 
Saving 
Total/spot ~190s 
After fine tuning # focus steps 
• Recent imaging suggests Med focus may need to do -15um -> + 15um or more 
due to slope on chip 
• Future mask design tip: High contrast region should been near the first 
tl spo.
Process #of images Before Now 
Coarse focus Joey focus 21 57s 40s 
Fine focus Spot focus Variable 76s-100s 44s 
Max: 25 med 
20 fine 
Total/spot ~160s '--' 115 s (Estimated) 
(Estimated) 
Im 1 tpJementmg fr amerate &ROI£ £ db k£ or ee ac ocus 
Process images Full ROI Crop 
Feedback 7 /iteration 
Acquire 30frames 2.2s with FPS 1.05s 
Summary ~ 21 s/iteration ~ 14s/iteration 
Improvement! 
Total/spot ~ 1 OOs (Measured) ~75s (Measured) 
Implementing RAM disk 
f
l --··-·----~-~~~:_. __ l # of;;;;;;;; I Wi;hout RAM~sk with ~--I 
Coarse Joey focus 21 40s 40s 
\ focus 
i -- -·· , ........ ·--··-·· ·-·~~· ····-, - ---· ·-··· .... _ ···-· " ..... "'"'"' ····-·----· - ···- -· -··---·-·------ • ·- •. -- '"'"-"" ··- . ·----~----···I 
! Offset 1 Comer 19 ! 13s 13s I 
! 1 detection I t 
!_ • .• . .•. ...... .... - _; •. ··- -. .. ·- · ' ..................... , "'"'· --· ..... ·-· , .. _.,... ........... - .......... ! 
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Fine focus Spot focus Variable 49s 45s 
Max: 25 
med 
20 fine 
Feedback ?/iteration 
Move 0.6s 0.6s 
Acquire 30frames 1.05s 1.03s 
Processing 0.18s 0.13s 
Summary ~ 14s/iteration ~ 12s/iteration 
No Change 
Total/spot ~75s- 90s ~66s- 90s 
(Measured) (Measured) 
I 1 t ROI £ fin £ moJemen mg or e ocus 
Process #of images Full ROI Crop 
Fine focus Spot focus Variable 49s 49s 
Max: 25 med 
20 fine 
No Change 
Total/spot ~75s (Measured) ~75s 
(Measured) 
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